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NF-KB   Nuclear transcription factor kappa B 
NKF KDOQI  National Kidney Foundation Kidney Disease Outcomes Quality Initiative 
NO  Oxide nitric 
ODD  O2 dependent degradation domain 
PAS Periodic acid of Shiff 
PBS  Phosphate buffered saline 
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RDW RBC distribution width 
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TfR1 Transferrin receptor 1 
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TSP-1 Thrombospondin-1 
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Resumo 
A doença renal crónica (DRC) é uma doença que afeta cerca de 7% das pessoas 
com mais de 30 anos, traduzindo-se em mais de 70 milhões de pessoas em países 
desenvolvidos por todo o mundo. A anemia é uma complicação da DRC que se 
desenvolve no início da doença, aumentando a sua frequência e gravidade com o 
declínio da função renal. Esta patologia tem sido principalmente associada à diminuição 
da produção de eritropoietina, através da falência renal e de outros fatores, tais como a 
inflamação crónica, a perda de sangue e deficiências em vitaminas. A terapêutica com 
eritropoietina recombinante humana (rHuEPO) para tratar a anemia associada à DRC 
reduziu os requisitos de transfusões e melhorou a qualidade de vida dos doentes. No 
entanto, existe uma grande variabilidade na resposta ao tratamento, e cerca de 10% dos 
doentes desenvolvem resistência à terapêutica com EPO, agravando o seu prognóstico. 
Apesar da investigação dos últimos anos, os mecanismos subjacentes ao 
desenvolvimento de resistência à rHuEPO permanecem ainda por elucidar. Modelos 
animais poderão ser ferramentas úteis para clarificar as características celulares e 
moleculares desta condição. 
Os nossos objetivos foram, usando um modelo animal de DRC induzida por 
nefrectomia (5/6), esclarecer os mecanismos subjacentes ao desenvolvimento de 
anemia e à evolução de lesão renal; estudar o efeito da rHuEPO per se; compreender a 
variabilidade na resposta/resistência ao tratamento com rHuEPO, focando a 
eritropoiese, o metabolismo de ferro, assim como as lesões renais, a hipóxia, a 
inflamação e a fibrose, no sangue, nos tecidos e a nível celular; finalmente, desenvolver 
modelos animais experimentais que possam ser úteis noutros estudos de anemia 
associada à DRC. 
Tal como esperado, o nosso modelo desenvolveu uma anemia precoce logo após 
a nefrectomia que persistiu durante o estudo. A anemia persistente não foi devida a 
uma deficiência de EPO pois o rim remanescente dos ratos foi ainda capaz de produzir 
EPO (níveis aumentados em soro), e o fígado pareceu aumentar a expressão génica de 
EPO, sugerindo que o rim remanescente, ou mesmo os tecidos extra-renais, foram 
capazes de compensar a produção de EPO. Além disso, a redução na expressão da 
hepcidina, provavelmente induzida por hipoxia, deve favorecer a absorção de ferro. Os 
nossos resultados sugerem que a persistência da anemia pode resultar de distúrbios no 
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metabolismo do ferro e, eventualmente, de uma alterada actividade/função da EPO que 
pode resultar do dano nas células do rim, e da inflamação local desenvolvida.  
A fim de elucidar os mecanismos subjacentes à persistência da anemia, foi 
utilizado o modelo animal previamente caracterizado, para avaliar o impacto de duas 
doses de rHuEPO (50 e 200 UI) nos mecanismos mencionados, nomeadamente na 
(dis)funcionalidade da EPO, no (dis)metabolismo e disponibilidade do ferro, na hipóxia 
renal, na inflamação e na fibrose do rim remanescente.  
Neste modelo de DRC, a anemia desenvolvida a longo prazo foi devida a uma 
atividade eritropoiética reduzida, uma vez que ratos com DRC foram capazes de corrigir 
a anemia quando tratados com rHuEPO; a inflamação local renal e o tipo (ligeiro ou 
avançado) de lesões renais são cruciais para o resultado desta anemia. O tratamento de 
ratos com DRC com rHuEPO leva ao desenvolvimento de anticorpos anti-rHuEPO e, por 
conseguinte, à anemia, após 9 semanas de tratamento. Além disso, o impacto deste 
tratamento depende da dose de rHuEPO usada, que deve ser suficiente para corrigir a 
anemia, prevenindo o rim e a hipertrofia cardíaca, mas não demasiado elevada pois 
conduzirá a um agravamento de lesões renais glomerulares e tubulointersticiais.  
Adicionalmente, a possibilidade do desenvolvimento de resistência à EPO 
exógena (tratamento com rHuEPO) foi também considerada e analisada pelo 
desenvolvimento de um modelo de rato de hipoplasia eritróide mediada por anticorpos 
induzida por rHuEPO, através de um tratamento a longo prazo com uma alta dose de 
rHuEPO (200 UI/Kg de peso corporal/semana) durante 9 semanas em ratos Wistar. Os 
resultados obtidos sugeriram que, neste modelo, os anticorpos anti-rHuEPO inibiram 
tanto a rHuEPO como EPO endógena levando à anemia; adicionalmente, o ferro estava 
aumentado, induzindo a expressão da hepcidina hepática, apesar da não evidência de 
inflamação, sendo ele o modulador chave de síntese hepcidina. 
Os resultados desta tese dão-nos mais conhecimento sobre os mecanismos 
subjacentes a diferentes respostas do tratamento com rHuEPO observado nos doentes 
com DRC, assim como sobre o desenvolvimento de resistência à rHuEPO; além disso, 
pode abrir novas janelas para identificar alvos terapêuticos putativos para esta condição, 
bem como para a resistência à rHuEPO, que ocorre em cerca de 10% dos doentes com 
DRC. Conseguimos também desenvolver dois modelos experimentais, de DRC e de PRCA, 
que são ferramentas úteis para futuros estudos, incluindo farmacológicos, nesta área. 
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Abstract 
Chronic kidney disease (CKD) is a debilitating disease affecting about 7% of people 
with more than 30 years and older, which translates to more than 70 million people in 
developed countries worldwide. Anemia is a common complication of CKD that develops 
early in the course of the disease, increasing its frequency and severity with the decline of 
renal function. It has been associated, mainly, with a reduced production of 
erythropoietin by failing kidneys and with other factors, including chronic inflammation, 
blood loss and vitamin deficiencies. Since the introduction of recombinant human 
erythropoietin (rHuEPO), erythropoiesis-stimulating agents (ESAs) have been used to treat 
CKD associated-anemia, reducing the requirements for transfusion and improving the 
quality of life in these patients. Nevertheless, there is a marked variability in the response 
to the treatment and about 10% of patients develop resistance to rHuEPO therapy, 
aggravating their prognosis. Despite the intense research during the last years, the 
mechanisms underlying the development of resistance to rHuEPO therapy remain 
unsolved. Animal models could be useful tools to clarify the cellular and molecular 
features of this condition. 
Our aims were, by using the remnant kidney rat model of CKD induced by (5/6) 
nephrectomy, to clarify the mechanisms underlying the development of anemia and the 
evolution of renal damage; to study the effect of rHuEPO per se; to understand the 
variability in the response/resistance to rHuEPO therapy, focusing on erythropoiesis, iron 
metabolism as well as on kidney lesion, hypoxia, inflammation and fibrosis, at blood, 
tissue and cellular levels; finally, to develop experimental animal models that can be 
useful in further studies on CKD associated-anemia.  
As expected, our model developed anemia early after nephrectomy, which 
persisted throughout the study. The persistent anemia was not due to EPO deficiency 
because the remnant kidney of rats was still able to produce EPO (increased serum EPO 
levels), and the liver seems to increase EPO gene expression, suggesting that the remnant 
kidney or even extra-renal tissues were able to compensate EPO production. In addition, 
the reduced expression of hepcidin, probably induced by hypoxia, should favour iron 
absorption. Our data suggest that the persistence of anemia may result from disturbances 
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in iron metabolism and, eventually, by an altered activity/function of EPO that might 
result from kidney cell damage and from the developed local inflammatory milieu.  
In order to contribute to elucidate the mechanisms underlying the persistence of 
anemia, we used the animal model of CKD induced by (5/6) nephrectomy, previously 
characterized, to evaluate the impact of two doses of rHuEPO (50 and 200IU) on the 
physiological/pathophysiological procedures above mentioned, namely EPO 
(dys)functionality, iron (dys)metabolism and availability, kidney hypoxia, inflammation 
and fibrosis of the remnant kidney.  
In this rat model of CKD, the anemia developed with long-term CRF is due to the 
synthesis of EPO with a reduced erythropoietic activity, as the CRF rats were able to 
overcome the anemia when treated with rHuEPO; the local kidney inflammation and the 
type (mild or advanced) of kidney lesions are crucial to the outcome of the anemia. A 
long-term treatment of CRF rats with rHuEPO leads to the development of rHuEPO 
antibodies and, therefore, to anemia, after about 9 weeks of treatment. In addition, the 
impact of this treatment depends on the rHuEPO dose, which should be enough to 
correct anemia, preventing kidney and heart hypertrophy, but not too high that will lead 
to worsening of advanced glomerular and tubulointerstitial kidney lesions. 
In addition, the possibility of development of resistance to exogenous EPO 
(rHuEPO therapy) was also considered and analyzed by the development of a rat model 
of antibody-mediated EH induced by rHuEPO, by long-term treatment with a high dose 
of rHuEPO (200 IU/Kg bw/week) during 9 weeks in Wistar rats. The results obtained 
suggested that in this model the formation of anti-rHuEPO antibodies inhibited both 
rHuEPO and endogenous EPO leading to anemia; in addition, iron was increased, 
triggering hepatic hepcidin expression, despite no evidence of inflammation, and is the 
key modulator of hepcidin synthesis. 
The findings of this thesis give further insights into the mechanisms behind the 
different responses to rHuEPO treatment observed in chronic kidney disease patients, as 
well as to the development of resistance to rHuEPO; moreover, it might open new 
windows to identify putative therapeutic targets for this condition, as well as for rHuEPO 
resistance, which occurs in about 10% of CKD patients. We managed also to develop two 
experimental models, of CKD and of PRCA, that will provide useful tools for further 
studies in this research area and, eventually, in pharmacological studies.  
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1. The Kidney 
1.1. Basic kidney anatomy and physiology 
Each kidney contains about 1 million functional units, the nephrons, consisting of 
numerous specialized cell types originating from distinct embryological lineages. Each 
nephron contains a filtrating body, the glomerulus, and a long tubule made of a dozen 
differentiated segments. The final parts of these tubules are interconnected to form the 
collecting ducts, which open into the renal pelvis. The basic principles of kidney 
physiology dictate the central role played by this organ in excretory, metabolic, and 
endocrine functions. Although the kidneys excrete only about 1.5 L of urine daily, they 
are perfused with 20% of the cardiac output and form about 180 L of ultrafiltrate every 
day, which is profoundly modified during tubular passage. This function exposes the 
kidney to the interior milieu unlike any other organ and at the same time makes the 
body composition very sensitive to changes in kidney function. The glomerular filtration 
barrier consists of the fenestrated endothelial cells, an elaborate basement membrane, 
and an intricate layer formed by the foot processes of highly differentiated epithelial 
cells called podocytes (Figure I-1).1 
 
 
Figure I-1. Basic kidney anatomy and physiology. (Taken from Kurts et al., 20132). 
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The filtration barrier is permeable to water, small solutes, and low-molecular-
weight proteins up to the mass of albumin, but largely precludes the filtration of plasma 
proteins with a mass of more than 60–70 kDa, especially if they are negatively charged. 
Thus, the glomerular filtration rate, the product of the filtration area, the hydraulic 
permeability, and the net ultrafiltration pressure, yields a large ultrafiltrate containing 
plasma solutes and several grams of low-molecular-weight proteins. Any disturbance in 
glomerular hemodynamics or structure can result in reduced glomerular filtration rate 
or increased leakage of proteins into the urine—two classic signs of renal disease. Along 
the tubular segments of the nephron, the ultrafiltrate undergoes a series of 
modifications with massive reabsorption of low-molecular-weight proteins, solutes, and 
water, secretion of a gel-like protein called uromodulin (Tamm-Horsfall protein) and 
elimination of excess potassium, acids, and bases (Figure I-1).3 
The processes affecting urine composition are mediated by polarised transport 
systems operating in the epithelial cells lining the tubules. The proximal tubule 
reabsorbs the bulk (about two-thirds) of filtered solutes and water. In addition, the cells 
lining these tubules possess multiligand receptors involved in the endocytic uptake of 
filtered proteins that include hormones, carrier proteins (eg, for vitamins), and enzymes. 
Once reabsorbed, these proteins are metabolised by proximal tubular cells, as the 
human urine is virtually devoid of plasma proteins under physiological conditions. This 
massive uptake of proteins plays an important role in metabolic clearance, hormone 
homoeostasis, and conservation of essential vitamins (vitamin D, vitamin A, and vitamin 
B12), and provides a protein-free milieu for the cells lining distal nephron segments.4 
Organic molecules and drug metabolites are secreted into the urine via specific 
transporters located in the last part of the proximal tubule. The tubule segments 
forming the loop of Henle generate the hypertonic environment in the medulla, 
necessary for concentrating the urine, and mediate the paracellular reabsorption of Ca2+ 
and Mg2+ under the control of the Ca2+/Mg2+-sensing receptor.5 Specialised epithelial 
cells, located at the junction between the thick ascending limb of the loop of Henle and 
the distal nephron (macula densa) sense the tubular NaCl concentration and interact 
with renin-containing granular cells  in the afferent arterioles to regulate the glomerular 
blood flow through a mechanism called tubuloglomerular feedback.6 The distal nephron, 
which includes the distal convoluted tubule, the connecting tubule, and the collecting 
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ducts, is responsive to aldosterone and vasopressin and regulates the final urine 
composition and concentration.7 Excretory, metabolic, and endocrine functions of the 
kidney mediate essential interactions with several organs, sustaining an array of vital 
functions (Figure I-2), including regulation of body water and thirst, blood pressure, 
ventilation, drug metabolisation, potassium balance, erythropoiesis, calcium and 
phosphate metabolism, and acid-base homoeostasis.  
 
 
Figure I-2. Effect of kidney function on essential homoeostatic processes. FGF, fibroblast 
growth factor; ANF, atrial natriuretic factor. (Taken from Eckardt et al., 2013 8). 
 
The regulation of NaCl excretion, which is crucial for extracellular fluid volume 
and blood pressure control, is influenced by the renin-angiotensin-aldosterone system, 
the atrial natriuretic peptide, the sympathetic nervous system and, to a lesser extent, 
the antidiuretic hormone arginine vasopressin.9 Renal excretion of potassium is mainly 
dependent on the distal tubular flow rate and the release of aldosterone and its action 
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on the principal cells of the distal nephron. The regulation of body water content 
(osmoregulation) involves the action of vasopressin on aquaporin mediated transport of 
water.10,11 The kidney is also a main site of systemic oxygen sensing, regulating the 
oxygen supply in red blood cells and, hence, tissue oxygen supply, through hypoxia-
inducible erythropoietin production in peritubular fibroblasts of the renal cortex.12 Apart 
from control of body homoeostasis, the kidney is also involved in immune function. 
Dendritic cells and macrophages, which form a network in the renal interstitium, 
contribute to innate and adaptive immunity and are increasingly recognised for their 
sentinel role against kidney injury and infection and their potential contribution to 
progression of kidney disease.13  
 
 
2. Chronic kidney disease  
2.1. Overview and definition, classification and staging of chronic kidney disease 
Chronic kidney disease (CKD) is a general term for heterogeneous disorders 
affecting the structure and function of the kidney. The variation in disease expression is 
related partly to the cause and pathology, severity, and rate of progression. Since the 
introduction of the conceptual model, definition, and staging of CKD 12 years ago,14-16 
the guidelines have recommended a shift from the concept of kidney disease as a life-
threatening disorder affecting few people who need care by nephrologists, to a common 
disorder of varying severity that not only merits attention by general internists, but also 
needs a concerted public health approach for prevention, early detection, and 
management.17 Although guidelines have had an important effect on clinical practice, 
research, and public health, they have also generated controversy.8,18-20 
Figure I-3 shows a conceptual model for the development, progression, and 
complications of CKD. The model includes antecedents associated with increased risk, 
disease stages, and complications, including death. Risks can be categorised either as 
susceptibility to kidney disease because of sociodemographic and genetic factors, or as 
exposure to factors that can lead to disease. Early stages of disease are often 
asymptomatic, are detected during the assessment of comorbid disorders, and can be 
reversible. Rapidly progressive diseases can lead to kidney failure within months; 
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however, most diseases evolve over decades and some patients do not progress during 
many years of follow-up. 8,14,20 
In 2002, the clinical practice guidelines of US National Kidney Foundation Kidney 
Disease Outcomes Quality Initiative (NKF KDOQI) defined CKD as kidney damage or 
glomerular filtration rate lower than 60 mL/min per 1.73 m2 for 3 months or longer, and 
proposed a classification scheme based on estimated glomerular filtration rate (eGFR).14 
Later analyses have shown that albuminuria also has an important effect on outcomes, 
21 which prompted the Kidney Disease: Improving Global Outcomes (KDIGO) Work 
Group on Evaluation and Management of Chronic Kidney Disease to include albuminuria 
in the revised 2012 classification.22 The causes of CKD are also included in the new 
scheme because they can affect outcomes and the choice of treatments. Early 
identification of CKD is needed to prevent disease progression and reduce the risk of 
cardiovascular morbidity and mortality. Public health approaches to enabling early 
identification are, therefore, receiving increasing attention. 
 
 
Figure I-3. Conceptual model for the development, progression and complications of CKD. 
Factors associated with increased risk of kidney disease (blue), stages of disease (green), and 
complications (including death; purple). Horizontal arrows show transitions between stages 
(kidney outcomes). Solid arrows pointing from left to right show progression of kidney disease. 
Grey triangles show continuous nature of changes in glomerular filtration rate and kidney 
damage. (Adapted from Levey et al., 2012 and Eckardt et al., 2013 8,20). 
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The diagnosis, treatment, and management of CKD depend on classification and 
staging of the disease as set forth by international, country-specific, and other clinical 
guidelines.14,23-26 As evidenced by a variety of definitions and staging systems in the 
scientific literature, identification of optimal patient care strategies and interpretation of 
data are complicated. To date, the most frequently cited and used CKD staging system is 
that developed by the National Kidney Foundation, Dialysis Outcomes Quality 
Initiative.14,17,27 
Although measurement of eGFR is considered the gold standard for diagnosing 
and evaluating progression of CKD, there is a movement among clinicians and 
researchers to improve clinical guidelines specifically related to diagnosis, classification, 
and staging. The following frequently reported criticisms of current guidelines have 
prompted the discussion for modification of current clinical guidelines.16 
• A diagnosis based on current eGFR estimation formulas is imprecise. 
• There is an absence of risk-stratification across patients; those at high risk for 
disease progression are not identified, and stage 3 is too broad (eg, stage 3 should be 
stratified into 3a (eGFR 45–59 mL/min/1.73 m2) and 3b (eGFR 30–44 mL/min/1.73 m2)). 
• Patient variability (age, sex, race, ethnicity) is not considered in current 
methods of evaluation (eg, eGFR and proteinuria estimation, at risk for progression, 
prognosis). 
In an effort to collaborate and provide a foundational set of international CKD 
guidelines that address these criticisms, KDIGO formed a dedicated workgroup. 
Publication of the KDIGO “Clinical practice guideline on CKD classification and 
management” was anticipated in 2012. The proposed guideline structure and associated 
discussion points were as follows: 22 
• Guideline 1: Definition and stages of CKD. Stages modified and enriched to 
include different degrees of proteinuria; splitting stage 3 into 3a and 3b; define 
differences between kidney damage and disease (Table I-1). 
• Guideline 2: Identification and evaluation of CKD. eGFR, high-risk population 
evaluation, appropriateness and frequency of testing. 
• Guideline 3: Estimation of glomerular filtration rate (GFR). New equations that 
address “within-individual” biological variability, age, and ethnicity. 
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Table I-1. Classification of chronic kidney disease based on GFR. 
Stage Description By severity 
eGFR (mL/min/1.73 m
2
) Related terms 
G1 Kidney damage with 
normal or ↑ eGFR 
 90 Albuminuria, proteinuria, hematuria 
G2 Kidney damage with 
mild ↓e GFR * 
60–89 Albuminuria, proteinuria, hematuria 
G3a Mild to moderate 
↓eGFR 
45–59 Chronic renal insufficiency, early 
renal insufficiency 
G3b Moderate to severe 
↓eGFR 
30-44 
G4 Severe ↓ eGFR 15–29 Chronic renal insufficiency, late renal 
insufficiency, pre-ESRD 
G5 Kidney failure < 15 (or dialysis) Renal failure, uremia, ESRD 
ESRD, end-stage renal disease; eGFR, estimated glomerular filtration rate.*Relative to young 
adult level. In the absence of evidence of kidney damage, neither GFR category G1 nor G2 fulfill 
the criteria for CKD. (Adapted from KDIGO, 2012 22). 
 
• Guideline 4: Estimation of proteinuria. Regional variability in methods; change 
lexicon from microalbuminuria to albuminuria mild, moderate, or severe (Table I-2). 
• Guideline 5: Definition of progression of CKD. Definition of change in eGFR, 
acute versus chronic change, duration and stability of change, prognostic indicators, 
frequency of testing. 
 
Table I-2.  Classification of chronic kidney disease based on albuminuria. 
Category 
AER 
(mg/24 hours) 
ACR (approximate equivalent) 
Related terms 
(mg/mmol) (mg/g) 
A1 <30 <3 <30 Normal to mild increase 
A2 30-300 3-30 30-300 Moderate increase * 
A3 >300 >30 >300 Severe increase 
AER, albumin excretion rate; ACR, albumin-to-creatinine ratio.*Relative to young adult level. 
(Adapted from KDIGO, 201222). 
 
Because of the complex nature of CKD, emphasis on well-defined disease 
classification and staging is paramount for optimal patient care. The evidence presented 
here elucidates several clinical unmet needs: for example, well-defined guidelines for 
use by primary care physicians, internists, and nephrologists; early identification, 
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prevention, and management of patients at risk for CKD (pre-CKD); “on-time” referral to 
a nephrologist when patients with early CKD are progressing to intermediate or 
advanced stages of CKD; optimal management for patients with confirmed CKD and 
those at risk for accelerated progression (eg, complex cases with multiple 
comorbidities); and educational programs and tools developed for primary care 
physicians, internists and nephrologists, to address a host of topics (eg, clinical 
guidelines, population-specific treatment, and management).  
Findings from experimental and clinical studies have suggested an important role 
for proteinuria in the pathogenesis of disease progression.28 Epidemiological studies 
have shown graded relations between increased albuminuria and mortality, and kidney 
outcomes in diverse study populations, in addition to, and independent of, low GFR and 
risk factors for cardiovascular disease.21,29,30 In view of these findings, an international 
conference recommended modification of disease classification to indicate prognosis by 
the addition of stages based on albuminuria, and an update of the 2002 guidelines 
(Figure I-4).20 
 
 
Figure I-4. Prognosis of chronic kidney disease by GFR and albuminuria. Colours show how 
adjusted relative risk is ranked for five outcomes from a meta-analysis of general population 
cohorts: all-cause mortality, cardiovascular mortality, kidney failure treated by dialysis and 
transplantation, acute kidney injury, and progression of kidney disease. For categories with GFR 
>15 mL/min per 1.73 m2 and albuminuria <2000 mg/g, ranks were averaged across outcomes. 
Mean rank numbers: 1–8=green, 9–14=pink, 15–21=orange, and 22–28=red. (Taken from Levey 
et al.,201220). 
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Kidney failure is traditionally regarded as the most serious outcome of CKD and 
symptoms are usually caused by complications of reduced kidney function. When 
symptoms are severe they can be treated only by dialysis and transplantation; kidney 
failure treated this way is known as end-stage renal disease (ESRD). Other outcomes 
include complications of reduced GFR, such as increased risk of cardiovascular disease, 
acute kidney injury, infection, cognitive impairment, and impaired physical function. 
Complications can occur at any stage, which often lead to death with no progression to 
kidney failure, and can arise from adverse effects of interventions to prevent or treat the 
disease.20 
 
 
2.2. Epidemiology of CKD 
According to the 2010 Global Burden of Disease study, CKD was ranked 27th in 
the list of causes of total number of global deaths in 1990 (age-standardised annual 
death rate of 15.7 per 100 000), but rose to 18th in 2010 (annual death rate 16.3 per 100 
000).31 An analysis of data on cause of death in the USA and Australia by Rao et al. 
(2012) showed that a substantial proportion of individuals who had died from diabetes 
had renal failure, but the cause of death was coded as diabetes without complication. 
Reported mortality from diabetes-related renal disease was estimated to be four to nine 
times less than the actual rate.32 
The incidence and prevalence of end-stage kidney disease differ substantially 
across countries and regions (Figure I-5). More than 80% of all patients receiving 
treatment for ESRD are estimated to be in affluent countries with large elderly 
populations and universal access to health care.33 The lowest bars reported from poor 
countries are largely due to patients not being accepted into renal replacement therapy 
(RRT) programmes, although where economies are growing, the numbers of patients 
being accepted for RRT are rising strikingly.34  
Projected worldwide population changes suggest that the potential number of 
cases of ESRD will increase disproportionately in developing countries, such as China and 
India, where the numbers of elderly people are expanding. This effect will be enhanced 
further if the trends of increasing hypertension and diabetes prevalence persist, 
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competing causes of death—such as stroke and cardiovascular diseases—are reduced, 
and access to treatment improves. In contrast to clinically apparent advanced-stage 
CKD, a precise calculation of the burden of less symptomatic or asymptomatic early-
stage chronic kidney disease, which accounts for 80–90% of all cases, is difficult.22 The 
estimates are usually based on a single-time measurement rather than on sustained 
demonstration of abnormality.  
 
 
Figure I-5. Annual incidence (A) and prevalence (B) rates of end-stage kidney disease in 
different countries. (Adapted from Jha et al., 2013 35). 
 
CKD is a debilitating disease affecting approximately 7% of all people aged 30 
years and older, which translates to more than 70 million people in developed countries 
worldwide.36 This number is likely to be much higher given the unknown prevalence in 
underdeveloped countries. The increased prevalence of diabetes, hypertension, and 
obesity and an aging population will perpetuate the rise of CKD.37,38 Patients have been, 
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and continue to be, diagnosed with CKD later in the disease cycle, and, therefore, they 
have to be prepared for life on dialysis or to undergo kidney transplant. However, with 
better screening, early management, and innovative pharmacologic therapies, the 
disease progression may be delayed and patients with CKD may enjoy healthier and 
more productive lives.39 Data from Portuguese Society of Nephrology40 shows the 
incidence in hemodialysis (HD) and peritoneal dialysis (PD) in last year 7 years, with an 
increase in last year (Figure I-6). 
 
 
Figure I-6. Global data of incidence of HD and DP in Portugal during 2007-2013. pmp, per 
million population (Taken from Portuguese Society of Nephrology40). 
 
Prevalence estimates for several modifiable risk factors affecting initiation and/or 
progression of disease have also increased. National Health and Nutrition Examination 
Survey 2001–2008 data report that diabetes, hypertension, cardiovascular disease, and 
congestive heart failure are more prevalent in patients with eGFRs, of 60 mL/min/1.73 
m2; additionally, the prevalence of hypertension is twofold and the prevalence of 
cardiovascular disease is fivefold greater compared with those with eGFR 60 
mL/min/1.73 m2. As the prevalence of diabetes, hypertension, and other risk factors 
rise, so does the severity of CKD. For example, the frequency of diabetes increased more 
than five times by CKD stage and eGFR category. Diabetes occurred in an estimated 7% 
of patients in stage 1/2, 18% of patients in early stage 3 (3a), 27% of patients in late 
stage 3 (3b), and 40% of patients in stages 4 and 5. Given the increase in CKD prevalence 
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and associated risk factors, more global epidemiological research is needed to better 
characterize the international burden of CKD. With improved patient-level definitions of 
CKD, large-scale epidemiological studies may present more adequately representative 
populations with CKD across countries.39 
 
 
2.3. Major pathophysiological contributors/complications associated to CKD 
Several factors contribute to the high risk of death in CKD (Figure I-7). Common 
risk factors for mortality in CKD patients include diabetes, hypertension, overweight, 
atherosclerosis, lipid disorders, smoking, and possibly salt and phosphate intake.41 Risk 
factors such as coronary artery disease and heart failure, left ventricular hypertrophy, 
electrolyte shifts, and vascular calcification might be important contributors to sudden 
death in CKD patients.42,43 
Cardiovascular disease is the single most common cause of death in patients with 
CKD and patients with late stage CKD (3b, 4 and 5) are at very high risk of cardiovascular 
events (eg, a 40-year-old dialysis patient has the same cardiovascular risk as an 80-year-
old patient without CKD). There is both an increased burden of traditional risk factors 
but also a constellation of novel risk factors. It appears that as CKD progresses, the 
associated CVD changes from typical atherosclerotic disease to a form of arterial 
stiffness is accompanied by structural heart disease so that dialysis patients die of 
similar causes as patients with advanced heart failure.44 Atherosclerosis is primarily a 
disease of the intima; although not a specific consequence of CKD, it is strongly 
aggravated by CKD.45 
Dialysis techniques cannot replace all the different physiological functions of the 
kidney. Dialysis-related factors, such as the use of central venous catheters for 
hemodialysis, increase the risk of death from infection and cardiovascular causes.46 
Transplantation related factors, such as the use of immunosuppressive drugs, 
increase the risk of infection and cancer and impair the cardiovascular risk profile.47 
These risk factors contribute to processes precipitating death. CKD results in accelerated 
ageing, particularly of the cardiovascular system.48  
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Uraemic toxins, including trimethylamine-N-oxide, have been linked to 
cardiovascular risk in the general population,49,50 whereas phosphate accumulation is 
thought to be a key driver of CKD mineral bone disorder.51 
 
 
Figure I-7. Pathophysiological links between potential contributors to mortality in CKD. 
Coloured lines represent a direct effect on mortality. Line thickness shows the magnitude of the 
effect. Dotted lines show a lesser effect than solid lines. *Diabetes, hypertension, overweight, 
atherosclerosis, lipid disorders, smoking, and possibly salt and phosphate intake. (Adapted from 
Ortiz et al., 201441). 
 
CKD induces a complex disturbance in mineral bone metabolism which is 
incompletely understood. As GFR falls, the kidney’s ability to excrete the phosphate 
absorbed in the diet is exceeded and hence serum phosphate starts to rise. This, in 
conjunction with reducing renal 1-hydroxylase activity (which converts 25-hydroxy-
vitamin D to the highly active 1,25-dihydroxy-vitamin D), leads to secondary 
hyperparathyroidism. Homeostatic PTH secretion is stimulated by high phosphate 
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concentrations, low concentrations of calcium and 1,25-dihydroxy-vitamin D, all 
attempting to normalize plasma calcium and phosphate. Although these biochemical 
changes may be evident in the later phases of stage 3 CKD, symptomatic bone disease 
(eg, with pain or pathological fractures) does not develop until patients have been on 
dialysis for many years. However, in children it has a significant effect on bone growth, 
mineralization and maturation at earlier stages of CKD. 
Currently, hyperphosphatemia is treated by dietary restriction and (when this is 
insufficient or unsuccessful) whith dietary phosphate binders which bind phosphate in 
the intestine and prevent its absorption. Some of the biochemical disturbances caused 
by CKD mineral bone disorder (CKD-MBD) are associated with mortality in dialysis and 
CKD patients. It is thought that this is mediated by vascular calcification which leads to 
arterial stiffening and structural heart disease. There is observational evidence that 
treatment of hyperphosphatemia with calcium-containing phosphate binders may in fact 
worsen vascular calcification (and hence increase the risk of cardiovascular disease) 
although trials are again lacking demonstrating a benefit of calcium-free phosphate 
binders over calcium.  
As the kidneys are central to acid-base balance, a metabolic acidosis develops 
which can interact with other complications (eg, worsen anemia, mineral bone disease 
and hyperkalemia). It is treated with oral sodium bicarbonate taken four times a day.52 
The sodium load of this treatment may worsen salt and water retention and hence 
hypertension; refractory acidosis is, therefore, one indication for starting dialysis. There 
are several other complications of CKD, such as hyperprolactinemia, low testosterone 
levels, sexual dysfunction, reduced fertility, erectile dysfunction, dysmenorrhea, 
neuropathy.44 
Sympathetic nerve activity, which contributes to hypertension and cardiovascular 
events, is markedly increased in CKD, due to activation of central sympathetic tone by 
diseased kidneys.53,54 Nocturnal hypoxemia due to sleep apnoea triggers sympathetic 
overactivity and is an independent predictor of cardiovascular death in patients on 
dialysis. Increased concentrations of asymmetric dimethyl arginine, an inhibitor of nitric 
oxide synthase, are associated with increased all-cause death. Both asymmetric 
dimethylarginine and sympathetic activity are part of the same pathophysiological 
pathway, which leads to an increased risk of death in CKD patients.55  
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The immune system is also altered in CKD. Innate immune activation leads to 
systemic inflammation whereas immune suppression predisposes to infection and 
cancer. Inflammation is associated with protein energy wasting and increased mortality. 
Left ventricular overload and excess sodium might be proinflammatory.41 
 
Table I-3. Common chronic kidney disease (CKD) risk categories and risk factors. 
Risk category Risk factors 
Susceptibility Older age, reduction in kidney mass, low birth weight, family history 
of CKD, US racial or minority status 
Initiation Diabetes, hypertension, autoimmune disease, systemic infections; 
urinary tract infections, stones, or obstruction; drug toxicity 
Progression Higher proteinuria, hypertension, poor glycemic control in 
diabetes, smoking, obesity, dyslipidemia, cardiovascular disease, 
high dietary-protein intake, decreased nephron number 
End-stage decline Lower dialysis dose, temporary vascular access for hemodialysis, 
anemia, lower serum albumin, late referral to nephrologist, mineral 
and bone disorders, metabolic acidosis 
Note: Modifiable risk factors are presented in bold. (Taken from Braun et al., 201239). 
 
The intertwined nature of risk factors and comorbid illnesses complicates the 
characterization of CKD. These terms are often used interchangeably due to the 
continuous and progressive nature of this disease. Some patients may have risk factors 
for developing CKD, while others may have risk factors contributing to the progression of 
CKD. Some comorbid illnesses are risk factors for both the initiation and the progression 
of disease. However, some risk factors are simply nonmodifiable patient characteristics. 
Table I-3 presents common risk categories and associated factors. As noted, some 
conditions fit across categories and the presence of multiple risk factors and/or 
comorbid illnesses leads to progression of CKD and increased mortality. Importantly, 
several of the debilitating risk factors and comorbidities are modifiable, and disease 
progression may be delayed with active patient–clinician collaboration and appropriate 
treatment.39 More attention to and early active management of modifiable risk factors 
and comorbidities are necessary to thwart rapid disease progression. 
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3. Anemia secondary to stage 5 of CKD 
3.1. Erythropoiesis and cytokine regulation  
In mammals, definitive erythropoiesis occurs first in the fetal liver with 
progenitor cells from the yolk sac.56 Within the fetal liver and the adult bone marrow, 
hematopoietic cells are formed continuously from a small population of pluripotent 
stem cells that generate progenitors committed to one or a few hematopoietic lineages 
(Figure I-8). In the erythroid lineage, the earliest committed progenitors identified ex 
vivo are the slowly proliferating burst forming unit-erythroid (BFU-E). Early BFU-E cells 
divide and further differentiate through the mature BFU-E stage into rapidly dividing 
colony-forming unit-erythroid (CFU-E).57 CFU-E progenitors divide 3 to 5 times giving rise 
to pro-erythroblast, the first erythrocyte precursor that will differentiate in different 
erythroblasts, undergoing many substantial changes, including a decrease in cell size, 
chromatin condensation, hemoglobinization, and enucleation, giving rise to the 
reticulocyte that will mature into the erythrocyte. 
A primary function of RBCs is to transport O2 from the lungs to O2-dependent 
tissues. Changes in O2 levels may lead both acute and long-term physiologic adaptations 
that might include an increase in respiratory and heart rate, vasoconstriction, and 
changes in blood volume. Erythropoiesis is a longer-term adaptation to boost O2-
carrying capacity by increasing the concentration of RBCs, and thus, hemoglobin (Hb) 
concentration. RBCs are the most abundant (99%) circulating cells in the bloodstream, 
representing 40% to 45% of total blood volume. In a healthy human with approximately 
5L blood, this represents approximately 2.5x1013 cells, a quantity substantial enough to 
provide the large O2 transport capacity needed to support aerobic respiration. In 
humans, the RBC lifespan is ∼100 to 120 days, with a daily loss of 0.8% to 1.0% of 
circulating RBCs. To match this loss, the body assumes a normal, prodigious production 
capacity of 2.5x1011 cells/day. RBC production results from a tightly controlled 
proliferation and differentiation pathway (Figure I-8). Early hematopoietic progenitors 
differentiate into burst-forming unit–erythroid cells, in which EPORs appear for the first 
time; however, EPO is not required at this stage.58 
Burst-forming unit–erythroid cells differentiate into colony-forming unit–
erythroid cells, which are dependent on EPO for survival, and there is a corresponding 
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rise in expression of EPORs.59,60 Continued stimulation with EPO triggers differentiation 
into erythroblasts, which enucleate to form reticulocytes and after a few days show loss 
of reticulin, resulting in RBCs. Reticulocytes and RBCs stop expressing EPOR and cease 
being responsive to EPO.60 
 
 
Figure I-8. Schematic diagram of the process of erythropoiesis. The various stages of erythroid 
differentiation are shown including the key cytokines that are involved in the proliferation, 
survival and differentiation of the erythroid progenitors. (Taken from Sinclair 2013 61). 
 
Erythropoietin is essential for the survival, proliferation, and differentiation of 
erythrocyte progenitors in bone marrow. Erythrocyte production is continuously 
adjusted to regulate the loss of senescent red blood cells and to guarantee optimal 
tissue oxygenation. Erythropoiesis is regulated by several cytokines, such as  granulocyte 
colony-stimulating factor (G-CSF), interleukin 6 (IL-6), stem cell factor (SCF), IL-1, IL-3, IL-
4, IL-9, IL-11, granulocyte macrophage colony-stimulating factor (GM-CSF), insulin- like 
growth factor (IGF-1), and, of course, EPO.62  
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The normally low concentration of EPO enables only a small percentage of 
progenitors to survive and proliferate, whereas the remaining progenitors undergo 
apoptosis. In contrast, when the concentration of EPO rises in blood (either 
endogenously or exogenously), many more burst-forming unit erythroid (BFU-E) and 
CFU-E escape from apoptosis and proliferate to result in the growth and maturation of 
proerythroblasts.63 
EPO acts synergistically with SCF, GM-CSF, IL-3, IL- 4, IL-9, and IGF-1 to induce red 
cell precursors to proliferate and mature from the stage of BFU-E and CFU-E cells to the 
normoblast stage.58,64 Thus, EPO is the critical growth factor that acts on bone marrow 
erythroid progenitor cells to prevent them from undergoing apoptosis.62  
A reduction in the number of red blood cells does not directly stimulate EPO 
synthesis and release. Instead, EPO production is controlled by the systemic availability 
of oxygen in a tightly regulated feedback loop. The oxygen-dependent control of EPO 
formation requires sensing mechanisms that perceive changes in the oxygen supply and 
translate them into alterations of EPO gene activity in the liver and kidneys. These 
mechanisms are the key element in the feedback control of erythropoiesis and are 
sensitive to conditions that affect arterial pO2 and tissue and venous pO2. EPO levels 
remain constant under physiological conditions, whereas in anemias and reduced renal 
oxygen supply EPO secretion increases with a resultant enhancement of erythrocyte 
production.65 In contrast, decreased EPO concentrations are typical of conditions with 
an increased oxygen supply or a reduced oxygen demand.66 
Erythropoiesis primarily occurs in the kidney, but other organs (liver, brain) also 
produce EPO. Interstitial fibroblasts produce EPO in the kidney, while hepatocytes 
produce EPO in the liver. Initially, EPO is synthesized as a 193-amino-acid precursor. A 
27-amino-acid signal peptide and C-terminal arginine are removed, and carbohydrate is 
added to three N-linked glycosylation sites and one O-linked glycosylation site. The 
secreted protein contains 165 amino acids and is heavily glycosylated, with 40% of its 
mass composed of carbohydrate. The structure of EPO is a compact globular bundle that 
contains four  helices. 
Generally, serum EPO concentrations of 10 to 25 mU/mL maintain Hb levels 
within the normal range of 12 to 17 g/dL. The terminal half-life (t ½ ) of EPO is ∼5 hours, 
which requires an average EPO production rate of 2 U/kg/day. The EPO production rate 
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per cell appears constant, with fluctuations in EPO synthesis resulting from changes in 
the number of cells producing the molecule. In cases of severe anemia, circulating EPO 
levels can increase up to 1000-fold because of a logarithmic increase in the number of 
cells producing EPO. Other factors affecting EPO levels and, therefore, erythropoiesis, 
include iron availability, nutritional status, disease or comorbidities, environmental 
conditions, and genetic factors (congenital polycythemias).57 
A direct correlation exists between RBC production and serum EPO 
concentrations. However, the rate of erythropoiesis change (4-fold) is small compared 
to the larger change in EPO concentrations (1000-fold).67-69 Thus, the magnitude of the 
increase in RBC concentration is primarily controlled by the length of time EPO 
concentrations are maintained, and not by the EPO concentration level per se (Figure I-
9).  
 
Figure I-9. Disproportion between half-life of recombinant human erythropoietin and lifespan 
of red blood cells. MEC, minimum effective dose (Taken from Elliott et el., 200857). 
 
Increased EPO synthesis has a prolonged effect due to the disproportionate 
relationship between EPO t ½ and RBC lifespan. Thirty minutes of hypoxia can result in 
production of EPO (t ½5 hours).70 In turn, EPO stimulates formation of enucleated 
reticulocytes (t ½ 51–5 days), which rapidly mature into RBCs that have a long lifespan 
(100-120 days). Thus, a short duration of EPO exposure results in a prolonged increase in 
RBC concentration.57 
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3.1.1. Erythropoietin receptor signaling 
EPO promotes the viability, proliferation and differentiation of mammalian 
erythroid progenitor cells via signals transduced by the specific cell surface EPO receptor 
(EPOR). The EPOR is a 508 amino acid protein and is a member of the cytokine receptor 
superfamily. Bone marrow erythroid progenitors are the major EPO target cells. During 
erythroid differentiation, cells become progressively more sensitive to EPO due to the 
appearance of EPORs, with late progenitors CFU-E and proerythroblasts having the 
highest EPOR expression (1000 receptors/cell).71,72 Interestingly, normal levels of 
progenitors are still observed, indicating that EPOR signaling is dispensable at the earlier 
stages of erythropoiesis, including BFU-E formation.58 Upon EPO binding, preformed 
receptor dimers undergo a conformational change which activates three major signal 
transduction pathways (JAK-STAT, PI3K-Akt, Ras-MAPK) (Figure I-10).73  
 
 
Figure I-10. EPO signaling pathways. The three main EPO signaling pathways are highlighted. 
(Adapted from Hodges et al., 2007 74). 
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As shown in Figure I-10, EPO binding causes the intracellular activation of EPOR-
associated Janus kinase 2 (JAK-2). In turn, JAK-2, EPOR and other signaling proteins are 
tyrosine-phosphorylated.75 Further, JAK-2 is an essential chaperone for transferring 
EPOR to the cell surface 76. The phosphorylated EPOR provides docking sites for proteins 
containing SRC homology 2 (SH2) domains. As referred, EPOR signaling involves signal 
transducers and activators of transcription, such as STAT-5, phosphatidyl-inositol 3-
kinase (PI-3K)/AKT (protein kinase B), and SHC/mitogen-activated protein kinase 
(MAPK). The action of EPO is terminated when the EPOR is dephosphorylated by the 
tyrosine phosphatase SHP-1 (Src homology phosphatase-1) and the EPO/EPOR-complex 
is internalized. In vitro studies suggest that about 60% of EPO is resecreted, and 40% 
undergoes proteasomal degradation after internalization.77 EPOR mediated EPO uptake 
by its target cells is considered a major mechanism of the degradation of circulating 
EPO.78 
 
 
3.1.2. Oxygen sensing pathway 
EPO production is primarily stimulated by hypoxia, which, depending on severity, 
increases serum EPO levels up to several hundred-fold.79 Hipoxia inducible factor (HIF) is 
a heterodimeric basic helix-loop-helix (bHLH) transcription factor that belongs to the PAS 
(PER/aryl hydrocarbon receptor nuclear translocator (ARNT)/single minded (SIM)) family 
of transcription factors. It consists of an O2-sensitive α-subunit and a constitutively 
expressed β-subunit, also known as the aryl hydrocarbon receptor nuclear translocator 
(ARNT).80-82 Three HIF α-subunits are known, HIF-1α, HIF-2α and HIF-3α. HIF-1 was first 
isolated from human Hep3B hepatoma cells sing DNA sequences that were derived from 
the 3′-hypoxia enhancer of the EPO gene.83,84 Together with HIF-2α (also known as 
endothelial PAS domain protein 1 (EPAS1) or HIF like factor, (HLF)), HIF-1α facilitates O2 
delivery and cellular adaptation to hypoxia by stimulating a wide spectrum of biological 
processes that include angiogenesis, anaerobic glucose metabolism, mitochondrial 
biogenesis and others.85 HIF-regulated genes are induced following the binding of HIF 
heterodimers to specific DNA consensus sequences and recruitment of transcriptional 
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co-factors. HIF-specific DNA elements are found in the regulatory regions of many O2-
sensitive genes and are referred to as hypoxia-response elements (HREs) (Figure I-11).  
 
 
Figure I-11. EPO is HIF-2-regulated. Shown is an overview of EPO gene regulation by HIF-2.The 
VHL-E3-ubiquitin ligase complex targets hydroxylated HIF-2α for proteasomal degradation. 
Hydroxylated HIF-α binds to the β-domain of VHL. The C-terminal α-domain links VHL to the E3-
ligase via elongin C. HIF-2α hydroxylation is carried out by O2- and iron-dependent HIF prolyl-4-
hydroxylases (HIF-PHD). In the absence of molecular O2, HIF-2α, which is constitutively 
synthesized, is no longer degraded and translocates to the nucleus where it forms a heterodimer 
with HIF-β. HIF-2α/β heterodimers bind to the HIF consensus binding site 5′-RCGTG-3′ and 
increase EPO transcription in the presence of transcriptional coactivators, such as CREB-binding 
protein (CBP) and p300. Hypoxic induction of EPO in the liver is mediated by the liver-inducibility 
element located in the 3′-end of the EPO gene. The hypoxic induction of EPO in REPC requires 
the kidney inducibility element. Nitric oxide, reactive O2 species, succinate and fumarate, cobalt 
chloride and iron chelators such as desferrioxamine inhibit HIF-PHDs, which results in increased 
EPO transcription. CoCl2, cobalt chloride; Fe2+, ferrous iron; HNF4, hepatocyte nuclear factor 4; 
NO, nitric oxide; ROS, reactive oxygen species; ub, ubiquitin (Taken from Haase, 201386). 
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While hypoxic suppression of certain genes has been found to be associated with 
HIF-1 and/or HIF-2 activation, it is unlikely that HIF acts as a direct transcriptional 
repressor.87 Under normoxia, all three HIF α-subunits are targeted for rapid proteasomal 
degradation by the von Hippel–Lindau tumor suppressor (VHL), which acts as the 
substrate recognition component of an E3 ubiquitin ligase.88,89 Whereas HIF-1 and HIF-2 
heterodimers function as transcriptional activators, splice variants of HIF-3α have been 
shown to be inhibitory.90,91 Although HIF-1 and HIF-2 share many transcriptional targets, 
certain genes and processes do not appear to be co-regulated. For example, anaerobic 
glycolysis appears to be predominantly controlled by HIF-1, whereas EPO synthesis and 
iron metabolism have emerged as HIF-2-regulated processes.92-95 
Under normal O2 conditions HIF-α-subunits are rapidly degraded following 
ubiquitylation by the VHL-E3 ubiquitin ligase complex, precluding the formation of 
transcriptionally active heterodimers. VHL-mediated poly-ubiquitylation requires 
hydroxylation of specific proline residues (Pro402 and Pro564 in human HIF-1α; Pro405 
and Pro531 in human HIF-2α), which are localized within its O2-dependent degradation 
domain (ODD).96-99 Hydroxylation of HIF-α is carried out by three major 2-oxoglutarate 
(2OG)-dependent oxygenases (prolyl-4-hydroxylase domain (PHD) proteins), PHD1, 
PHD2 and PHD3, also known as egl nine homolog (EGLN) 2, EGLN1, and EGLN3, 
respectively. These enzymes belong to a larger family of proteins, in humans there are 
over 60 members, which couple the oxidative decarboxylation of 2OG to various 
chemical processes, which aside from O2-sensing, include collagen synthesis and fatty 
acid metabolism. In mammals, these reactions produce succinate and CO2 and appear to 
be limited to hydroxylation and demethylation initiated by hydroxylation.100 HIF 2OG 
oxygenases function as O2 sensors as they require molecular O2 for catalysis. Under 
hypoxia, hydroxylation is inhibited and HIF signaling is activated.101 
To add complexity to the regulation of this pathway, HIF increases transcription 
of PHD2 and PHD3. Furthermore, protein turnover of PHD1 and PHD3 is hypoxically 
regulated by Siah proteins, which themselves are hypoxia-inducible. All three PHDs are 
expressed in the kidney where they control HIF activity.102,103 
The transcriptional activity of HIF is modulated by a second hypoxic switch, which 
operates within the carboxy-terminal transactivation domain of HIF-α. The factor 
inhibiting HIF (FIH) is a 2OG oxygenase that catalyzes the hydroxylation of an asparagine 
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residue within the C-terminal transactivation domain of HIF-α, thereby inhibiting the 
binding of co-activators CREB-binding protein (CBP) and p300 to the HIF transcriptional 
complex. Conversely, FIH inactivation facilitates CBP/p300 recruitment and results in 
increased HIF target gene expression under hypoxia. In the kidney, FIH has been 
detected in renal EPO-producing cells (REPC), podocytes and in the distal tubule.104,105 
While the role of PHDs and FIH in the regulation of HIF activity is well established, 
alternative hydroxylation targets have been identified and are likely to have impact on 
hypoxia and EPO responses in the kidney.106,107 Furthermore, it is likely that renal EPO 
synthesis is modulated by epigenetic changes that are carried out by non-HIF 2OG 
oxygenases. Although nothing is known about their role in renal physiology, 2OG 
oxygenases, catalyze the demethylation of methylated histones, and are likely to provide 
additional functional links between alterations in renal pO2 levels and gene expression. 
101,108 Although in vitro approaches identified HIF-1 as the transcription factor 
responsible for the hypoxic induction of EPO,101 HIF-2 has now emerged as the main 
regulator of EPO production in vivo. 86 
 
 
3.2. Stage 5 of anemia of CKD  
3.2.1. Diagnosis and definition 
The definition of anemia in CKD patients has been changing across guidelines 
over the last few years. In 2004 the Revised European Best Practice Guidelines on 
Anemia indicated as a definition for anemia in CKD the following: “In patients living 
below 1500 m, Hb values were considered below normal if they were <11.5 g/dL in 
women and <13.5 g/ dL in men (<12 g/dL in those aged >70 years)”.109 This definition 
had the advantage of differentiating the definition of anemia between older or younger 
males but did not differentiate between post-menopausal and younger women. It had 
perhaps the disadvantage of missing anemia diagnosis in male patients >70 years, given 
a relatively low threshold in this category. 
In 2006 the KDOQI guidelines on anemia suggested that the diagnosis of anemia 
should be made, and further evaluation should be undertaken, when Hb concentrations 
were <13.5 g/dL in adult males and <12.0 g/dL in adult females.110 This definition was 
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obtained from the mean Hb of the lowest fifth percentile of the sex-specific general 
adult population and assumes a lack of adjustment downward for age in males and an 
adjustment upward for iron deficiency in females.110 This definition is simple and easy to 
remember, increasing the likelihood that physicians may apply it in everyday clinical 
practice. 
The new KDIGO suggestion22 is based on the World Health Organization (WHO) 
definition of anemia.111 It is true that this definition has been applied across populations, 
but it also true that it has been derived from very few data using older methodologies by 
a WHO expert committee.112 Its primary aim was to screen for malnutrition and it is 
therefore perhaps inappropriately applied to the general population of developed 
countries, and especially so for a population of patients affected by a chronic disease. 
Given that the majority of the European population is of Caucasian ethnicity, it should 
also be taken into account that Caucasian men have an Hb set point that is 1–2 g/dL 
higher than African Americans.113 Similar differences have been described between 
Caucasian, African American and Asian women. According to the Scripp-Kaiser database, 
the lower limit of normality of Hb values should be of 13.7 g/dL for Caucasian men aged 
between 20 and 60 years and 13.2 g/dL for older men. For women of all ages the set 
point should be 12.2 g/dL.114 
 
 
3.2.2. Etiology 
Although anemia in patients with CKD may develop in response to a wide variety 
of causes, erythropoietin deficiency is the primary cause of anemia associated with CKD. 
Erythropoietin is the hormone responsible for maintaining the proliferation and 
differentiation of erythroid progenitor cells in the bone marrow. Loss of peritubular cells 
leads to an inappropriately low level of circulating erythropoietin. Other factors in the 
genesis of renal anemia include functional or absolute iron deficiency, blood loss (either 
occult or overt), the presence of uremic inhibitors (for example, parathyroid hormone, 
inflammatory cytokines), reduced half-life of circulating blood cells, and deficiencies of 
folate or Vitamin B12.115 
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3.2.2.1. Insufficient erythropoietin production 
A reduced production of erythropoietin (EPO) is the main cause of the 
development of renal anemia. The main stimulus to increase synthesis of EPO is tissue 
hypoxia, which normally leads to an exponential increase in serum EPO levels.116,117 This 
feedback is affected in patients with pathological conditions involving the kidneys, as the 
developing anemia is not adequately compensated by a sufficient increase in the EPO 
production.118-120 
Normal serum EPO concentrations in humans vary between 10 to 30 mU/mL (2 
to 7 pmol/L), as determined by radioimmunoassay. EPO concentrations are increased 
under a variety of conditions, largely reflecting alterations of oxygen delivery to tissues. 
The expected compensatory response to anemia is an increased rate of erythropoiesis, 
with an inverse relationship between the concentration of the hormone and the Hb 
concentration.121 Although the anemia of chronic renal failure is a complex disorder in 
which many factors may play a role, the main defect is absolute or relative EPO 
deficiency. In most patients with substantially impaired renal function, EPO production is 
impaired at any given hematocrit concentration.122 Why EPO production remains 
inappropriately low in patients with CKD remains unclear, this could be because the 
EPO-producing cells are lost, because they experience higher levels of oxygen for a given 
hematocrit level, or because the relationship between local oxygenation and EPO 
production is altered.123 Several lines of evidence suggest that diseased kidneys are 
hypoxic and that this chronic decrease in oxygen availability, in fact, may contribute to 
disease progression.124 A defect in EPO synthesis, rather than a lack of the hypoxic 
stimulus, may lead to the failure of EPO production.  
 
 
3.2.2.2. Disturbances in iron metabolism 
Iron deficiency, or its limited availability for erythropoiesis, is an important 
pathogenetic mechanism for the development of renal anemia. Hepcidin is currently 
believed to play a crucial role in the regulation of iron metabolism. This hormone was 
discovered by Krause et al. (2000)125 and independently by Park et al. (2001).126 
Bioactive hepcidin is composed of 25 amino acids and is synthesized mainly in 
hepatocytes (Figure I-12). The regulation of iron absorption and its distribution into the 
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tissues is mediated by regulation of the expression of its receptor, ferroportin, which is 
known to be the sole cellular iron exporter. 
 
 
Figure I-12. Molecular and functional pathways of hepatocyte hepcidin synthesis. Three 
molecular pathways can be distinguished: the HFE/TfR2, BMP/SMAD, and JAK/STAT. This 
proposed model depicts 2 iron signals to hepcidin, 1 mediated by intracellular iron stores (Fe) 
and the other by circulating iron (Tf-Fe2). Hepatocellular iron stores increase the expression of 
BMP-6, which serves as an autocrine factor by interacting with surface BMP receptors. HJV is a 
BMP coreceptor that augments BMP binding. The consequent activation of intracellular SMAD 
proteins transduces a signal to increase hepcidin transcription. HJV is subject to cleavage by 
furin, which is regulated by iron and hypoxia, to form a soluble component (sHJV) 127. sHJV can 
subsequently act as a decoy coreceptor and antagonist of BMP-6 induced hepcidin synthesis. 
Under low iron conditions membrane bound HJV is also cleaved by matriptase-2 (scissors) again 
weakening the BMP-6 signal. Extracellular Tf-Fe2 mediates a second iron signal. In this scheme, 
Tf-Fe2 displaces HFE from TfR1. HFE is then liberated to interact with TfR2. The HFE–TfR2 
complex activates hepcidin transcription via BMP/SMAD signaling. Several studies have provided 
indirect evidence for the involvement of the hepatic ERK/MAPK signaling pathway in hepcidin 
regulation by iron through TfR2 and/or HFE.128 Hypoxia influences liver-specific stabilization of 
HIF-1, which induces matriptase-2 and the subsequent cleavage of HJV 129. The latter pathway 
may be synergistic to the increased release of sHJV upon its cleavage by furin under hypoxic 
conditions. Erythropoiesis is controlled in part by EPO production in the kidney and 
communicates with the hepatocyte by the proteins GDF15 and TWSG1, which inhibit the 
BMP/SMAD signaling to hepcidin. Inflammatory stimuli, such as IL-6, induce hepcidin synthesis 
through the janus kinase/signal transducer and activator of transcription-3 (JAK/STAT) pathway. 
These pathways have recently been reviewed.128 pO2, partial oxygen pressure; sTfR: soluble TfR; 
BMPR, BMP receptor; IL-6R: IL-6 receptor. (Taken from Kroot et al., 2011130). 
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Hepcidin synthesis is induced by excess iron levels or inflammation, while it is 
inhibited by increased erythropoiesis or hypoxia. Increased hepcidin levels are known to 
block iron absorption from food in the intestines and its release from iron stores. The 
activation of erythropoiesis logically leads to the suppression of hepcidin production and 
subsequent mobilization of iron from its stores. Synthesis of hepcidin is stimulated by 
proinflammatory cytokines, in particular IL-6.131 However, based on current knowledge, 
the evaluation of hepcidin for the diagnosis of iron deficiency in dialyzed patients is not 
used in routine clinical practice.132  
Daily iron loss is small in normal individuals. Iron is lost by the desquamation of 
skin epithelial cells, intestinal tract mucosa, growth of hair and nails, and through the 
bile, sweat, and urine. The total iron loss in adult males as measured by radioisotope 
techniques is 0.5 to 1.5 mg daily. The expected daily iron loss in women is higher than in 
men.133 Under normal circumstances, physiological iron loss is fully compensated by iron 
reabsorption from food. In dialyzed patients, however, physiological iron loss is 
increased by a number of other circumstances that could easily induce iron deficiency. 
The main factor that leads to iron deficiency in dialyzed patients is excessive blood loss 
during dialysis, especially the significant amount of residual blood that remains inside 
the dialyzer, dialysis sets, and needles after each hemodialysis. It is generally accepted 
that the average annual loss of iron in dialyzed patients is 1.5-2.0 g.133,134 
The normal daily intake of iron is 10 to 15 mg and the maximum absorption is 
about 20%. Therefore, the amount of iron that the body of dialyzed patients can absorb 
from regular food is not able to compensate for these substantial losses. Thus, dialyzed 
patients, who receive no iron supplementation therapy, can very easily develop a 
negative iron balance and depletion of tissue iron stores.135,136 The body of a healthy 
adult normally contains 4-5 g of iron. Iron deficiency is defined as a condition where the 
amount of iron in the body decreases to a level that is characterized by a depletion of 
iron stores in bone marrow, liver and spleen and it, usually, develops when occurs an 
imbalance between the iron supply to the tissues and the real needs.133  
Under normal circumstances, storage iron accounts for approximately 30% of the 
body’s total iron, and it is stored in the macrophages of the reticuloendothelial system, 
the bone marrow, liver, and spleen, and in the liver parenchymal cells. Iron is stored as 
ferritin or as hemosiderin. Ferritin is composed of an inorganic core called holoferritin, 
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which is surrounded by a protein envelope. Hemosiderin granules are large aggregates 
of ferritin molecules with higher iron content. Hemosiderin further contains fats and, 
unlike ferritin, it is soluble in water. Under normal circumstances, iron is primarily stored 
as ferritin, and the ferritin/hemosiderin ratio is 60:40.120  
To evaluate the functional iron status, we can use a variety of other laboratory 
parameters, such as iron plasma concentrations (pFe), transferrin, and transferrin 
saturation (TSAT), ferritin and soluble transferrin receptors. Low pFe levels may have 
different causes and in differential diagnosis is very important to differentiate low pFe 
levels due to an actual iron deficiency from reactive hyposideremia due to a disturbed 
iron absorption or iron mobilization, as is the case in infectious processes, tissue 
damage, and malignant tumors.137 Organic and ionized forms of iron are highly toxic and 
rather insoluble and, for this reason, the transport of iron in the body is bound to a 
protein component, transferrin. Transferrin is a glycoprotein with a molecular weight of 
79550 Da. The main site of transferrin production is the liver. Transferrin has two 
binding sites for iron, which allow the existence of apoferric, or diferric transferrin.  In 
addition to iron bound in the oxidized form, transferrin can, also, bind other metal ions, 
of which binding to aluminum may have adverse effects on the erythropoiesis in 
dialyzed patients. In patients with sideropenic anemia, the ability of the serum to bind 
iron is increased, and iron deficiency leads to an icrease in the synthesis of transferrin. 
Transferrin is known to control the internal transfer of iron from the site of absorption 
to the places of iron consumption or storage, and back, when utilizing the iron released 
from macrophages or from the disintegrating red blood cells.138 Circulating iron bound 
to transferrin in the plasma is transported into cells via receptors expressed on the cell 
membranes, triggering receptor-mediated endocytosis. In the acidic environment of the 
cell endossoma, iron is released from transferrin and in the mitochondria, after 
reduction by mitochondrial ferrochelatase, is incorporated into the heme. The final 
phase is exocytosis of apotransferrin back into the blood plasma. Iron deficiency results 
in a compensatory increase in the number of transferrin receptors in the erythroid cells. 
The serum concentration of these transferrin receptors is also increased and its 
evaluation is already performed in hematologic studies, as its value is independent of 
inflammation, unlike transferrin and ferritin.139 Since pFe and transferrin are subject of 
numerous reactive changes under various pathological conditions, the relationship 
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between these two values, known as TSAT, is considered to be a more accurate indicator 
of the metabolic status of iron. Under physiological conditions, the binding capacity of 
transferrin is 20-45% saturated with iron. Decreased transferrin saturation is one of the 
indicators of iron deficiency. Iron is most efficiently uptaken by erythroblasts at 30-60% 
transferrin saturation. If the saturation exceeds 60%, iron is stored in the mononuclear 
phagocyte system cells.135  
 
 
3.2.2.3. Other factors contributing to the development of anemia  
Several other factors have been identified that may further exacerbate anemia in 
patients with impaired renal function, such as inflammatory processes or tumors, 
vitamin B12 and folic acid deficiencies, drugs or uremic inhibitors of erythropoiesis.  
Suppression of erythropoiesis occurs during severe infectious processes, 
inflammatory diseases, and malignancies. Inflammation is often accompanied by 
malnutrition and both have a significant role in the development of anemia, usually 
known as the MIA syndrome (malnutrition, inflammation and anemia). The main causes 
are: increased production of cytokines, such as, IL-1, IL-6, TNF-alpha and interferon-
gamma that block the release of iron from iron stores (through an increase in hepcidin 
synthesis triggered by IL-6), reduce the production of endogenous EPO, and inhibit 
erythropoiesis. Inflammation increases iron uptake within cells of the reticuloendothelial 
system. This leads to limitation of iron availability for erythroid progenitor cells and 
subsequently to decreased erythropoiesis. A key role in this chronic inflammation-
related anemia is played by hepcidin, whose synthesis and serum levels increase up to 
100-fold during inflammation. In the laboratory, this condition is confirmed by increased 
serum ferritin concentrations, and reduced pFe, transferrin levels and TSAT.140,141  
In patients with renal disease, reduced intravascular survival of red blood cells is 
caused by chronic hemolysis, which is the result of accumulation of hypothetical uremic 
toxins in the blood. The most important uremic toxins in the pathophysiology of renal 
anemia are polyamines, such as spermine, spermidine, putrescine and cadaverine. 
Polyamines are organic cations involved in cell growth and maturation that reduce the 
proliferative activity of erythroid cells in the bone marrow by a direct toxic effect that is 
independent on their interaction with EPO.142 Renal anemia may be exacerbated by a 
|  Introduction 
Resistance to rHuEPO therapy - studies in experimental models of anemia and CKD|  33 
lack of folic acid or vitamin B12. Deficiency of vitamin B12 or folic acid is uncommon, 
occurring in less than 10% of dialyzed patients; in these cases, the anemia has a 
macrocytic pattern. Folic acid deficiency may occur particularly in dialyzed patients, 
because folic acid is dialyzable; serum folate levels are also decreased after dialysis. The 
loss of folic acid during the dialysis outweighs the loss of folic acid in the urine of normal 
people, which is about 10 g/24h. The minimum recommended daily dose of folic acid in 
dialyzed patients is 50 g.143,144 
A decrease in hemoglobin levels may occur in aluminum intoxication. The anemia 
induced by the accumulation of aluminum has a microcytic and hypochromic pattern. 
Aluminum competes with iron for the binding on the transferrin molecule, increasing its 
binding to free receptors, in particular in patients with iron deficiency. In addition, 
aluminum has been demonstrated to suppress the cytosolic uroporphyrinogen 
decarboxylase and mitochondrial ferrochelatase, disturbing heme synthesis.145  
Hypoproliferative anemia may also be exacerbated by fibrous osteodystrophy, 
which is usually caused by severe secondary hyperparathyroidism.146 Excessive 
parathormone levels are known to reduce EPO production, increase hemolysis, and 
suppress progenitor of red blood cell line in the bone marrow.147  
Anemia may be further aggravated by drugs, particularly by ACE inhibitors. ACE 
inhibitors suppress the synthesis of erythropoietin in a dose-dependent manner via 
enhanced oxygenation in the peritubular region due to decrease in vascular resistance in 
efferent arterioles, decreased serum concentration of IGF-1 and increased apoptosis of 
progenitor erythroid cells CD34+.148,149  
Drugs are an important contributor to anemia in recipients of renal allografts. 
After kidney transplantation anemia is a highly prevalent disorder affecting 
approximately 40% of patients and has been associated with a decline of graft function. 
Immunossuppressors play an important additional role. Azathioprine, mycophenolate 
mofetil and mycophenolate sodium have a direct antiproliferative effect on bone 
marrow cells. Sirolimus and everolimus (mTOR inhibitors) can lead to microcytic anemia. 
Cyclosporine A and mTOR inhibitors are known to induce hemolytic uremic syndrome 
and hemolytic anemia in transplant patiens. Another immunosuppressive agent, 
antithymocyte globulin (ATG) can decrease hemoglobin concentration via toxic effect on 
bone marrow.150  
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3.3. Treatment of anemia in CKD - The KDOQI and KDIGO guidelines 
Renal anemia is treated by erythropoiesis-estimulanting agents (ESAs), to 
stimulate red blood cell production, and with iron supplementation, as 
recommended.109 Iron is a crucial element of treatment, whether to address absolute 
iron deficiency (a lack of stored iron characterised by low TSAT <20% and serum ferritin 
levels below <100 ng/ml) or functional iron deficiency (inadequate release of iron from 
iron stores, characterised by low TSAT <20% and serum ferritin levels above 100 
ng/ml).151 Previous treatment guidelines issued by the National Kidney Foundation 
Kidney Disease Outcomes Quality Initiative (NKF KDOQI) recommended that iron 
supplementation therapy should be sufficient to maintain iron stores, prevent iron-
deficient erythropoiesis and achieve and maintain target haemoglobin levels. Whilst 
delivery of iron by the intravenous (i.v.) route was regarded as optimal for patients on 
hemodialysis, for those not requiring hemodialysis both oral and i.v. administration were 
deemed appropriate.110 Oral iron is self-administered at home, whereas i.v. iron must be 
administered by a healthcare professional. The regimens for administration of i.v. iron 
highlight how treatment of renal anemia in people not requiring hemodialysis can 
impact on their life. Limitations on the maximum dose of iron administered by i.v. 
injection can mean that administration is divided over several appointments over a 
period of one to five weeks. Depending on the preparation, appointments may reach 
four hours in duration, partly due to restrictions on the rate of injection and, in some 
cases, requirement for a test dose or postdose observation period. These test doses and 
observation periods stem from the possibility for anaphylactic reactions with i.v. iron 
preparations; these are of particular concern in high molecular weight iron dextran 
formulations, although warnings are found in the prescribing information of many 
formulations.152 Put into the context of a patient’s daily routine, the implication of these 
regimens is that, as well as the time spent being treated, a patient must spend time 
travelling to and from the clinic or hospital at which treatment is administered. This 
must be repeated for as many appointments as is necessary for the patient to receive 
the appropriate total dose of iron to replenish their iron stores; and then again, in the 
future, when iron levels require further repletion. However, it is important to balance 
these implications with the potential benefits of i.v. iron. For example, a recent meta-
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analysis highlighted that up to 60% of people with CKD not undergoing hemodialysis can 
reach their haemoglobin target and maintain it by i.v. iron repletion.153 This is supported 
by the recommendations in the KDIGO Clinical Practice Guidelines on Anemia in CKD22 
that recommend initial IV iron for individuals requiring an increase in haemoglobin 
concentration. 
KDIGO (Kidney Disease Improving Global Outcomes) working group published in 
August 2012 new recommendations for treating anemia in patients with CKD. The new 
recommendations have created many changes affecting clinical practice, in comparison 
to the previous ones. Newly recommended were higher serum levels of ferritin (500 
g/L) and for transferin saturation (30%). ESAs should be administered only following 
suitable supplementation of iron levels. Another important change is the lower 
recommended Hb concentration for which an intervention using ESAs is indicated. ESAs 
should be administered when Hb levels are in the range 9-10 g/dL. In patients with 
symptoms of the anemic syndrome, ESAs can be applied with Hb  10 g/dL. It is 
generally recommended that during maintenance ESAs therapy, the Hb level should not 
exceed 12 g/dL in adult patients.22  
The conclusions and subsequent analyses of CHOIR,154 CREATE155 and TREAT156 
trials were key considerations in the development of the KDIGO Guidelines.22 Published 
in August 2012, with the aim of assisting clinical decision making, the guidelines evaluate 
the strength of current evidence regarding the diagnosis and evaluation of anemia in 
CKD as well as its treatment by red cell transfusion, iron supplementation and ESAs.  
 
 
4. Recombinant human erythropoietin  
The human EPO gene was cloned in 1985,157,158 allowing for clinical development 
of recombinant human erythropoietin (rHuEPO), a biotechnological advance that 
revolutionized anemia treatment. Endogenous EPO and rHuEPO share the same amino 
acid sequence, with slight differences in the sugar profile.159 In clinical practice, rHuEPO 
is typically administered as a bolus injection, and the dose is titrated to give the desired 
effect. Attempts to improve or ‘‘reengineer’’ rHuEPO to meet the demands of patients 
and caregivers resulted in additional ESAs with increased serum half-lives (compared 
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with rHuEPO), as well as different receptor binding properties and in vivo biological 
potencies.160-162 The characteristics and properties of these new ESAs allowed extension 
of the dosing intervals beyond the original thrice weekly.163,164 All ESAs share the same 
mechanism of action, binding to and activating the EPO receptor (EPOR), but differences 
in pharmacokinetic, pharmacodynamic, and receptor-binding properties affect their 
clinical use.  
 
 
4.1. Therapeutic uses of recombinant erythropoiesis-stimulating agents 
The primary goal of the treatment with recombinant erythropoiesis-stimulating 
agents (ESAs) is to abolish the need for RBC transfusions. Hemoglobin concentrations 
[Hb] <10 g/dL are associated with an increased risk of morbidity and mortality in CKD 
patients.165,166 The current NKF KDOQI guidelines recommend a target [Hb] of 11-12 g/dL 
on ESA treatment.110 ESA associated changes in health-related quality of life (HRQOL) 
include improvements in physical symptoms (vitality, energy, performance), while 
domains of social functioning and mental health are little ameliorated.167 ESAs are also 
administered to avoid RBC transfusions in cancer patients receiving myelosuppressive 
chemotherapy.168  
 
 
4.1.1. Different types of ESAs 
4.1.1.1. Epoetins 
The epoetins currently available are produced using recombinant DNA 
technology in chinese hamster ovary (CHO) cell lines, which leads to a glycosylation 
structure that differs from endogenous human EPO.159  
Epogen , an epoetin alfa formulation produced by Amgen (Thousand Oaks, CA, 
USA), was approved by the Food and Drug Administration (FDA) for the treatment of 
anemic CKD patients on hemodialysis in 1989. The drug was originally derived from CHO 
cells maintained in roller bottles, which were later replaced by bioreactors. In addition, 
animal-derived additives have been replaced by synthetic molecules in modern 
recombinant manufacturing processes.169 In 2000, Amgen received FDA approval for the 
manufacture of epoetin alfa at its new facilities in Longmont, CO, USA. Furthermore, 
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epoetin alfa has been distributed in the USA by Johnson & Johnson (J&J, New Brunswick, 
NJ, USA), under the name of Procrit, for other indications through an agreement with 
Amgen. Outside the USA epoetin alfa has been marketed under the names of Eprex or 
Erypo (J&J subsidiary Ortho Biotech, Bridgewater, NJ, USA), which was approved in the 
European Union (EU) by the European Medicines Agency (EMA) in 1988.  
NeoRecormon, an epoetin beta originally manufactured by Boehringer 
Mannheim and subsequently by F. Hoffmann-LaRoche (Penzberg, Germany), received 
EU approval in 1990. Although epoetin beta differs slightly from epoetin alfa in 
glycosylation,159,170 the two medicines are used for the same major indications (primarily 
anemias associated with CKD or myelosuppressive chemotherapy treated cancers) and 
are considered as interchangeable by healthcare professionals. 
The native EPO has a half-life of 8.5 hours. After a subcutaneous injection, the 
half lives of rHuEPOs in plasma increase in the following manner: epoetin alfa to 20.5 
hours and epoetin beta to 24 hours. Different sialic acid-containing carbohydrate 
components added to the 165 amino acids of epoetin alfa and epoetin beta confer 
longer half-lives to these compounds.171 For epoetin alfa and epoetin beta, the 
recommended dosing to achieve and maintain hemoglobin levels between 10–12 g/dL is 
as follows: for anemia associated with CKD it is given subcutaneously (intravenous route 
is used for hemodialysis patients because of convenience), 50–100 units/kg three 
times/week; for anemia associated with chemotherapy it is given subcutaneously, 150 
units/kg 3 times/week or 10,000 units 3 times/week or 40,000 units once weekly. 
Hemoglobin levels should not exceed 12 g/dL.172 
In 2009 the EMA granted a marketing authorization for another CHO cell-derived 
rhEPO, epoetin theta (brand names: Biopoin, CT Arzneimittel, Berlin, Germany; 
Eporatio, Ratiopharm, Ulm, Germany), which was developed by Merckle Biotec (Ulm, 
Germany) using epoetin beta as a comparator. Epoetin theta is not a biosimilar but a 
stand-alone product.173 It is approved for the treatment of symptomatic anemia in adult 
patients with CKD or myelosuppressive chemotherapy-treated cancer. 
Differing from the other epoetins, epoetin omega (Repotin, Bioclones, Cape 
Town, South Africa) is produced in epo cDNA-transfected Syrian baby hamster kidney 
(BHK) cells. Epoetin omega has an N-glycan with phosphorylated oligomannoside chains, 
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and it possesses less O-glycans than the CHO cell-derived rhEPOs.159,174 There is little 
known about the clinical use of epoetin omega. 
Epoetin delta (Dynepo, Shire Pharmaceuticals, Wayne, PA, USA) is the first 
human cell line derived Epo and therefore has a human-type glycosylation profile. In a 
multicenter, open-label, uncontrolled study on predialysis CKD patients, epoetin delta 
was found to be an effective and well-tolerated agent for the management of 
anemia.175,176 It is approved for clinical use in European countries but not in the United 
States.  
 
 
Figure I-13. Molecular structures of epoetin alfa (A) and darbepoetin alfa (B). (Taken from 
Elliott et al., 200857) 
 
Furthermore, second-generation ESAs with a prolonged survival in circulation are 
available. Darbepoetin alfa (Aranesp; Amgen), which was approved in the USA and the 
EU in 2001, possesses two additional N-glycans as a result of site-directed 
mutagenesis.160,177 These additional N-linked oligosaccharide chains are accomplished by 
substitutions at five positions along the 165-aminoacid backbone without altering the 
tertiary structure. These additional carbohydrates confer a three times longer terminal 
half-life and a five times lower affinity for EPO receptors relative to erythropoietin alfa. 
After a subcutaneous injection, the half live of darbepoetin alfa in plasma is 49 hours.171 
Despite different pharmacodynamic and pharmacokinetic properties, all these products 
are considered to have similar clinical efficacy (Figure I-13).161 
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For darbepoetin alfa, the recommended dosing to achieve and maintain 
hemoglobin levels between 10–12 g/dL is as follows: for patients with anemia of CKD it 
is given intravenously or subcutaneously, 0.45 g /kg once weekly; for anemia 
associated with chemotherapy it is given subcutaneously, 2.25 g/kg once weekly or 200 
g every two weeks or 500 g once every 3 weeks. Hemoglobin levels should not exceed 
12 g/dL like reported previously.172 
Continuous Erythropoietin Receptor Activator (CERA) (Mircera, Hoffmann-La 
Roche Inc. (Roche), Nutley, N.J), is composed of a large methoxy-polyethylene glycol 
polymer chain integrated into the EPO molecule and linked primarily by amide bonds.178 
This results in a longer half-life of approximately 130 hours after both intravenous and 
subcutaneous administration. Compared with epoetin alfa, CERA has different binding 
characteristics at the EPO receptor, mainly because it associates with the receptor more 
slowly, but its better stability gives it a longer half-life.179,180 In multiple, randomized 
phase III trials, CERA has been found to be as safe as currently-approved and inuse ESAs 
and has been shown to be efficacious in the management of anemia of CKD when given 
intravenously at 2-week or 4-week dosing intervals.164,181 
CERA is another recently available ESAs obtained by adding a large water-soluble 
polyethylene glycol moiety to epoetin beta,182 leading to a higher molecular weight ∼60 
kDa) and a longer half-life. The total binding affinity of CERA for the EPO receptor is 50–
100 times less than that of epoetin beta, mainly because of its much slower binding 
rate.183 It has been suggested that the binding of CERA to the EPO receptor is too brief 
for internalization, thus leading to repeated cycles of receptor binding, stimulation, and 
dissociation, and a consequently greater erythropoietic activity.178 Animal studies have 
shown that, despite its lower receptor affinity, CERA induces a greater erythropoietic 
response than epoetin alfa or epoetin beta,162 thus indicating greater potency in vivo, 
although these differences may be partially influenced by the different doses of the 
drugs. It has been hypothesized that CERA elimination is mediated by hematopoietic and 
nonhematopoietic EPO receptor pathways. Unlike that of EPO, the nonerythropoietic 
pathway is saturable, which may mean that an increasing fraction of CERAs used for 
erythropoiesis for increasing concentrations because of greater bioavailability. 
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All ESAs are effective in correcting renal anemia and increasing hemoglobin 
levels, but the choice of which to use should also consider their pharmacokinetics and 
pharmacodynamics, their administration route, and economic issues.  
Following the publication of a number of trials indicating no benefit (and even 
possible harm) when ESAs are used to achieve near-normal hemoglobin levels in CKD 
patients, the hemoglobin target has become a major subject of discussion. According to 
the position statement of the Anemia Group of the European Renal Best Practice, it 
should be about 11–12 g/dL; however, a risk– benefit evaluation is warranted in 
individual patients, and high ESAs doses driven by hyporesponsiveness should be 
avoided.184 
 
 
4.1.1.2. Biosimilar epoetins in the European Union 
Since developers of biosimilars usually do not have access to the originators’ 
proprietary data they engineer their own manufacturing process to obtain a product as 
similar as possible to the original.185 Because biosimilars are not fully identical to their 
reference product, the proof of bioequivalence is not sufficient for their approval. In this 
regard, they differ from generic drugs. The EMA committee for Medicinal Products for 
Human Use (CHMP), which is responsible for the scientific assessment of the products 
("European Public Assessment Reports", EPARs), has exhibited guidelines on: i) the 
studies necessary to show “the similar nature, in terms of quality, safety and efficacy” in 
comparison to the originator’s product, ii) the quality requirements regards the purity of 
the product and its components, iii) the non-clinical and clinical pharmacodynamic and 
toxicokinetic issues, and iv) the product-specific requirements for epoetins.173 For their 
approval biosimilar epoetins must demonstrate therapeutic equivalence with the 
reference product in at least two randomized, parallel-group (and preferably double-
blind) clinical trials, ideally in patients with anemia due to CKD. After all, the EMA has 
stated that "since the mechanism of action of epoetin is the same for all currently 
approved indications and there is only one known epoetin receptor, demonstration of 
efficacy and safety in renal anemia will allow extrapolation to other indications of the 
reference medicinal product with the same route of administration".173 
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Two biosimilar epoetins have been approved by the EMA, namely substance 
HX575 and substance SB309.173 Both products exhibit minor differences in the structure 
of their glycans compared to the reference product (Eprex/Erypo). There is no 
evidence suggesting that these differences are clinically relevant. Different lots of 
recombinant glycoproteins from innovator companies may also vary in their 
glycosylation profiles 186. The quality of the biosimilar epoetins proved to be high when 
studied by high-performance size-exclusion chromatography, SDS-PAGE, and capillary 
zone electrophoresis.187 The two biosimilar epoetins differ in formulation, while 
substance HX575 is stabilized by polysorbate-80 and several amino acids, similar to the 
original epoetin alfa (Eprex/Erypo), substance SB309 is stabilized by polysorbate-20, 
similar to epoetin beta (NeoRecormon). According to the European Pharmacopoeia, 
the activity (International Units, IU) of clinically used rHuEPOs must be assessed by in 
vivo bioassay in mice and confirm that “The estimated potency is not less that 80% and 
not more than 125% of the stated potency”. Thus, the potency of clinically used 
epoetins can vary within this range.188  
Substance HX575 (Rentschler Biotechnologie, Laupheim, Germany) was the first 
biosimilar epoetin with marketing authorization in the EU. HX575 has received the 
International Nonproprietary Name (INN) “epoetin alfa” despite its slightly different 
glycosylation pattern compared to the reference drug (Eprex/Erypo). HX575 has 
elevated levels of high-mannose structures and lower levels of N-glycolyl-neuraminic 
acid and diacetylated neuraminic acids. HX575 is traded as Binocrit by Sandoz and as 
Epoetin alfa Hexal by Hexal Biotech (Holzkirchen, Germany), both Novartis 
subsidiaries, and as Abseamed by Medice Arzneimittel Putter (Iserlohn, Germany), a 
Sandoz licensing partner. HX575 has proved therapeutic equivalence with 
Eprex/Erypo on intravenous administration in an open, randomized, parallel-group 
study of 80 healthy males189 and in a doubleblind randomized, parallel-group, 
multicenter Phase III trial involving 479 anemic CKD patients on hemodialysis. In the CKD 
patients, Hb concentrations and epoetin dosages remained stable throughout the study 
period of 56 weeks. The long-term safety profile of HX575 was found to be similar to 
that of the comparator epoetin alfa. No neutralizing anti-EPO antibodies (Abs) were 
detected.190  
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Substance SB309 (Norbitec, Uetersen, Germany) has received EU approval with 
the INN “epoetin zeta” (Silapo, Stada, Bad Vilbel, Germany, and Retacrit, Hospira, 
Lake Forest, IL, USA). SB309 has less O-glycans, and lower levels of N-glycolyl-neuraminic 
acid and O-acetyl neuraminic acid than the reference drug (Eprex/Erypo). According 
to the EPAR, SB309 was about 10% less potent than the reference product, when 
administered i.v. to CKD patients. However, the difference was apparently not intrinsic 
to the biosimilar but due to a relative high active substance content of the 
Eprex/Erypo batch used in the approval study.191 In study with 609 patients with CKD 
and anemia ([Hb] <9 g/dL) that received either SB309 or Eprex/Erypo i.v., one to 
three times per week for 24 weeks the dosing was titrated individually to achieve a 
target [Hb] of 11 - 12 g/dL. The mean SB309 dose over the last 4 weeks of treatment was 
182 ± 118 IU/kg/week, compared with 166 ± 110 IU/kg/week for the reference product. 
No unexpected adverse events were reported, and no patients developed neutralizing 
anti-EPO Abs.192  
 
 
4.1.1.3. Other strategies for stimulating erythropoiesis  
The inhibition or activation of transcription factors modulating EPO gene 
expression may be an alternative for stimulating erythropoiesis. The hypoxia-inducible 
transcription factors (HIFs) are central components in the cellular responses to hypoxia; 
under normoxic conditions, EPO gene expression is suppressed as a result of HIF 
inactivation because of O(2)-dependent enzymatic hydroxylation and subsequent 
degradation of their alpha-subunit. 2-oxoglutarate analogs, which prevent HIF alpha 
hydroxylation, have emerged as promising tools for the stimulation of erythropoiesis 
and angiogenesis (the so called HIF stabilizers). Concern related to HIF stabilizers is 
related to the fact that the HIF system promotes the transcription of many other genes; 
careful evaluation of other effects than erythropoiesis stimulation seems mandatory. 
GATA genes are an evolutionarily conserved family, which encode a group of important 
transcription factors involved in the regulation of several processes, including the 
development of the heart, hematopoietic system, and sex gonads. Some of these factors 
also regulate EPO gene transcription.193,194 
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Another possible strategy to increase erythropoiesis is the inhibition of the 
hematopoietic cell phosphatase. This protein, also known as src homology domain 2-
containing tyrosine phosphatase 1, binds and activates the negative regulatory domain 
of the EPO receptor, inhibiting transduction inside the cell.195 Hematopoietic cell 
phosphatase inhibitors may be thus a novel target molecule to treat renal anemia 
and/or sensitize patients to EPO action. 
Finally, EPO gene therapy has been proposed for the management of anemic 
patients with CKD. A number of different techniques have been tried, such as the 
delivering of naked plasmid DNA into skeletal muscles,196,197 the subcutaneous 
implantation of autologous bone marrow stromal cells genetically engineered to secrete 
EPO,198 viral transfection,199 and the use of artificial human chromosome.200 EPO gene 
therapy has the theoretical advantage of releasing small but continuous amount of EPO 
into the circulation, but has still a number of problems, such as immunogenicity and the 
difficulty to exactly tune the exact amount of EPO needed to correct anemia and 
maintaining a level of expression that sufficiently promotes erythropoiesis in the long 
term.201 
 
 
4.2. Non-hematological beneficial effects of rHuEPO therapy 
The pleiotropic effects of ESAs appear to result from the existence of two 
different, EPOR with different affinities for ESAs. In erythroid cells, ESAs bind to the 
EPOR homodimers in picomolar concentrations, whereas on the other cells and tissues, 
higher local ESAs concentrations are needed (nanomolar range) to trigger the activation 
of a heterodimer EPOR, constituted by EPOR and CD131 (beta common receptor – βcR), 
that is expressed in the different tissues, namely, brain, heart and kidney.202 
Functional EPOR has been identified in non-erythroid cells such as endothelial, 
muscle, and neural cells, and there is increasing evidence that EPO can act to stimulate 
cell proliferation and cell-specific function, or promote cell survival in these tissues.203 In 
contrast to erythropoiesis, which is mediated by an EPOR homodimer, EPO signaling in 
some non-erythroid tissue employs a heteromeric receptor consisting of EPOR and the 
cR used by GM-CSF, IL-3, and IL-5.202  
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It has become apparent that the pleiotropic effects of ESAs in non-erythroid 
tissues are the result of EPO binding to EPOR, and, as in erythroid cells, the EPO-EPOR 
interaction initiates a signal transduction process that regulates the survival, growth, 
and differentiation of the involved tissue. EPO and EPOR have been shown to play a 
physiological role in many non-erythroid cells, including endothelial cells 204, 
megakaryocytes,205 heart,206 uterus,207 breast208 and testes,209 however in some tissues, 
as brain (neurons, astrocytes, and microglia),210,211 kidney,212 female reproductive 
system,213 cardiomyocytes,214 lymphocytes and monocytes, 215 the signaling mechanism 
can be different since EPO can interact with EPOR and CD131 heterodimers.216 EPO and 
EPOR exhibit a beneficial role in neural, cardiovascular, and retinal tissues and in 
immune function and tissue repair.  
Higher doses of ESAs than those required to treat anemia are needed to exert 
pleiotropic effects in some tissues, which, inevitably, activate the hematopoietic 
pathway, and increase the risk of ESAs side effects. The use of ESAs as a tissue protective 
agent in patients without anemia, presents a risk to these patients as the activation of 
the hematopoietic system would be a side effect. 
 
 
4.3. Adverse effects of rHuEPO therapy 
All ESAs approved, until now, for the treatment of anemia present some 
disadvantages as immunogenicity, and the storage and stability, as well as the 
administration route have to be considered. ESAs are associated with some adverse 
effects, namely, cardiovascular effects, such as hypertension, retinopathy, neurotoxicity 
and thrombotic events; the impact of ESAs therapy on survival outcomes needs to be 
considered carefully in the design of future clinical studies.  
Hypertension, which either develops or worsens in 20–30% of renal patients on 
rHuEPO therapy, is usually controlled without serious consequences.217,218 Several 
mechanisms can explain the rise in blood pressure (BP) mediated by ESAs. Renal anemia 
is a factor predisposing to increased BP, due to the increased sympathetic activity and 
impaired nitric oxide (NO) availability.219 ESAs impair the balance between vasodilating 
and vasoconstrictor factors, since it induces the production of vasoconstrictors as 
endothelin-1 (ET-1), thromboxane B2 (TXB2) and prostaglandin 2α (PGF2α), and reduces 
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the production of the vasodilatory prostacyclin 2 (PGI2). A chronic treatment with ESAs 
appears to impair the vasodilatory capacity of endothelial NO, through an increase in the 
asymmetrical dimethylarginine (ADMA), an inhibitor of eNOS. ESAs seem to induce 
hypersensitivity to angiotensin II, a recognized vasoconstrictor. An increase in the 
concentration and hypersensitivity of noradrenaline, a vasoactive substance, may 
contribute also to the hypertension associated to ESA therapy.220,221 
ESAs have the capacity of stimulating thrombopoiesis, increasing platelet count; 
however, ESAs also increase platelet reactivity, promoting a prothrombotic effect.222 In 
some preclinical studies, very high doses of rHuEPO in conjunction with hypoxia has 
been associated with a paradoxical neurotoxic effect, suggesting the need for further 
work to determine dose-response conditions, to optimize the neuroprotective effects of 
EPO.223-225 Several clinical studies evaluating rHuEPO therapy in CKD patients have raised 
the possibility that higher target haemoglobin levels may be associated with increased 
cardiovascular events and all-cause mortality, as well as a potential increased risk of 
arteriovenous access thrombosis.154,155,226 Some other hemostatic disturbances have 
been described, as an increased expression in E selectin, P selectin, von Willebrand 
factor and plasminogen activator inhibitor-1, which may favor bleeding episodes, and 
increase the risk of thrombosis and thromboembolism.220 
A serious complication associated with ESAs administration is pure red cell 
aplasia (PRCA), an immunogenic side effect that results from the production of anti-EPO 
antibodies induced by ESAs administration.227-229 Although this disorder occurs very 
rarely, the number of reported cases has increased in recent years, with the introduction 
os ESAs biosimilars to treat CKD patients in some countries. Patients with CRF-associated 
anemia receiving subcutaneous injections of one particular formulation of recombinant 
epoetin- also developed more frequently PCRA. This rare condition develops suddenly 
and is caused by the production of EPO-neutralizing antibodies that eliminate the 
biological activity of the recombinant protein as well as of endogenous EPO.230 Low 
reticulocyte counts, a marked decrease in bone marrow erythroblasts, resistance to EPO 
therapy, and presence of anti-EPO antibodies are key features for the diagnosis of PRCA. 
Peptides and protein drugs have the potential to elicit host immune responses that can 
limit efficacy or cause adverse reactions. 227,231 
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Indeed, the methods used to produce ESAs may not eliminate completely 
impurities or aggregated proteins that may trigger the immune response in patients.229 
Immunoprecipitation assays have shown that anti-EPO antibodies are directed against 
the protein moiety of the molecule.228 
 
 
5. Resistance to recombinant human erythropoietin therapy 
5.1. Definition and etiology 
The NKF KDOQI defined the hyporesponsiveness to erythropoietin as the 
presence of at least one of the following three conditions: i) a significant decrease in Hb 
level at a constant ESAs dose; ii) a significant increase in the ESAs dose requirement to 
preserve a target Hb level, or iii) a failure to raise the Hb level to values higher than 11 
g/dL despite an ESAs dose equivalent to erythropoietin greater than 500 IU/kg/week.22 
Similarly, European guidelines also recommend to consider ESAs resistance when 
a patient either fails to attain the target hemoglobin concentration while receiving more 
than 300 IU/kg/week (20,000 IU/week) of erythropoietin or 1.5 mg/kg of darbepoetin-
alfa (100 mg/ week), or has a continued need for such high dosages to maintain the 
target Hb concentration.232 The erythropoietin resistance index (ERI), calculated by the 
ratio between the rHuEPO dose/kg/week and the Hb concentration (g/dL), is an 
alternative method, considered by some authors, as a better way to measure the degree 
of ESAs resistance. An ERI value higher than 0.02 g/kg/week/g Hb indicates resistance 
to ESAs; additionally the time course of ERI may be important to demonstrate the 
degree of response to these agents.233  
The main cause of ESAs resistance is iron deficiency, but rHuEPO-resistant 
anemia persists in some HD patients even after sufficient iron supplementation.234 Iron 
deficiency may be absolute – with a ferritin concentration less than 100 mg/L – or 
functional – when the ferritin concentration is greater than 100 mg/L and total 
saturation of transferrin (TSAT) less than 20%. Besides noncompliance (that should be 
checked when EPO is self-administrated), other recognized causes of ESAs resistance in 
patients with adequate iron stores include concomitant inflammation or infection, 
neoplasia, chronic hemolysis, hemoglobinopathies, severe hyperparathyroidism, 
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aluminum intoxication, vitamin B 12 or folate deficiencies, inadequate dialysis, 
myelosuppressive agents, myelodysplasia, antibody-mediated pure red cell aplasia, 
thyroid dysfunction, and some drugs, including RAAS blockers (Figure I-14).235-238 
 
 
Figure I-14. Causes of ESAs-resistant anemia in CKD. (Taken from Kanbay et al., 2010239) 
 
 
5.2. Causes of resistance to recombinant human erythropoietin 
5.2.1. Iron deficiency and hepcidin deregulation 
The most common cause of an incomplete response to EPO is iron deficiency 
absolute or functional, as previously described. Iron deficiency was shown to be present 
in as many as 25–37.5% of CKD patients presenting with anemia. Enhanced iron 
utilization due to EPO-induced red blood cell formation can quickly deplete iron stores, 
especially if previously reduced by poor iron absorption, occult gastrointestinal bleeding, 
or dialysis-related blood losses. Because of ongoing iron losses,240 the need for iron 
supplementation is ubiquitous in the ESRD population. The diagnosis of iron deficiency 
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in this setting can be somewhat challenging in that the ferritin level is often elevated 
due to systemic inflammation. Whereas a low serum ferritin level does imply iron 
deficiency, a high ferritin level cannot be used to rule out iron deficiency. Most workers 
in this area agree that the saturation of transferrin is a more helpful indicator of iron 
deficiency. It is estimated that a transferrin saturation of less than 20% has a sensitivity 
of 100% and a specificity of 80% for iron deficiency in the ESRD population, provided 
that hypoproteinemia is not present.241 
Iron uptake from plasma to erythroid precursor cells is regulated by different 
proteins: transferrin receptor, hemochromatosis (HFE) protein and DMT1 
(NRAMP2/DCT1). HFE gene mutations are associated with a reduction in the amount of 
rHuEPO necessary to support erythropoiesis in HD patients.242 Conversely, some DMT1 
gene mutations are associated with an inhibition of intestinal iron absorption and a 
decrease in erythroid cell precursor iron uptake, resulting in hypochromic and microcytic 
anemia.243 Hepcidin may also be involved in the pathogenesis of anemia of 
inflammation. Growing evidence suggests that low-grade inflammation causes an 
increase in hepcidin production, limiting the availability of iron for erythropoiesis, thus, 
providing a direct link between inflammation and metabolism of iron.244-246 Costa et al. 
(2008) demonstrated in 50 HD patients (25 nonresponders and 25 responders to rHuEPO 
therapy) and 25 healthy controls, that prohepcidin and soluble transferrin receptor, 
together with CRP, were good markers of resistance to rHuEPO therapy.238 On the other 
hand, Kato et al. (2008) measured the peak intensity of serum hepcidin-25, the major 
form of mature hepcidin, in 24 HD patients and compared those between rHuEPO-
hyporesponsive and rHuEPO-responsive patients in a cross-sectional study. This group 
found that serum hepcidin measurement, using currently available assays, was not valid 
in predicting rHuEPO responsiveness in chronic HD patients.247 Clearly more work is 
required to provide a useful therapeutic biomarker and index for treatment monitoring. 
 
 
5.2.2. Cytokines and inflammation 
Uremic toxins are implicated in the propagation of proinflammatory cytokines, 
such as IL-1, IL-6, interferon- (IFN-), and tumor necrosis factor alfa (TNF-). These 
cytokines downregulate the expression of EPO receptors on erythroid progenitors and 
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disrupt iron recycling by blocking its release from reticuloendothelial cells, and by 
inducing hepcidin synthesis.248 Inhibition of erythropoiesis by cytokines, such as TNF- 
and IFN-, is also important for erythropoietin resistance.141 In CKD patients, elevated 
levels of IL-1, IL-6, TNF- and CRP (suggestive of a chronic inflammatory status) have 
been frequently described.249 Del Vecchio et al. (2005) reported that cytokine-induced 
inflammation suppresses bone marrow erythropoiesis in HD patients and is a possible 
cause of anemia.250 Shinzato et al. (2008) found higher levels of ferritin, hs-CRP and IL-6 
in 19 HD patients with rHuEPO-resistant anemia, compared to control HD patients 
without anemia and iron deficiency.251 Kalantar-Zadeh et al. (2003) confirmed the strong 
association between indices of EPO hyporesponsiveness and high levels of inflammatory 
markers in a larger cohort of 339 HD patients. Primary and secondary neutrophil 
granules contain elastase and lactoferrin, respectively, which are commonly used as 
indirect markers of neutrophil activation in vivo.252 Costa et al., (2008) evaluated the 
neutrophil activation state in CKD, in 63 HD patients under rHuEPO treatment (32 
responders and 31 nonresponders to rHuEPO therapy), compared with controls, and 
fount that CKD patients presented with significantly higher CRP, and neutrophils and 
elastase levels; moreover, nonresponders to the rHuEPO therapy showed significantly 
higher elastase levels than responders to rHuEPO therapy, which could be related to the 
rise in neutrophils and be part of the enhanced inflammatory process found in these 
patients. On the other hand, plasma levels of lactoferrin and the lactoferrin/neutrophil 
ratio did not differ between groups. Therefore, elastase, but not lactoferrin may be a 
better marker of resistance to rHuEPO therapy in CKD patients under hemodialysis.253 
 
 
5.2.3. Pure red cell aplasia 
Resistance to biological effects of EPO may result from its neutralization by 
circulating antibodies or by its inactivation by binding to soluble plasma receptors which, 
usually, lead to pure red cell aplasia (PRCA). The immunogenicity of rHuEPO may be 
enhanced by subcutaneous administration and by certain host biological factors. Indeed, 
several cases of PCRA were associated to the subcutaneous administration of rHuEPO, 
particularly of Eprex which was removed the European market.254 
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PRCA is a syndrome characterized by a severe normocytic anemia, 
reticulocytopenia, and absence of erythroblasts from an otherwise normal bone 
marrow. This is a very rare cause of ESA resistance in ESRD patients. For example, HD 
patients who were either hypo or normoresponsive to epoetin treatment were tested 
for anti-erythropoietin antibodies, and, the prevalence of anti-erythropoietin antibodies 
in HD patients without symptoms of PRCA was determined by screening sera of 536 
patients, using ELISA.255 Positive results were also verified by radioimmunoprecipitation 
assay and neutralizing activity was determined by bioassay. Anti-erythropoietin 
antibodies were detected in 3 hyporesponsive and 3 normoresponsive patients, 
suggesting that anti-erythropoietin antibodies are not a major cause of ESA 
hyporesponsiveness.255 Similarly, in a multicenter, cohort study of 1677 patients with 
incident end-stage renal disease, 57 patients with inadequate EPO response were 
identified; however, only 2 of these 57 patients were positive for anti-EPO antibodies 
and one patient had clinical PRCA. In another study, with 1346 patients without 
evidence of inadequate EPO response, only one patient tested borderline positive for 
anti-EPO antibodies. The incidence of EPO-induced PRCA and EPO antibodies was very 
low in this study.256 
 
 
5.2.4. Other potential causes of resistance to rHuEPO therapy 
Erythropoiesis-stimulating agents hyporesponsiveness represents an important 
diagnostic and management challenge. As already referred, other recognized causes of 
resistance to rHuEPO therapy have been reported, such as malnutririon,257 secondary 
hyperparathyroidism,258-260 uremic toxins, inadequade dialysis 261,262, angiotensin-
modelating agents,263-266 oxidative stress,267,268 vitamin B12, folate or L -carnitine 
deficiencies,269-271 neoplasia, chronic hemolysis, hemoglobinopathies, aluminum 
intoxication, myelosuppressive agents, myelodysplasia, thyroid dysfunction, and some 
drugs, including RAAS.235-238 Enhancing ESA responsiveness is critically important to 
minimizing the high cost of ESA therapy as well as improving clinical outcomes. 
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6. Animal models of chronic renal failure and erythropoietic disturbances 
Surgical manipulations of experimental animals have been widely used to model 
CKD, in order to mimic the injury that causes renal disease or reproduce their 
consequences. The pre-requisite of developing a renal failure model is to define a target 
range of renal insufficiency, in order to achieve a stable uremic milieu allowing 
experimental manipulation. Animal models of chronic renal failure (CRF) have been 
mostly achieved by partial ablation of renal parenchyma, and the two most common 
techniques employed were surgical resection or infarction.272 However, there are other 
animal models described in the literature to induce chronic renal failure, including 
microembolism by michrospheres 273, electrocoagulation of the renal cortex274 and 
cryosurgery.275 
 
 
6.1. Nephrectomy (or renal ablation): resection versus infarction model 
In the resection model, a portion of one kidney is resected, followed by 
contralateral nephrectomy. With the animal in ventral recumbent position, a 2–3 cm 
skin incision is made, caudal to the rib cage, on the left side. After further muscle 
incision, the left kidney is gently dissected from the overlying fat and adrenal gland. A 
single silk thread is placed around the renal pedicle. The upper and lower kidney poles 
are excised after lifting the thread (in order to temporarily occlude the vascular flow 
during cutting). Meticulous resection is made under direct vision, to ensure that the 
remnant kidney represents the percentage wanted. With the remnant kidney wrapped 
in hemostatic gauze, it is returned into the abdominal cavity. Muscle wall is then 
sutured. One week after the first surgical procedure, right uninephrectomy is 
performed.272 
The (5/6) surgical nephrectomy model has been the most used prototype, 
although different ways to achieve (5/6) reduction of nephron mass have been proposed 
and practiced.276,277 This model involves substantial removal of renal mass or nephron 
number, followed by compensatory renal hypertrophy in the remnant kidney. The 
glomerular changes, in proportion to the amount of nephrons damaged, are 
characterized by hyperperfusion and hyperfiltration. Increasing workload by the 
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remaining pool of nephrons characterizes the progression of renal injury, namely chronic 
renal failure.278-281 However, the 5/6 nephrectomy model has several limitations, 
including a substantial mortality rate, non-reversibility, and phenotypic alterations 
related to the surgical procedure rather than impaired kidney function.282 Furthermore, 
the method is associated with relatively large inter-individual and inter-laboratory 
differences and its availability may be limited by lack of surgical expertise and the 
appropriate operating facilities. 
Our group283 (Garrido et al., 2009) has previously characterized a CRF model 
induced by (¾) nephrectomy which is consistent with a moderate degree of renal failure 
and a modest and quickly compensated anemia, though presenting a disturbance in iron 
metabolism. Despite the reasonable degree of functionality of the remnant kidney, as 
suggested by the correction of anemia, as well as by the kidney hypertrophy and the 
moderate structural modifications (lesions) observed, several important cardiovascular 
modifications were developed. This model of (3/4) nephrectomy have been established 
as a good tool to study the cellular/molecular pathophysiological mechanisms 
underlying moderate stages of chronic renal failure, as occurs in humans, and, even 
more relevant, to evaluate the efficacy of therapies used to prevent, treat or correct 
cardio-renal anemia syndromes and complications in early stages.283 
Concerning the infarction model, it involves a large reduction of the blood flow 
through the renal artery from one kidney and contralateral nephrectomy. Briefly, the 
left kidney is exposed and decapsulated in a similar manner as above described. Instead 
of surgical ablation of renal tissue, the left renal arterial branches are isolated with blunt 
forceps and, by using sterile silk suture, the blood flow is largely reduced. Functional 
nephrectomy is, thus, achieved by renal tissue infarction. Discoloration of 75% of the 
kidney reflects ischemia that will progress to infarction. Right unilateral nephrectomy is 
then performed as in the resection model above mentioned. Both techniques are 
described in a variety of animal species. Ideally, these techniques should induce a 
reproducible degree of glomerular filtration rate. Decrease of renal mass by different 
methods might represent different degrees of renal injury and, thus, different stages of 
chronic renal failure.272  
The reduction of renal mass is, thus, achieved by either infarction or surgical 
excision of both poles, with removal of the contralateral kidney. It enables to investigate 
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the influence of pharmacological, nutritional and other factors on functional and 
morphological renal parameters. The (5/6) nephrectomy produced by infarction is 
characterized by high plasma renin levels. By contrast, reduction of an equivalent 
amount of renal parenchyma by surgical excision does not result in the development of 
hypertension and plasma renin activity is normal to low. In this model of surgical 
nephrectomy, the initially normal remnant nephrons undergo compensatory functional 
and structural adaptations. Glomerular hypertension is one of the main factors 
responsible for the development of renal injury. Morphological studies show progressive 
focal segmental to global glomerulosclerosis, accompanied by increasing proteinuria and 
deteriorating renal function.284 
In both models, the remnant kidney is histologically normal at the moment of 
chirurgical intervention, further undergoing a progressive impairment of renal function. 
In several cases of severe human renal diseases, the decrease in the number of 
functioning nephrons is associated with marked tubulointerstitial changes, and relatively 
undamaged nephrons coexist with those that are extensively damaged, until the intact 
nephrons spontaneously deteriorate. These features are common in both 
immunologically and non-immunologically mediated kidney diseases. Progressive CRF is 
histologically characterized by tubulointerstitial, glomerular and vascular lesions.  
Few studies have shown that administration of low erythropoietic doses of EPO 
may retard progression of renal disease in rats with renal mass reduction285 and in 
diabetic db/db mice.286 High doses of EPO have been consistently shown to accelerate 
progression of renal disease in animals with renal mass reduction.285,287,288 The 
contribution of high levels of EPO to progression of renal disease is strengthened by the 
recent demonstration of a strong link between development of severe diabetic 
proliferative retinopathy and nephropathy with a polymorphism of the EPO gene 
promoter that causes increased EPO production.289 Thus, while physiologic levels of EPO 
seem to confer vital benefits through its numerous non-erythropoietic and 
erythropoietic actions, data derived from experimental animals, as well as from 
randomized clinical trials, suggest that high doses of EPO can accelerate progression of 
chronic renal disease. Further studies are required to elucidate the molecular 
mechanisms underlying these effects. 
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6.2. Models of erythropoietin-deficient or dysfunctional EPO 
6.2.1. Pure red cell aplasia  
As referred, antibody (Ab)-mediated pure red cell aplasia (PRCA) is an 
immunological pathology associated with the production of neutralizing Abs that inhibit 
the erythropoietic activity of endogenous EPO and recombinant erythropoiesis-
stimulating agents (ESAs). Although very rare, the number of reported cases has, more 
recentetly, with the use of rHuEPO biosimilars to treat patients with CKD-associated 
anemia receiving subcutaneous injections of one particular formulation of recombinant 
epoetin- have also shown a higher prevalence of PRCA. This disorder is differentiated 
from classic forms of PRCA that are caused by chemical toxemia (i.e. erythroblastopenia 
induced by chemical compounds), lymphoproliferative neoplasms, thymoma, human 
parvovirus B19 and certain autoimmune disorders.290 
Genovese et al. (1975)291 described two experimental models for PRCA. In the 
first model, the administration of serum IgG from a case of PRCA, to normal mice, 
induced a sustained inhibitory effect on erythropoiesis, with a progressive decline of the 
hematocrit values and an inverse rise of EPO levels in serum. Thus, the 
physiopathological pattern of PRCA type I was established. In the second model, a rabbit 
producing anti-EPO cross-reacting with endogenous EPO was subjected to a booster 
injection of EPO. The rise of the immune response was associated with disappearance of 
erythroid precursors from marrow smears, subsequent decline of circulating 
reticulocytes and worsening of the anemia, thus reproducing the physiopathological 
pattern of PRCA type II.291 This model could be useful for studies of the effects of 
resistance to rHuEPO therapy in CKD. 
 
 
6.2.2. Erythropoietin-deficient anemia 
Few in vivo models exist that display a phenotype similar to the anemia of CRF, 
specifically, low RBC production in conjunction with depleted serum EPO levels. Models 
involving chemical injections are used to directly destroy RBCs, leading to the 
development of anemia. For instance, the injection of phenylhydrazine (PHZ) results in 
the destruction of RBCs by binding to hemoglobin proteins within these cells,292 
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triggering their destruction and, therefore, an anemia. However, regardless of the 
methods employed, these techniques lead to a rapid increase in serum EPO levels and 
are not representative of an EPO-deficient anemia. To overcome this limitation, 
nephrectomy has been used to create an EPO-limiting environment in vivo. However, as 
we observed in the surgical model already described, this model involves an invasive 
procedure and is therefore not appropriate for large-scale experiments. In addition, 
these animals experience a shortened lifespan, which prevents the study of long-term 
effects of low EPO production. Finally, nephrectomized animals seem to be still able to 
produce EPO in secondary tissues, such as the liver.293 
The introduction of transgenic mice technology has also yielded some innovative 
mouse models for the study of EPO function; however, they also have limitations. As 
referrred, EPO-knockout mice are embryonic lethal, making it an ineffective model to 
study anemia and erythropoiesis in the adult system.58 EPO is not necessary for 
erythroid lineage commitment; however, it is needed to assure the survival of erythroid 
progenitors (CFU-E) that would differentiate into RBCs.  
In order to obtain a preclinical model for an EPO-deficient anemia, Zeigler et al., 
(2010)294 developed a mouse in which EPO is silenced by Cre recombinase. After 
induction of Cre activity, EPOKO/flox mice experience a significant reduction of serum EPO 
levels and, consequently, develop a chronic, normocytic and normochromic anemia.294 
The authors showed that the conditional deletion of EPO in the adult animal results in an 
anemia of EPO deficiency. These transgenic animals have the ability to survive for long 
term studies, unlike the previously used models, including those using nephrectomy. 
Thus, EPOΔ/Δ mice will be a valuable tool for the development of new therapeutic 
approaches for the treatment of the anemia of CKD. In addition, this model will allow 
the study of erythropoiesis under EPO-limiting conditions as well as studies analyzing the 
contribution of extra-renal EPO production to erythropoiesis. Furthermore, analyzing 
the stress-induced erythropoietic response in these animals has the potential to discover 
new erythropoiesis regulating mechanisms that are masked by EPO in the currently used 
models. Elucidating these mechanisms has the potential to identify new target 
opportunities for the treatment of anemia.294  
The erythropoietic agents have the potential to play a therapeutic role in several 
pathologies. Considering that the use of ESAs might have negative consequences (e.g., 
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increased blood pressure and thromboembolism), the risks of EPO therapy should be 
weighed against the potential beneficial effects of improving anemia, quality of life, 
neurocognitive performance, and of decreasing the impact of ischemia in brain, heart, 
and other organs. Although an animal model can never be a perfect match for human 
disease, adequate animal models have provided valuable insights into the mechanisms 
in anemia/CKD. There is now clear experimental evidence from animal models that EPO 
can reduce the severity of renal injury induced by ischemia reperfusion, systemic shock, 
and nephrotoxic insults, and may also contribute to clarify the process of 
regeneration/amelioration of renal damage. Further studies, supported by the proper 
animal models, might improve the knowledge about some areas that remain to be 
elucidated, concerning the use of rHuEPO in kidney diseases/anemia, including the 
mechanisms behind resistance to therapy and the impact of high doses on hemodialysis 
patients, but also the putative therapeutic relevance of erythropoietin on cardiac and 
neuronal disorders, namely due to the cytoprotective actions previously documented. 
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1. Rationale, aims and outline 
 
Anemia is a common complication in hemodialysis patients. This anemia is due to 
the inability of the failing kidneys to secrete erythropoietin (EPO) to stimulate 
erythropoiesis. The introduction of recombinant human EPO (rHuEPO) therapy in the 
early 1990s led to a significant reduction in anemia and improved patients’ quality of 
life. However, there is a marked variability in the sensitivity to rHuEPO, with up to 10-
fold variability in dose requirements to achieve correction of anemia. About 5-10% of 
the patients show a marked resistance to rHuEPO therapy, worsening patient’s 
prognosis. To better clarify the mechanism underlying resistance to rHuEPO therapy, our 
team studied in previous work1-9 the systemic changes associated with that resistance, in 
two groups of chronic kidney disease (CKD) patients, one responder and the other non-
responder to rHuEPO therapy. This study was focused on inflammation, leukocyte 
activation, iron status, oxidative stress and erythrocyte damage. Non-responders 
presented a mild to moderate hypochromic anemia, even with the administration of 
higher rHuEPO doses. As all patients were under iron and folate prophylactic therapies, 
and iron and vitamin B12 serum levels were normal, these changes could not be 
attributable to a deficiency in these erythropoietic nutrients. Non-responders to rHuEPO 
therapy seem, therefore, to present a “functional” iron deficiency characterized by the 
presence of adequate iron stores, but apparently with an inability to sufficiently mobilize 
iron to adequately support erythropoiesis. Inflammation, a hallmark in these patients, 
was higher in non-responders; C-reactive protein (CRP) was inversely correlated with 
hypocromia, serum iron and transferrin saturation, suggesting that the enhanced 
inflammation, may lead to trapping of iron within the macrophages and to a reduction in 
serum iron levels.  
Further studies are needed to understand the mechanisms explaining the 
marked variability in the response/resistance to rHuEPO therapy; however, to clarify 
these mechanisms we need to perform blood, cellular and tissue studies that cannot be 
performed in humans, due to ethical limitations. In accordance, we figured that the use 
of appropriate animal models could be useful to estimate the pathophysiology of CKD 
and the rHuEPO response/resistance. 
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With this perspective, we developed a rat model of chronic renal failure (CRF) 
induced by 3/4 surgical nephrectomy.10 We found that this model was consistent with a 
moderate degree of renal failure, showing a modest and quickly compensated anemia, 
erythropoietic disturbances, hypertension, dyslipidemia and oxidative stress.11 These 
preliminary studies showed us that we needed to perform a larger nephrectomy to 
achieve a model of renal failure similar to those found in patients with stage 5 of CKD. 
 
The aims of the present work were: 
1. To contribute to a better understanding of the anemia of chronic kidney disease.  
In that way, we evaluated, by using an experimental animal model of CRF induced by 
5/6 surgical nephrectomy, the development of anemia and the evolution of renal 
damage, focusing on iron impairment, erythropoiesis and inflammation at blood, 
tissue and cellular levels. The results of this study are presented in Chapter III. 
2.  To understand the mechanisms explaining the marked variability in the 
response/resistance to rHuEPO therapy, by using an experimental animal model of 
CRF, induced by 5/6 surgical nephrectomy, and focusing on renal damage, iron 
impairment, erythropoiesis and inflammation, at blood, tissue and cellular levels; 
moreover, to explain the persistence of anemia in CRF rats, observed in the previous 
study (Chapter III). Indeed, we found that anemia persisted throughout the protocol, 
in spite of normal EPO levels. The results of these studies are presented in Chapter IV. 
3. To study the effect of rHuEPO per se on some of the mechanisms previously 
described. 
By performing this study, besides the evaluation of the impact of rHuEPO on iron 
metabolism, erythropoiesis and inflammation at blood and molecular levels, we 
managed to develop a rat model of antibody mediated erythroid hypoplasia induced 
by rHuEPO. The results of these studies are presented in Chapter V. 
4. Finally, as this study involved animal research, to develop experimental animal 
models that can be used in following studies of our team, to be applied in this area of 
research or in other is which the CKD associated-anemia and PCRA could be used. 
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1. Abstract 
Anemia is a common complication of chronic kidney disease (CKD) that develops 
early and its severity increases as renal function declines. It is mainly due to a reduced 
production of erythropoietin (EPO) by the kidneys; however, there are evidences that 
iron metabolism disturbances increase as CKD progresses. Our aim was to study the 
mechanisms underlying the development of anemia of CKD, as well as renal damage, in 
the remnant kidney rat model of CKD induced by 5/6 nephrectomy. We found that this 
model of CKD presented a sustained degree of renal dysfunction, with mild and 
advanced glomerular and tubulointerstitial lesions. Anemia developed 3 weeks after 
nephrectomy and persisted throughout the protocol. The remnant kidney was still able 
to produce EPO and the liver showed an increased EPO gene expression. In spite of the 
increased EPO blood levels, anemia persisted and was linked to low serum iron and 
transferrin levels, although iron storage was normal, as showed by ferritin; serum IL-6 
and CRP levels showed the absence of inflammation. The reduced expression of hepcidin 
favours iron absorption, as suggested by the increased expression of duodenal 
ferroportin. However, iron contents remain reduced which might be due to advanced 
kidney lesions. Our data suggest that the persistence of anemia may result from 
disturbances in iron metabolism and, eventually, by an altered activity/function of EPO 
that might result from kidney cell damage and from the developed local inflammatory 
milieu, as showed by the increased gene expression of different inflammatory proteins 
in the remnant kidney. 
 
 
 
 
 
Key words: Iron dysmetabolism; anemia; chronic kidney disease, renal hypoxia, 
inflammation, fibrosis 
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2. Introduction 
Chronic kidney disease (CKD) is a pathological condition that results from a gradual 
and permanent loss of kidney function over time, usually, months to years. CKD can result 
from primary diseases of the kidneys, however, diabetic nephropathy and hypertension 
are the main causes of CKD.1 Anemia is a common complication of CKD that develops 
early in the course of the disease, increasing its frequency and severity with the decline of 
renal function. The incidence of anemia is less than 2% in CKD stages 1 and 2, about 5% in 
CKD stage 3, 44% in CKD stage 4 and more than 70% in end-stage renal disease (ESRD).2 
This condition is associated with a decreased quality of life3, increased hospitalizations,4,5 
cardiovascular complications - angina, left ventricular hypertrophy (LVH) and chronic 
heart failure – and mortality.6-9 
Anemia is mainly associated with a reduced production of erythropoietin (EPO) by 
the kidneys. However, there are also evidences that iron metabolism disturbances 
increase as the CKD progresses. The reasons for this high proportion of CKD patients with 
iron disturbances are not well clarified; however, inflammation has been proposed to play 
an important role. In fact, previous works reported that ESRD patients under hemodialysis 
present higher hepcidin serum levels, increased markers of inflammation (such as CRP 
and IL-6) and reduced iron absorption and mobilization, thus presenting lower levels of 
iron and transferrin.10-12 Increased hepcidin production during inflammation and infection 
explains sequestration of iron in the macrophages and inhibition of intestinal iron 
absorption, the two hallmarks of the anemia of inflammatory diseases. 
During the last few years the mechanisms underlying hepcidin and iron regulation 
have been largely studied. In addition, the impact of renal hypoxia, through hypoxia-
inducible factors (HIFs), on iron metabolism, on kidney lesion or regeneration, as well as 
on hepcidin expression, have been extensively debated.13-15 Experimental models using 
transgenic mice, knockout for some of the key mediators, have been crucial to reveal 
some of these new findings.16,17 Uremic rat models have been characterized and used for 
long time by our group as well as by other authors as tools to study the 
pathophysiological events underlying kidney disease development, including those with 
renal failure induced by nephrectomy and infarction.18-20 However, the information is still 
scarce concerning the characterization of iron dysfunction associated with hypoxic anemia 
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of chronic kidney disease, namely in the 5/6 nephrectomized rat, which is one of the most 
used rat model of CKD. In this sense, we intended to elucidate the mechanisms underlying 
the development of anemia and evolution of renal damage in the remnant kidney rat 
model of CKD induced by 5/6 nephrectomy, focusing on iron impairment and kidney 
hypoxia, inflammation and fibrosis. 
 
 
3. Material and methods 
3.1. Animals and experimental protocol 
Male Wistar rats (Charles River Lab., Inc., Barcelona, Spain) weighing ±300g were 
maintained in an air conditioned room, subjected to 12 h dark/light cycles and given 
standard rat diet (IPM-R20, Letica, Barcelona, Spain) ad libitum and free access to tap 
water. Animal experiments were conducted according to the European Communities 
Council Directives on Animal Care and the National Authorities. 
 
 
 
Figure III-1. Experimental protocol. 
 
 
The rats were divided into two groups (7 rat each): Sham group – subjected to 
chirurgical process but without kidney mass reduction and chronic renal failure (CRF) 
group – induced by a two-stage (5/6) nephrectomy, with subtraction firstly of about 2/3 
of the left kidney by left flank incision and, one week later, complete removal of the 
right kidney through identical incision/procedure. All the animals have completed 12 
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weeks of protocol (Figure III-1). Body weight (BW) was monitored throughout the study 
and blood pressure (BP) and heart rate (HR) measures were obtained using a tail-cuff 
sphygmomanometer LE 5001 (Letica, Barcelona, Spain).  
 
 
3.2. Sample collection and preparation 
At the beginning of the experiments (T0) and at 3 (T1), 6 (T2) 9 (T3) and 12 (T4) 
weeks after the surgical 5/6 nephrectomy, the rats were subjected to intraperitoneal 
anesthesia with a 2 mg/kg BW of a 2:1 (v:v) 50 mg/mL ketamine (Ketalar, Parke-Davis, 
Lab. Pfeizer Lda, Seixal, Portugal) solution in 2.5% chlorpromazine (Largactil, Rhône-
Poulenc Rorer, Lab. Vitória, Amadora, Portugal), to collect blood by venipuncuture, from 
the jugular vein, into vacutainer tubes without anticoagulant (to obtain serum) or with 
K3EDTA for hematological and biochemical studies; at T0, T1, T2 and T3 only 3 mL of 
blood were collected, to minimize interference with erythropoiesis mechanism, in order 
to monitor anemia and renal function; at the end of protocol (T4) 10 mL of blood were 
collected, to perform all the biochemical and hematological assays. 
At the end of the protocol, after collection of blood, the rats were sacrificed by 
cervical dislocation; kidneys, duodenum, liver and heart were immediately removed, 
placed in ice-cold Krebs-Henseleit buffer and carefully cleaned. A bone marrow aspirate 
from the femur was also performed. 
 
 
3.3. Biochemical and hematological assays 
Serum creatinine and blood urea nitrogen (BUN) were used as renal function 
markers; glicose, total cholesterol (Total-c), triglycerides (TGs), creatine kinase (CK), 
aspartate transaminase (AST) and alanine transaminase (ALT) were analysed through 
automatic validated methods and equipments (Hitachi 717 analyser, Roche Diagnostics 
Inc., Massachusetts, USA). 
Red blood cells (RBC) count, hematocrit (Hct), hemoglobin (Hb), reticulocyte 
count (Ret) mean cell hemoglobin (MCH), mean cell hemoglobin concentration (MCHC), 
mean cell volume (MCV), platelet count (PLT), platelet distribution width (PDW), RBC 
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distribution width (RDW) and white blood cells count (WBC) were assessed in whole 
blood K3EDTA (Coulter Counter
, Beckman Coulter, Inc., Fullerton, California, USA).  
Serum iron concentration was determined using a colorimetric method (Iron, 
Randox Laboratories Ltd., North Ireland, UK), whereas serum ferritin and transferrin 
were measured by immunoturbidimetry (Laboratories Ltd., North Ireland, UK).  
Serum levels of interleukin-6 (IL-6), interferon  (IFN-), transforming growth 
factor beta 1 (TGF-1) and vascular endothelial growth factor (VEGF) were all measured 
by rat-specific Quantikine ELISA kits from R&D Systems (Minneapolis, USA). High-
sensitive C-reactive protein (hsCRP) was determined by using a rat-specific Elisa kit from 
Alpha Diagonostic International (San Antonio, USA). Serum levels of erythropoietin (EPO) 
were evaluated by rat specific ELISA kit (MyBioSource, USA).  
Quantification of total bilirubin was performed by a colorimetric test of 
diazotized sulfanilic acid reaction (Roche Diagnostics Inc., Massachuasetts, USA); 
circulating levels of glucose and uric acid were determined by routine automated 
technology (ABX Diagnostics, CA, USA).  
 
 
3.4. Flow cytometry  
To study leukocyte activation, the mononuclear cells were then isolated from the 
other blood cells by density gradient centrifugation (700g, 20 min. at room temperature) 
(Histopaque-1077 and -1119, from Sigma-Aldrich, Sintra, Portugal) followed by 3 
washing steps with phosphate buffered saline solution (PBS, pH =7.4), supplemented 
with 3% (v/v) fetal bovine serum (FBS). We used antibodies against CD3, CD4, CD8 and 
CD25 (all from BD Biosciences, San Diego, CA, USA), conjugated either to FITC, PE or 
PerCP. Fluorochrome-conjugated isotype-matched antibodies were used as negative 
controls. For surface staining, mononuclear cells (≈1 × 106 cells in 100 μl PBS containing 
3% (v/v) fetal bovine serum and 0.1% NaN3) were incubated with 1 μg antibody in the 
dark, at room temperature, for 30 minutes and then washed three times with PBS 
supplemented with FBS 3% (v/v); 400 µl of PBS supplemented with 3% (v/v) FBS was 
finally added to each tube. The treated samples and controls were analyzed by flow 
cytometry within a 1h period. Flow cytometric analysis was carried out in a FACS Calibur 
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(San Jose, CA, USA) based on the acquisition of 20000 events. Detectors for forward 
(FSC) and side (SSC) light scatter were set on a linear scale, whereas logarithmic 
detectors were used for all three fluorescence channels (FL-1, FL-2 and FL-3). 
Compensation for spectral overlap between FL channels was performed for each 
experiment using single-color-stained cell populations. For the experimental samples, a 
corresponding isotype control was used to set gates, or positive/negative cell 
populations. All data were analyzed using FlowJo software (TreeStar Inc, Ashland, OR, 
USA). 
 
 
3.5. Gene expression analysis 
In order to isolate total RNA, 0.2 g samples of liver, duodenum and kidney, from 
each rat, were immersed in RNA laterTM (Ambion, Austin, USA) upon collection and 
stored at 4°C for 24h; afterwards, samples were frozen at -80 ºC. Subsequently, tissue 
samples weighing 50±10 mg were homogenized in a total volume of 1 ml TRI Reagent 
(Sigma, Sintra, Portugal) using a homogenizer, and total RNA was isolated as described in 
the TRI Reagent Kit. To ensure inactivation of contaminating RNAses, all material used 
was cleaned and immersed in RNAse-free water (0.2% diethyl pyrocarbonate) for 2h and 
finally heated at 120ºC for 1h. RNA integrity (RIN, RNA Integrity Number) was analyzed 
using 6000 Nano ChipW kit, in Agilent 2100 bioanalyzer (Agilent Technologies, 
Walbronn, Germany) and 2100 expert software, following manufacturer instructions. 
The yield from isolation was from 0.5 to 1.5 μg; RIN values were 7.0–9.0 and purity 
(A260/A280) was 1.8–2.0. The concentration of the RNA preparations were confirmed 
with NanoDrop1000 (ThermoScientific,Wilmington, DE, USA). Possible contaminating 
remnants of genomic DNA were eliminated by treating these preparations with 
deoxyribonuclease I (amplification grade) prior to RT-qPCR amplification. Reverse 
transcription and relative quantification of gene expression were performed as 
previously described.21  
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Table III-1. List of primer sequences (F: forward; R: reverse). 
Gene Primer sequences 
EPO 
F: 5’-AGGGTCACGAAGCCATGAAG-3’ 
R: 5’-GAT TTC GGC TGT TGC CAG TG-3’ 
EPOR 
F: 5’-GCG ACT TGG ACC CTC TCA TC-3’ 
R: 5’-AGT TAC CCT TGT GGG TGG TG-3’ 
Hamp 
F: 5’-GAA GGC AAG ATG GCA CTA AGC-3’ 
R: 5’-CAG AGC CGT AGT CTG TCT CG-3’ 
TfR2 
F: 5’-CAA GCT TCG CCC AGA AGG TA-3’ 
R: 5’-CGT GTA AGG GTC CCC AGT TC-3’ 
SLC40A1 
F: 5’-CAG GCT TAG GGT CTA CTG CG-3’ 
R: 5’-CCG AAA GAC CCC AAA GGA CA-3’ 
HJV 
F: 5’-GCC TAC TTC CAA TCC TGC GT-3’ 
R: 5’-GGT CAA GAA GAC TCG GGC AT-3’ 
TF 
F: 5’-GGC ATC AGA CTC CAG CAT CA-3’ 
R: 5’-GCA GGC CCA TAG GGA TGT T-3’ 
Hfe 
F: 5’-CTG GAT CAG CCT CTC ACT GC-3’ 
R: 5’-GTC ACC CAT GGT TCC TCC TG-3’ 
DMT1 
F: 5’-CAA CTC TAC CCT GGC TGT GG-3’ 
R: 5’-GTC ATG GTG GAG CTC TGT CC-3’ 
TfR1 
F: 5’-GCT CGT GGA GAC TAC TTC CG-3’ 
R: 5’-GCC CCA GAA GAT GTG TCG G-3’ 
TMPRSS6 
F: 5’-CCG AAT ATG AGG TGG ACC CG-3’ 
R: 5’-GGT TCA CGT AGC TGT AGC GG-3’ 
BMP6 
F: 5’-GCT GCC AAC TAT TGT GAC GG-3’ 
R: 5’-GGT TTG GGG ACG TAC TCG G-3’ 
IL-6 
F: 5’-ATG TTG TTG ACA GCC ACT GC-3’ 
R: 5’- TTT TCT GAC AGT GCA TCA TCG-3’ 
IL-1 
F: 5’-CTC TGT GAC TCG TGG GAT GAT G-3’ 
R: 5’-CAC TTG TTG GCT TAT GTT CTG TCC-3’ 
CTGF 
F: 5’-CGT AGA CGG TAA AGC AAT GG-3’ 
R: 5’-AGT CAA AGA AGC AGC AAA CAC-3’ 
NF-kB 
F: 5’-ACC TGA GTC TTC TGG ACC GCT G-3’ 
R: 5’-CCA GCC TTC TCC CAA GAG TCG T-3’ 
VEGF 
F: 5’- GAA GTT CAT GGA CGT CTA CCA G -3’ 
R: 5’- CAT CTG CTA TGC TGC AGG AAG CT -3’ 
TNF- 
F: 5’- CCC AGA CCC TCA CAC TCA GAT CAT -3’ 
R: 5’ – GCA GCC TTG TCC CTT GAA GAG AA-3’ 
18S 
F: 5’-CCA CTA AAG GGC ATC CTG GG-3’ 
R: 5’-CAT TGA GAG CAA TGC CAG CC-3’ 
Actb 
F: 5’-GAG ATT ACT GCC CTG GCT CC-3’ 
R: 5’-CGG ACT CAT CGT ACT CCT GC-3’ 
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Real-time qPCR reactions were performed for erythropoietin (EPO), 
erythropoietin receptor (EPOR), transferrin receptor 2 (TfR2), hepcidin (Hamp), 
ferroportin (SLC40A1), hemojuvelin (HJV), transferrin (TF), hemochromatosis (Hfe), 
divalent metal transporter 1 (DMT1), transferrin recptor 1 (TfR1), matriptase-2 
(TMPRSS6), interleukin-6 (IL-6) and bone morphogenic protein 6 (BMP6); vascular 
endothelial growth factor (VEGF), interleukin-1 beta (IL-1), nuclear transcription factor 
kappa B (NF-kB), connective tissue growth factor (CTGF) and tumor necrosis factor alpha 
(TNF-) which were normalized in relation to the expression of beta-actin (Actb), and 
18S ribosomal subunit (18S).Primer sequences are listed on Table III-1. Results were 
analyzed with SDS 2.1 software (Applied Biosystems, Foster City, CA, USA) and relative 
quantification calculated using the 2-ΔΔCt method.22 In liver tissue we studied the EPO, 
EPOR, TfR1, TfR2, Hamp, Il-6, SLC40A1, HJV, TF, Hfe, BMP6 and TMPRSS6 gene 
expression; in duodenum tissue the gene expression of DMT1 and SLC40A1 were 
studied, and in the kidney we evaluated the expression of EPO, EPOR, Il-6, IL-1, TNF-, 
NF-kB, CTGF and VEGF genes. 
 
 
3.6. Histopathological analysis 
Tissue samples were fixed in neutral formalin 10% and embedded in paraffin 
wax; afterwards, 4μm thick sections for routine histopathological studies were stained 
with hematoxylin and eosin (HE). Periodic acid of Shiff (PAS) was used to evaluate and 
confirm the levels of mesangial expansion, thickening of basement membranes and 
sclerotic parameters. For PAS staining, the tissue samples were fixed in neutral formalin 
10%, embedded in paraffin wax, and 4μm thick sections were immersed in water and 
subsequently treated with 1% aqueous solution of periodic acid (1%), then washed to 
remove any traces of the periodic acid, and finally treated with Schiff’s reagent. All 
samples were examined by light microscopy using a Microscope Zeiss Mod. Axioplan 2. 
The degree of injury visible by light microscopy was scored in a double-blinded fashion 
by two pathologists. Lesions were evaluated on the total tissue on the slide. Glomerular 
and tubulointerstitial lesions were divided in mild and advanced. Mild glomerular 
damage was assessed by evaluating thickening of Bowman’s capsule, hyalinosis of the 
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vascular pole, glomerular atrophy, hypercellularity and dilatation of Bowman´s space. 
Advanced glomerular damage was assessed by grading sequentially four main lesions, 
from the less to the worse one: 1 – thickening of glomerular basement membrane 
(GBM), 2 – mesangial expansion, 3 – nodular sclerosis and 4 – global glomerulosclerosis. 
When advanced lesions were presented at a given glomeruli, the analysis of mild lesions 
become unavailable. Mild tubulointerstitial lesions included tubular hyaline droplets, 
tubular basement membrane (TBM) irregularity, tubular dilatation, interstitial 
inflammatory infiltration and vacuolar tubular degeneration. Advanced tubulointerstitial 
lesions were assessed evaluating the presence of hyaline cylinders, tubular calcification, 
necrosis and the association of interstitial fibrosis and tubular atrophy (IFTA). The 
evaluation of vascular lesions was focused on arteriolar hyalinosis, arteriolosclerosis and 
arteriosclerosis.  
A semiquantitative rating for each slide ranging from normal (or minimal) to 
severe (extensive damage) was assigned to each component. Severity of lesions was 
graded according to the extension occupied by the lesion (% area): 0 – absent/normal: 0 
%; 1 – <25%; 2 – 25–50%; 3 – >50%. The final score for each sample was obtained by the 
average of scores observed in individual glomeruli in the analysed microscopic fields. 
Tubulointerstitial damage was evaluated and graded by the same semiquantitative 
method. When using PAS, the rating was set for intensity and extension of staining, 
ranging from 0 (no staining) to 3 (intense and extensive staining), referring tissue 
specificity scoring when adequate.  
 
 
3.7. Immunohistochemistry analysis 
Liver and renal cortex/medulla paraffin sections (4 µm) from each sample were 
dewaxed in xylene, rehydrated in a series of ethanol washes, and placed in distilled 
water before staining procedures. The samples were processed for indirect immune 
detection using a mousse and rabbit specific horseradish peroxidase (HRP)/ 
diaminobenzidine (DAB) detection IHC kit (ab80436, Abcam Inc, Cambridge, UK), 
according to the manufactory’s protocol. Negative controls were included in each 
staining series, by omission of the primary antibodies. Antigen retrieval was performed 
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for 20 minutes for paraffin-embedded tissue in the preheated Citrate Buffer (10 mM 
Citric Acid, pH 6.0) using a pressure cooker. Between incubations with the antibodies, 
the specimens were washed two to four times in buffer PBS (pH 7.4). All incubations 
were performed overnight at 4ºC in a humidified chamber. In this study, we employed 
primary antibodies from Abcam Inc. (Cambridge, UK) for detection of hepcidin (dilution 
1:150; ab81010) and CTGF (dilution 1:250, ab6992), and from Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA) from detection of NF-κB p50 (dilution 1:500, sc-114); HIF-2 
(dilution 1:250, sc-28706) and HIF-2 (dilution 1:100, sc-5581). For 
immunohistochemical quantification, ten 400x microscopic views of liver and renal 
cortex and medulla per slide were selected randomly and photographed using a Leica 
DFC480 microscope (Leica Microsystems, Wetzlar, Germany). Intensity and area of 
positive staining, detected by brown staining were used as criteria: intensity was 
evaluated as weak (1), moderate (2) or strong (3); the percentage of area was 
quantified. A staining score (Quick Score) was then calculated according to previously 
described,23 using the formula: Quick Score = intensity (1, 2 or 3) multiplied by area 
(percentage). The final score (out of maximum of 300) for each group was obtained 
averaging the individual scores of each animal. 
 
 
3.8. Data analysis 
For statistical analysis, we used the IBM Statistical Package for Social Sciences 
(SPSS), version 20 (2011). Significance level was accepted at p less than 0.05. Results are 
presented as means ± standard error of means (SEM). Comparisons between groups 
were performed using non-parametric tests (Mann-Whitney test). 
 
 
4. Results 
4.1. Body and tissue weights and blood pressure 
At the end of experimental protocol (12 weeks), a significant decrease (p<0.001) 
of BW was observed in CRF rats, when compared to Sham. In addition, KW and KW/BW 
(p<0.001 for both) presented higher values in the CRF animals. While HW was 
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unchanged, HW/BW ratio was higher (p<0.01) in CRF rats. Despite the lower value 
(p<0.01) of LW in the CRF group, LW/BW was higher (p<0.05) when compared with the 
Sham group (Table III-2). CRF rats presented a significantly higher (p<0.01) systolic blood 
pressure at the final time, when compared with the Sham animals, but similar values 
were found for DBP, MBP and HR (Table III-2). 
 
 
4.2. Biochemical and hematological data 
The biochemical and hematological data for the Sham and CRF groups are 
presented in Tables III-2 and III-3 and Figure III-2. The CRF rats presented significantly 
(p<0.001) increased serum BUN and creatinine concentrations three weeks after the 
partial 5/6 nephrectomy.  
 
 
Figure III-2. Renal and hematological data throughout the follow-up period of 12 weeks. 
Evolution of BUN (A), creatinine (B), hemoglobin (C) and hematocrit (D) values throughout the 
experimental protocol. Results are presented as mean ± SEM: *- p < 0.05, **- p < 0.01, and ***- 
p < 0.001 versus Sham group. BUN, blood urea nitrogen. 
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The values remained elevated until the 9th week, after which a further increase 
was observed at the final time (p<0.001 and p<0.05, respectively), when compared with 
the Sham group (Figures III-2A and III-2B). Concerning the other biochemical 
parameters, similar values were observed, except for Total-c, ALT, hsCPR and VEGF, 
which were significantly higher in CRF rats (p<0.05) at the final time (Table III-2 and 
Figure III-8B). 
 
 
Table III-2. Body and tissue weights, blood pressure and biochemical data at the final time. 
Parameters 
Final time (12 weeks) 
Sham group CRF group 
Body and tissues weights    
BW (Kg) 0.45±0.02 0.36±0.01 *** 
KW (g) 1.22±0.03 1.65±0.04 *** 
KW/BW (g/Kg) 2.72±0.05 4.61±0.22 *** 
HW (g) 1.16±0.03 1.24 ± 0.07 
HW/BW (g/Kg) 2.58±0.08 3.48±0.25 ** 
LW (g/Kg) 13.33±0.48 11.32±0.34 ** 
LW/BW (g/Kg) 29.61±0.65 31.43±0.71 * 
Blood pressure and heart rate   
SBP (mmHg)  117.7  1.15 134.1  4.6 ** 
DBP (mmHg)  112.0  0.58 111.5  4.5 
MBP (mmHg)  114.3  1.45 121.3  4.5 
HR (beats/min)  360.7 1.20 373.0  9.2 
Biochemical data   
Glicose (mmol/L)  9.460.31 8.660.60 
TGs (mmol/L) 1.050.14 1.580.32 
Total-c (mmol/L)) 1.250.06 2.440.54 * 
CK (U/L)  540.5758.94 473.0085.57 
ALT (U/L)  35.172.21 42.0018.53* 
AST (U/L)  80.577.84 139.4370.70 
Bilirubin (µmol/L) 8.04e-51.03e-5 1.03e-41.71e-5 
hsCRP (µg/mL)  262.2512.43 225.317.95 * 
INF- (pg/mL)  23.303.10 25.512.26 
TGF-β1 (ng/mL) 75.745.62 84.133.85 
Results are presented as mean ± SEM: *- p < 0.05, **- p < 0.01, and ***- p < 0.001 versus Sham 
group. ALT, alanine transaminase; AST, aspartate transaminase; BW, body weight; CK, creatine 
kinase; DBP, diastolic blood pressure; HR, heart rate; hsCRP, high-sensitive C reactive protein; 
HW, heart weight; IFN-, interferon  ; KW, kidney weight; LW, liver weight; SBP, systolic blood 
pressure; TGs, triglycerides; TGF-β1, transforming growth factor beta 1; Total-c, total 
cholesterol; VEGF, vascular endothelial growth factor. 
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Three weeks after the 5/6 nephrectomy, the CRF rats developed anemia, as 
showed by the significant decline of Hb and HTC (p<0.001); the anemia persisted along 
the protocol. Analysing the results at the end of the protocol, we found that CRF animals 
showed significantly (p<0.01) decreased RBC count, and a trend towards a reduced 
reticulocyte count, when compared to the Sham rats. The MCV, MCH, RDW, PLT count 
and PDW values were similar and MCHC was significantly higher. Moreover, we found 
that WBC count, as well lymphocytes CD3+, CD3+CD4+, CD3+CD4+CD25+ and CD3+CD8+ 
counts were similar for both groups. However, the percentage of activated cytotoxic T 
cells (CD3+CD8+CD25+) was significantly increased in the CRF group (p<0.01) versus Sham 
(Table III-3). 
 
Table III-3. Hematological data at the final time. 
Parameters 
Final time (12 weeks) 
Sham group CRF group 
Hematological data   
RBC (x 1012/L)  7.940.08 6.530.43 ** 
Ret (x109/L)  181.226.82 168.1417.32 
MCV (fL)  52.520.53 51.930.69 
MCH(pg)  18.080.18 18.360.24 
MCHC (g/dL)  34.600.08 35.370.19 ** 
RDW (%)  11.482.53 18.343.23 
PLT (x 109/L)  713.7515.19 769.0073.17 
PDW (%)  16.340.18 16.440.20 
WBC (x 109/L)  1.780.30 5.011.76 
T Lymphocytes (%) 57.201.36 54.672.91 
CD3+CD4+ T cells (%) 72.180.60 72.481.16 
CD3+CD4+ CD25+ T cells (%) 5.970.62 5.850.70 
CD3+CD8+ T cells (%) 24.161.34 28.172.17 
CD3+CD8+ CD25+ T cells (%) 0.400.04 0.630.01** 
Results are presented as mean ± SEM: *- p < 0.05, **- p < 0.01, and ***- p < 0.001 versus Sham 
group. Hb, hemoglobin; Hct, hematocrit; MCH, mean cell hemoglobin; MCHC, mean cell 
hemoglobin concentration; MCV, mean cell volume; PDW, platelet distribution width ; PLT, 
platelets; RBC, red blood cells; RDW, RBC distribution width; Ret, reticulocytes; WBC, white 
blood cells. 
 
 
4.3. Serum EPO and liver and kidney EPO and EPOR mRNA expression 
At the final time, serum EPO was significantly higher (p<0.05) in the CRF group 
when compared with the Sham (Figure III-3A). In addition, there was a significant 
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(p<0.01) overexpression of EPO mRNA in the kidney and liver tissues of the CRF rats, 
when compared with the Sham animals (Figure III-3B and III-3C, respectively). 
Concerning EPOR mRNA, a significant (p<0.01) overexpression was found in the kidney 
tissue of the CRF rats, accompanied by a reduced (p<0.01) expression in the liver, when 
compared with the Sham group (Figures III-3B and III-3C, respectively). 
 
 
Figure III-3. Serum EPO and kidney and liver gene expression of EPO and EPO receptor. Serum 
EPO (A), EPO and EPOR mRNA levels/18s expression (% of Sham group) in kidney (B) and liver (C) 
tissues, at the end of the study (12 weeks). Results are presented as mean ± SEM: *- p < 0.05, 
and **- p < 0.01 versus Sham group. EPO, erythropoietin. 
 
 
4.4. Iron metabolism 
To study iron metabolism we evaluated several markers at blood and tissue (liver 
and duodenum) levels. When compared to sham group, we found a significant decrease 
in serum iron (p<0.001) and transferrin (p<0.001) in CRF rats, (Figures III-4A1 and III-4A3), 
and similar values for serum ferritin (Figure III-4A2).  
No significant changes between groups were found for liver mRNA expression of 
IL-6, sTfR2, TMPRSS6 and SLC40A1 (Figure 3B); however, there was a significantly lower 
liver mRNA expression of Hamp, sTfR1, TF, BMP6, Hfe, HJV (p<0.01 for all), BMP6 
(p<0.05) and HIF-2 (p<0.001) in the CRF rats when compared with the Sham ones 
(Figure III-4B); in the duodenum, a significant mRNA overexpression (p<0.05) of SLC40A1 
and a similar mRNA expression of DMT1 (Figure III-4C), were observed in CRF rats.  
The immunohistochemical expression of liver hepcidin (Figures III-5A1- III-5A3) 
and of HIF-2 (Figures III-5B1- III-5B3) presented similar values for CRF and Sham rats.  
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Figure III-4. Mediators of iron-hepcidin metabolism in serum, liver and duodenum. Serum iron 
(A1), ferritin (A2) and transferrin (A3) levels; relative gene expression mRNA levels/18s (% of Sham 
group) in liver (B) and duodenum (C) tissues, at final time (12 weeks). Results are presented as mean 
± SEM: *- p < 0.05, **- p < 0.01, and ***- p < 0.001 versus Sham group. BMP6, Bone morphogenic 
protein 6; DMT1, divalent metal transporter 1; HFE, Hemochromatosis; HJV, Hemojuvelin; IL-6, 
interleukin-6; SLC40A1, ferroportin; TMPRSS6, matriptase-2; sTfR2, soluble transferrin receptor 2; Tf, 
transferrin and TfR1, transferrin receptor 1. 
 
 
Figure III-5. Liver protein expression (by immunohistochemistry) of hepcidin (A1-A3) and HIF-2 
(B1-B3). Results are presented as mean ± SEM: *- p < 0.05, **- p < 0.01, and ***- p < 0.001 versus 
Sham group. Hamp, hepcidin antimicrobial peptide; HIF-2, Hypoxia inducible factor 2 alpha. 
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4.5. Kidney lesions  
No significant histomorphological changes were found in the kidneys of Sham 
rats at the end of the experimental period (Figures III-6A1 and III-6B1, Tables III-4 and III-
5). However, the CRF rats presented several glomerular (cortex) and tubulointerstitial 
(medulla) lesions. Concerning the mild glomerular lesions, most of the animals of the 
CRF group presented thickening of Bowman´s capsule (score: 1.570.43; p<0.01), 
hyalinosis of vascular pole (score: 0.860.14; p<0.01), glomerular atrophy (score: 
0.860.14; p<0.01) and hypercellularity (score: 1.000.00; p<0.01), while in Sham rats 
the lesions were absent (Table III-4 and Figure III-6).  
 
 
Table III-4. Scoring and distribution (%) of mild and advanced glomerular lesions. 
Mild lesions  
Score 
0  
Absent 
1 
<25% 
2 
25-50% 
3 
>50% 
Total  
Score 
Thickening of 
Bowman´s 
Capsule 
Sham, n (%) 7 (100%) 0 0 0 0.000.00 
CRF, n (%) 1 (14.3%) 3 (42.9 %) 1 (14.3%) 2 (28.6 %) 1.570.43** 
Hyalinosis of 
the vascular 
pole 
Sham, n (%) 7 (100%) 0 0 (0 %) 0 (0 %) 0.000.00 
CRF, n (%) 1 (14.3%) 6 (85.7%) 0 0 0.860.14** 
Glomerular 
atrophy 
Sham, n (%) 7 (100%) 0 0 0 0.000.00 
CRF, n (%) 1 (14,3%) 6 (85.7%) 0 0 0.860.14** 
Hypercellularity 
Sham, n (%) 7 (100%) 0 0 0 0.000.00 
CRF, n (%) 0 7 (100%) 0 0 1.000.00** 
Dilatation of 
the Bowman’s 
Space 
Sham, n (%) 7 (100%) 0 0 0 0.000.00 
CRF, n (%) 5 (71.4%) 2 (28.6%) 0 0 0.290.18 
TOTAL GROUP 
SCORE 
Sham  0.000.00 
CRF  0.910.12*** 
 
Rat  
Groups 
Advanced glomerular lesions  
None of 
the 
previous 
lesions (0) 
Thickening 
of GBM 
(1) 
Mesangial 
expansion 
(2) 
Nodular 
sclerosis 
(3) 
Global 
Glomerulosclerosis 
(4) 
TOTAL 
GROUP 
SCORE 
Sham, n (%) 7 (100%) 0 0 0 0 0.000.00 
CRF, n (%) 0 1 (14.3%) 5 (71.4%)  1 (14.3%) 0 2.00.22** 
Results are presented as mean ± SEM: *- p < 0.05, **- p < 0.01, and ***- p < 0.001 versus Sham 
group. 
 
 
|  Iron-hepcidin dysmetabolism and renal hypoxia and inflammation in CKD 
Resistance to rHuEPO therapy - studies in experimental models of anemia and CKD|  103 
In addition, all CRF rats presented at least one of the advanced glomerular 
lesions, namely mesangial expansion, that was present in 5 out of 7 rats (Table III-4 and 
Figure III-6A3). The total score of both mild (0.910.12; p<0.001) and advanced 
(2.000.22; p<0.01) glomerular lesions showed a significantly increased value in CRF rats 
(Table III-4 and Figure III-6A4). 
 
 
Table III-5. Scoring and distribuition (%) of mild and advanced tubulointerstitial lesions. 
Mild  
Lesions 
 
Score 
0 
Absent 
1  
<25% 
2  
25-50% 
3 
>50% 
Total 
Score 
Tubular 
Hyaline 
Droplets 
Sham, n (%) 7 (100%) 0 0 0 0.000.00 
CRF, n (%) 0 7 (100%) 0 0 1.000.00 ** 
TBM 
Irregularity 
Sham, n (%) 7 (100%) 0 0 0 0.000.00 
CRF, n (%) 0 3 (42.9%) 2 (28.5%) 2 (28.5%) 1.860.34** 
Tubular 
Dilatation 
Sham, n (%) 7 (100%) 0 0 0 0.000.00 
CRF, n (%) 2 (28.5%) 1 (14.3%) 2 (28.5%) 2 (28.5%) 1.570.48* 
Interstitial 
Inflammatory 
Infiltrate 
Sham, n (%) 4 (57.2 %) 3 (42.9%) 0 0 0.290.18 
CRF, n (%) 0 0 7 (100%) 0 2.000.00** 
Vacuolar 
Tubular 
Degeneration 
Sham, n (%) 0 7 (100%) 0 0 1.000.00 
CRF, n (%) 3 (42.9%) 3 (42.9%) 1 (14.3%) 0 0.710.29 
TOTAL GROUP 
SCORE 
Sham   0.260.08 
CRF   1.430.15*** 
 
Advanced 
Lesions 
 
Score 
0 
Absent 
1 
<25% 
2 
25-50% 
3 
>50% 
Total 
Score 
Hyaline 
cylinders 
Sham, n (%) 6 (85.7%) 1 (14.3%) 0 0 0.140.14 
CRF, n (%) 0 1 (14.3%) 6 (85.7%) 0 1.860.14** 
Tubular 
Calcification 
Sham, n (%) 7 (100%) 0 0 0 0.000.00 
CRF, n (%) 7 (100%) 0 0 0 0.000.00 
Necrosis 
Sham, n (%) 7 (100%) 0 0 0 0.000.00 
CRF, n (%) 2 (28.6%) 5 (71.4%) 0 0 0.710.18* 
IFTA 
Sham, n (%) 7 (100%) 0 0 0 0.000.00 
CRF, n (%) 0 3 (42.9%) 4 (57.1%) 0 1.570.20** 
TOTAL GROUP 
SCORE 
Sham   0.040.04 
CRF   1.040.16*** 
Results are presented as mean ± SEM: *- p < 0.05, **- p < 0.01, and ***- p < 0.001 versus the 
Sham group. TBM, tubular basement membrane; IFTA, interstitial fibrosis and tubular atrophy. 
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Concerning the mild tubulointerstitial lesions, most of the animals of the CRF 
group presented tubular hyaline droplets (score: 1.000.00; p<0.01), TBM irregularity 
(score: 1.860.34; p<0.01), tubular dilatation (score: 1.570.48; p<0.05) and interstitial 
inflammatory infiltration (score: 2.000.00; p<0.01) (Table III-5 and Figure III-6). 
Considering advanced tubulointerstitial lesions, the formation of hyaline cylinders 
(score: 1.860.14; p<0.01) and IFTA (score: 1.570.20; p<0.01) were the most relevant 
lesions observed in CRF rats, when compared with Sham rats (Table III-5 and Figures III-
6B2- III-6B3). Once again, total score of both mild (1.430.15; p<0.001) and advanced 
(1.040.16; p<0.001) tubulointerstitial lesions showed a significantly increased value in 
the CRF rats (Figure III-6B4).  
 
 
Figure III-6. Glomerular and tubulointerstitial lesions. Representative glomerular (cortex) and 
tubulointerstitial (medulla) lesions observed in kidneys of CRF and Sham groups, at the final time 
(PAS staining): A1 – normal glomerulus histology in the Sham rats; A2 – glomerular atrophy and 
thickening of glomerular basement membrane; A3 – glomerulus presenting mesangial expansion; A4 – 
total score of mild and advanced glomerular lesions in both rat groups; B1 – normal tubulointerstitial 
histology in the Sham rats; B2 – hyaline cylinders; B3 – interstitial fibrosis and tubular atrophy (IFTA); 
B4– Total score of mild and advanced tubulointerstitial lesions in both rat groups. Results are 
presented as mean ± SEM: **- p < 0.01 , and ***- p < 0.001 versus Sham group. 
 
 
4.6. Renal expression of hypoxia inducible factors and other markers of kidney lesion 
The immunohistochemical study showed a significant increase (p<0.01) in the 
expression of HIF-2 and HIF-2 in the kidney of CRF rats, as compared to Sham rats 
(Figures III-7A and III-7B, respectively). In addition, a significant overexpression of IL-6, 
IL-1 and TNF- mRNA in the CRF rats was found, when compared with Sham rats 
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(p<0.001); contrarily, a significant downexpression of NF-kB, CTGF and VEGF (p<0.01) 
was found in the remnant kidney of CRF rats, when compared with Sham ones (p<0.001) 
(Figure III-8A). Serum values for IL-6 were similar for both groups, while a significantly 
higher concentration for VEGF was observed in the CRF rats (p<0.05) (Figure III-8B). 
 
 
Figure III-7. HIF-2 and HIF-2 immunohistochemical expression in the kidney. Kidney 
immunohistochemical expression of HIF-2 (A) and HIF-2 (B) in the renal cortex of sham (1) and CRF 
(2) rats and corresponding Quick scores (3). Results are presented as mean ± SEM: ***- p < 0.001 
versus Sham group. HIF-2, hypoxia inducible factor 2 alpha, and HIF-2, hypoxia inducible factor 2 
beta. 
 
 
Figure III-8. Mediators of inflammation, fibrosis and angiogenesis. Relative gene expression 
mRNA levels/18s (% of Sham group) of mediators of kidney lesions (A) and serum IL-6 and VEGF- 
levels (B). Results are presented as mean ± SEM: *- p < 0.05, and **- p < 0.01 versus Sham group. 
CTGF, connective tissue growth factor; IL-1β, interleukin-1 beta; IL-6, interleukin-6; NF-kB; nuclear 
transcription factor kappa B; TNF-, tumor necrosis factor alpha; VEGF, vascular endothelial growth 
factor. 
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Concerning protein expression of NF-kB in the kidney tissue, a significantly higher 
immunoreactivity in the cortex and in the tubular epithelial cells (medulla) of the CRF 
rats was found, when compared with the Sham ones (p<0.01) (Figures III-9A2 and III-9B2, 
respectively). CTGF was weakly expressed in the glomerular (cortex) and interstitial cells 
(medulla) of Sham rat’s kidneys (Figures III-9C1 and III-9D1, respectively), while a 
significantly increased (p<0.01) expression was noted in the glomeruli and interstitial 
cells (medulla) of the CRF rats (Figures III-9C2 and III-9D2, respectively).  
 
 
Figure III-9. Kidney protein expression (by immunohistochemistry) of NF-kB and CTGF in renal 
cortex (A1-A3 and C1-C3, respectively) and medulla (B1-B3 and D1-D3, respectively). Results are 
presented as mean ± SEM: *- p < 0.05, and **- p < 0.01 versus Sham group. CTGF, connective tissue 
growth factor; NF-kB; nuclear transcription factor kappa B. 
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5. Discussion 
Chronic kidney disease (CKD) is a general term for heterogeneous disorders 
affecting the structure and function of the kidney. The variation in the clinical pattern of 
the disease has been associated to its etiology, severity and rate of progression. Since 
the introduction of the conceptual model for definition and staging of CKD and the 
establishment of the clinical practice guidelines to treat kidney disease patients, the 
disease evolved from a life-threatening disorder affecting few people who needed care 
by nephrologists, to a common disorder of varying severity that deserves the attention 
of a multidisciplinary team and needs a concerted public health approach for 
prevention, early detection and management.24,25 
Early detection of renal failure and initiation of treatment contribute to prevent 
or delay some of these associated adverse effects.26 Anemia, one of the most common 
complications of CKD, develops in the early phases of the disease, increasing its severity 
as the disease progresses, contributing to a patient’s poor quality of life.27 Anemia is 
mainly associated with a reduced production of EPO by the failing kidneys and with 
disturbances in iron metabolism. However, the clear relationship between renal and 
extra-renal EPO production, iron deficiency, hypoxia and evolution of kidney lesions 
remain to be elucidated.  
Animal models of CKD have been used as a tool to study the pathophysiological 
mechanisms underlying different stages of renal disease and of the associated anemia, 
as well as to test the efficacy of different therapies. The (5/6) nephrectomy model is the 
most used model of CKD, although there are different ways to achieve (5/6) reduction of 
nephron mass.26,28 This model involves substantial removal of nephrons, followed by 
compensatory renal hypertrophy of the remnant kidney. Increasing workload by the 
remaining nephrons leads to progression of renal injury, namely to CKD.29-32 
The results of the present study confirmed that the surgical (5/6) nephrectomy 
model of CKD produced a sustained stage of renal insufficiency, as shown by the 
significantly increased BUN and creatinine concentrations, after three weeks of the 
surgical procedure (Figure III-2); these values persisted for more 6 weeks, after which a 
further increment was observed, at the 12th week, the end of protocol. In addition, a 
significant increase in KW and in KW/BW ratio were found in CRF rats (Table III-2), 
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showing a compensatory renal proliferation/hypertrophy of the remnant kidney, as 
previously described for this model.33 A trend towards an increase in HW and a 
significant increase of HW/BW ratio was also found, suggesting the development of left 
ventricule hypertrophy, which is a cardiac complication found in the CKD patients. In 
fact, besides the anemia secondary to renal insufficiency, CKD patients usually develop 
cardiac failure that further aggravates renal disease. This triad of dysfunctions, known as 
cardio-renal anemia syndrome, is responsible for the serious complications observed in 
these patients.34,35 The progression of kidney disease and its associated 
cardiac/cardiovascular complications are the major causes of morbidity and mortality in 
these patients. One of the most prevalent co-morbidities is hypertension, which is 
present at all stages of CKD.36 Our results confirmed the development of systolic 
hypertension, which is a typical feature in CKD rat model (Table III-2). Usually, 
hypertension is inversely proportional to the residual functional renal mass, as occurs in 
human pathology.37,38 
As widely occurs in human CKD, we also observed the development of anemia, 
secondary to renal mass reduction, as shown by the reduced Hb and HTC values in the 
CRF rats, three weeks after nephrectomy that persisted along the following 9 weeks. 
Moreover, the reticulocyte count showed a trend towards reduced values, suggesting a 
reduced erythropoietic response to overcome the anemia. However, we found that 
serum EPO concentration was increased in CRF rats at the final time (T4), as compared 
to sham animals (Figure III-3), suggesting that EPO production is not reduced in this 
model of CKD-associated anemia, and that the remnant kidney or even extra-renal 
tissues were able to compensate EPO production. When peritubular fibroblasts in the 
kidney sense reduced oxygen tension, the production of hypoxia inducible factor is 
induced, via oxygen sensitive prolyl hydroxylases (PHDs), triggering the activation of 
hypoxia response genes, leading to an increase in the production of EPO.39 In the 
present work, we found a notable overexpression of EPO mRNA and EPOR mRNA in the 
kidney tissue of the CRF rats, as compared to Sham rats, as well as, an increased 
expression of HIF-2 in the kidney tissue (Figure III-7). These results suggest that the 
reduction of Hb levels in CRF rats, by leading to a reduced oxygen kidney perfusion, 
induced renal EPO production in response to low oxygen tension. The kidney is not the 
only organ able to adapt to EPO production, in response to low oxygen tension.40,41 
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Apparently, chronic hypoxia is also sensed by a HIF-dependent mechanism in which a 
nitric oxide (NO)-mediated redistribution of blood flow from inner organs to the skin is 
able to cause a secondary increase in renal EPO production.42 Extra-renal EPO 
production has been also described in the liver, although its contribution to the 
circulating EPO concentration in adults is highly debatable, even in kidney disease 
states.41 Actually, we found a significantly increased liver EPO mRNA expression in CRF 
rats (Figure III-3), accompanied by a reduced expression of EPOR mRNA. In spite of the 
increased serum EPO levels found in CRF rats, anemia persisted in these animals 
throughout the protocol, suggesting a blockade and/or a reduction in the activity of EPO. 
This hypothesis is supported by the fact that, when we administered rHuEPO (200 
IU/Kg/week) to these CRF rats, a rise in hemoglobin level was observed, reaching similar 
or even higher values than those found in the sham group (data presented in next 
chapter). Following the translation of the EPO gene, three N-linked and one O-linked 
carbohydrate chains are added to erythropoietin; these chains normally exhibit 
heterogeneity in the type of carbohydrate moieties incorporated, chain length and 
branching configuration;43,44 healthy individuals may present up to four residues on each 
N-linked carbohydrate chain, or up to two residues on the O-linked chain. Indeed, a 
variability in sialic acid composition may45 affect the circulating half-life of erythropoietin 
and the interactions with its receptor; in general, increasing sialic acid content correlates 
with longer and greater potency of EPO.46 Although the current understanding is, 
probably, incomplete, it is known that erythropoietin gene (EPO) expression is tightly 
regulated by several stimulators, namely, hypoxia-inducible transcription factors and 
hepatocyte nuclear factor 4α, and by several inhibitors, including nuclear factor kappa B 
and GATA2.47 
Iron is essential for the production of mature red blood cells and a normal iron 
metabolism is crucial to maintain body iron levels.10,48,49 A disturbance in iron 
homeostasis is a hallmark of the anemia of CKD, which, usually, presents as a functional 
iron deficient anemia, with low serum iron and transferrin alongside with normal or 
even high ferritin.50 In accordance, we found that CRF rats, as compared to Sham rats, 
showed a significant decrease in serum iron and transferrin levels and similar values for 
ferritin (Figure III-4). Therefore, in spite of the reduced serum iron, the anemia is not 
iron deficient, as the iron storage is normal, as showed by ferritin levels. In CKD patients 
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the functional iron deficient anemia is explained by the underlying inflammatory 
process, with increased hepcidin levels.51 Indeed, it has been reported that hepcidin 
plays pivotal role in the development of the anemia associated with CKD.10 Hepatocytes 
play a dual role in iron metabolism, acting as the major site of iron storage and of 
secretion of the iron regulatory hormone hepcidin (codified by the gene Hamp).51 
Hepcidin orchestrates systemic iron fluxes by controlling iron absorption through 
enterocytes and iron mobilization from macrophages. Hepcidin binds to the iron 
exporter ferroportin (SLC40A1, Solute carrier family 40, member 1) on the surface of 
iron-releasing cells, triggering its degradation and, therefore, reducing the iron 
absorption through the linkage of iron to transferrin.51 Hamp expression is elevated in 
inflammatory conditions (through IL-6 dependent pathway), in increased erythropoiesis 
and iron overload, and down-regulated during hypoxia or iron deprivation.52 In this 
animal model, a systemic inflammatory state cannot be recognized, as showed by CRP 
and IL-6 serum values that are similar for the two groups (Table III-2). However, a local 
renal inflammation, as suggested by the increased expression of IL-6, IL-1 and TNF- 
mRNA in the kidney tissue (Figure III-8), might contribute to alter EPO renal 
production/function and, therefore, erythropoiesis.  
The evidence for hypoxic regulation of Hamp remains controversial. Some 
studies show that Hamp is suppressed by hypoxia through HIF-1- and (possibly) HIF-2-
dependent pathways.13,53-55 Indeed, Hamp contains some HREs in its promoter region 
and its expression might be reduced directly by hypoxia.13 The evidence for this, 
however, is conflicting, as a recent study showed that HIF-1α and HIF-2α knockdown 
failed to reverse human Hamp repression by hypoxia; in addition, inducers of HIF (CO, 
hypoxia, oxalylglycine) also showed controversial results.56 Furthermore, deletion of 
putative HREs in the human Hamp promoter did not alter its response to hypoxia. Choi 
et al. (2007)57 also showed that the hypoxic downregulation of Hamp was independent 
of HIF-1 overexpression or knockdown; however, they suggested that the suppression 
of Hamp during hypoxia may involve HIF-2. Our results are in accordance with this, as 
we observed a markedly increased kidney expression of HIF-2 in renal medulla of CRF 
rats (Figure III-7). It is known that the expression of Hamp is modulated through several 
hepatocyte cell-surface proteins including Hfe, TfR2, HJV, TMPRSS6 and IL-6. Regardless 
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of the underlying molecular mechanism of reduction of Hamp expression during 
hypoxia, a decrease in hepcidin leads to an increased iron uptake and absorption at the 
duodenum, as well as to an increased iron release from the macrophages, favoring Hb 
synthesis and erythropoiesis.14 Actually, we found a significant downregulation in liver 
mRNA expression of Hamp, sTfR1, TF, Hfe, HJV and BMP6 in CRF rats, as compared with 
the Sham rats (Figure III-4), together with a significant duodenal overexpression of 
SLC40A1 gene in CRF rats and similar values for the expression of DMT1 gene (Figure III-
4), suggesting that iron absorption in the enterocytes was normal or even enhanced, as 
the increase in duodenal ferroportin expression may occur to counteract the low iron 
levels observed in CRF rats; in addition, hypoxia might contribute to the significantly 
decreased liver Hamp mRNA expression in CRF rats. Likewise, the absence of 
inflammation in CRF rats, as showed by normal values of serum and liver IL-6 expression, 
as well as of reduced serum hs-CRP, are in agreement with lower liver Hamp mRNA 
expression in these animals.  
This model of CKD has been associated to glomerulosclerosis and progressive 
tubulointerstitial damage. Although the mechanisms of tubular injury are poorly clarified 
in this and in other models of renal disease, proteinuria has a crucial role.58 It has been 
proposed that filtered iron may have also a role in tubular injury, when associated with 
proteinuria. Actually, in proteinuric states, as a result of the glomerular leak of 
transferrin, iron might be released from transferrin in the acid milieu of the tubular 
lumen.58 In fact, iron accumulation is observed in the proximal tubule in human CKD,59 
as well as in rat models with nephropathy58,60,61 and seems to be associated with the 
progression of CKD. The glomerular leakage of iron may explain the reduced serum iron 
and transferrin observed in CRF rats. Indeed, considering the anemia in the absence of 
inflammation, a rise in serum iron would be expected to face the needs for 
erythropoiesis. Naito et al. (2012)62 studied the effect of dietary iron restriction on the 
renal damage developed in a rat model of CKD, presenting nephron hyperfiltration, 
glomerulosclerosis and tubulointerstitial injury, and found that iron restriction 
attenuated these changes in CKD rats. This beneficial effect of iron restriction on renal 
damage is consistent with the results previously reported in the different models of 
renal disease.63,64 
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It is widely accepted that, regardless of the initial cause of renal failure, 
tubulointerstitial fibrosis is the major cause of disease progression in CKD.65,66 Typically, 
the functional impairment in CKD correlates with tubulointerstitial fibrosis, and with 
glomerulosclerosis. Tubulointerstitial damage is closely correlated with reduced 
creatinine clearance and is currently the best predictor of disease progression.66 Hypoxia 
and altered O2 perfusion are also potential players in the development of renal injury.
66 
As referred, in response to low oxygen supply, HIFs are produced triggering the 
expression of the hypoxia response genes, increasing the production of EPO, VEGF and 
of glycolytic enzymes. It is unclear if the increase in HIF has a renoprotective role, or if it 
contributes to interstitial fibrosis and/or tubular atrophy. This duality of effects has also 
been described for VEGF, another target gene of HIFs.67 We found significantly high 
serum VEGF levels (almost three fold the control value) (Figure III-8), probably explaining 
the repression in VEGF gene expression in the remnant kidney of CRF. Under hypoxic 
conditions in renal injury, the HIF system is activated, even before any histological 
evidence of tubulointerstitial damage,68,69 and the degree of HIF expression seems to 
correlate with the extent of tubular injury. However, whether this increased activity is 
beneficial or harmful is unclear and may well depend on the context, the cell type 
affected and/or the duration of HIF expression. Another major target gene for HIF is the 
pro-fibrotic connective tissue growth factor (CTGF).70 In our study, CRF rats presented 
several glomerular and tubulointerstitial lesions (Figure III-6). Mild glomerular lesions 
were observed in most of the CRF rats, presenting thickening of Bowman capsule, 
hyalinosis of vascular pole, glomerular atrophy and hypercellularity. All CRF rats 
presented at least one advanced glomerular lesion; mesangial expansion was the more 
frequent lesion (Table III-3). Regarding the mild tubulointerstitial lesions, most of the 
CRF rats presented tubular hyaline droplets, TBM irregularity, tubular dilatation and 
interstitial inflammatory infiltration. Concerning advanced tubulointerstitial lesions, 
hyaline cylinders and IFTA were the most relevant lesions observed in CRF rats (Table III-
5). As referred, besides hypoxia, CRF rats showed local inflammation in the remnant 
kidney, as suggested by overexpression of IL-6, IL-1 and TNF- genes, as well as NF-kB, 
a key mediator of inflammation. In addition, we found an overexpression of CTGF in the 
glomeruli and in interstitial cells (medulla), in agreement with the existence of 
tubulointerstitial lesions and fibrosis.  
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This model of CKD induced by 5/6 nephrectomy presented a sustained degree of 
renal dysfunction with mild and advanced glomerular and tubulointerstitial lesions. An 
anemia developed early after nephrectomy and persisted throughout the study. The 
remnant kidney was still able to produce EPO and the liver seems to increase EPO 
production. In spite of the increased EPO blood levels, the anemia persisted and was 
linked to low serum iron and transferrin levels, although iron storage was normal, and to 
absence of inflammation. The development of glomerular and tubular kidney damage 
may underlie iron leakage, explaining the reduction in iron. Actually, the reduced 
expression of hepcidin, probably induced by hypoxia, should favour iron absorption; 
indeed, iron absorption seems to be increased, as suggested by the increased expression 
of duodenal ferroportin. The persistence of anemia may result from the disturbance in 
iron metabolism and, eventually, by an altered activity/function of EPO that might result 
from hypoxic kidney cell damage and from the developed local inflammatory milieu.  
These findings might contribute to elucidate the mechanisms behind anemia 
persistence in chronic kidney disease patients, even when erythropoietin levels are not 
reduced, and open new windows to identify putative therapeutic targets for this 
condition, as well as for rHuEPO resistance, which occurs in a worrying percentage of 
CKD patients. 
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1. Abstract 
Despite of the multifactorial nature of anemia of CKD, the most well-known 
cause is inadequate erythropoietin production. Recent studies from our laboratory using 
the remnant kidney rat model of CKD showed that anemia persisted in spite of normal 
EPO serum levels, suggesting that anemia may result from disturbances in iron 
metabolism and from an altered activity/function of EPO that might result from kidney 
cell damage and from the developed kidney local inflammatory milieu. Our aim was to 
elucidate the mechanisms explaining the persistence of anemia in this model induced by 
5/6 nephrectomy, by using two rHuEPO doses (50 and 200 UI/kg/week) and focusing on 
iron metabolism, kidney hypoxia, inflammation and fibrosis.  
CRF rats showed a persistent anemia, a significant increase in BUN and creatinine 
levels, kidney hypertrophy, heart hypertrophy, arterial hypertension and glomerular and 
tubulointersititial kidney lesions. The lowest dose of rHuEPO (50IU) was unable to 
correct anemia and CRF-induced iron reduction; kidney hypertrophy and angiogenesis 
were enhanced. The highest dose (200IU) reduced kidney hypertrophy and angiogenesis 
and corrected anemia; serum iron increased and an overexpression of Tf, TfR2, BMP6, 
Hfe, HJV and Hamp mRNA was found in the liver; in addition, while tubular kidney 
lesions were aggravated, there was a more unfavorable environment for a normal EPO 
synthesis as well as for iron availability, which might be due to improved glomerular 
function. 
Our data suggest that the anemia developed in rats with long-term CRF is due to 
reduced erythropoietic activity, as the CRF rats were able to overcome the anemia when 
treated with rHuEPO. The local kidney inflammation and the type of kidney lesions seem 
to be crucial to the outcome of the anemia. A long-term treatment of CRF rats with 
rHuEPO leads to the development of rHuEPO antibodies and, therefore, to anemia, after 
about 6 weeks of treatment. In addition, the impact of this treatment depends on the 
rHuEPO doses, which should be enough to correct anemia, preventing kidney and heart 
hypertrophy, but not too high that will lead to worsening of glomerular and 
tubulointerstitial kidney lesions.  
Keywords: Anemia; chronic renal failure; rHuEPO therapy; iron metabolism, kidney 
hypoxia, fibrosis, inflammation, kidney damage. 
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2. Introduction 
Chronic kidney disease (CKD) is a debilitating disease affecting about 7% of 
people with more than 30 years and older, which translates to more than 70 million 
people in developed countries worldwide.1 This number is likely to be much higher given 
the unknown prevalence in underdeveloped countries. The increased prevalence of 
diabetes, hypertension and obesity, as well as the aging of the population, will 
perpetuate the rise of CKD.2,3 Several studies have documented that patients with CKD 
are at higher risk of cardiovascular disease than the general population, and show a 
higher rate of cardiovascular mortality.4-6 In particular, end-stage renal disease (ESRD) 
patients have a 500-fold greater rate of cardiovascular mortality than age-matched 
controls with normal renal function.7 Due to the asymptomatic nature of this disease, 
CKD is not frequently detected until its later progress, resulting in lost opportunities for 
prevention. Progress to kidney failure or other adverse outcomes could be prevented or 
delayed through early detection and treatment of CKD.8,9 
Anemia, very common in patients with CKD, is already observed in early stages of 
CKD (stage 3) and its prevalence and severity increases as renal failure progresses to 
more advanced stages.10 Despite the multifactorial nature of anemia, the most well-
known cause is inadequate erythropoietin (EPO) production. Indeed, a complex chain of 
events associated to the disease, including chronic inflammation, blood loss, vitamin 
deficiencies, decreased iron absorption and utilization, might contribute also to the 
anemia of CKD. As renal failure progresses, the contribution of EPO deficiency to anemia 
increases.10,11 
Recombinant human erythropoietin (rHuEPO) treatment has been used to 
correct anemia, particularly in end stage renal disease (ESRD) patients11-13, reducing the 
requirements for transfusion, improving quality of life, reducing left ventricular 
hypertrophy and improving morbidity and mortality in these patients.14-16 However, the 
target hemoglobin value has been subject of debate in recent years; in fact, randomized 
studies and meta-analyses showed that a total correction of the anemia (hemoglobin 
concentration > 12 g/dL) with ESA treatment is not associated with increased survival or 
with a significant improvement in the quality of life of the patients. Instead, it has been 
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associated with a potential increase in adverse cardiovascular effects, including 
increased risk of stroke, venous thromboembolism and mortality. 17-19 
In addition, there is a marked variability in the sensitivity to rHuEPO, with up to 
10-fold variability in dose requirements to achieve correction of the anemia. Up to 5–
10% of CKD patients show weak responses to ESA,20 this ESA hyporesponsiveness is 
associated with higher morbidity and mortality in end-stage renal disease (ESRD) 
patients.21,22 Although the mechanisms underlying this variability in ESA response are 
unclear,23,24 ESA resistance has been associated with inflammation, oxidative stress and 
iron deficiency, as major causes, and blood loss, hyperparathyroidism, aluminium 
toxicity and vitamin B12 or folate deficiencies, as minor causes.15,23,24 In addition, a 
serious adverse effect of the long-term administration of rHuEPO is pure red cell aplasia 
(PRCA), although rare. RHuEPO is weakly immunogenic, however, it may induce the 
production of immunoglobulin G antibodies against the recombinant molecules and the 
residual endogenous EPO.25-30 This adverse effect is more common since the 
introduction of biosimilar products, which could allow more patients to have access to 
these high-cost therapies. 
Despite a profusion of mechanistic and therapeutic insights, the treatment of 
anemia may be the most controversial aspect of CKD management. Recent evidences 
suggest that CKD anemia might be due to defective hypoxic signaling rather than an 
inability of the EPO-producing cells to synthesize EPO.31 A disturbance in iron 
homeostasis is also a hallmark of the anemia of CKD, which usually presents as a 
functional iron deficient anemia, with low serum iron and transferrin alongside with 
normal or even high ferritin.32 This functional iron deficient anemia has been explained 
by the underlying inflammatory process in CKD patients, presenting increased hepcidin 
levels.33 Hepcidin controls enterocyte iron absorption and macrophage iron mobilization 
by linking to the iron exporter ferroportin present on the surface of those iron-releasing 
cells, triggering its degradation.33 A recent study of our group34, using the remnant 
kidney rat model of CKD induced by 5/6 nephrectomy, showed that along 9 weeks after 
nephrectomy the rats presented a sustained degree of renal dysfunction and an anemia 
developed 3 weeks after nephrectomy that persisted along the protocol, in spite of the 
high levels of serum EPO. This anemia was associated with low serum iron and 
transferrin levels, although the iron storage was normal, in the absence of systemic 
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inflammation; advanced kidney lesions were observed that might allow the leakage of 
iron-transferrin complexes and, therefore, the persistence of anemia may result from 
iron disturbances due to kidney lesions; another hypothesis is that an altered 
activity/function of EPO results from hypoxic kidney cell damage and/or from the local 
inflammatory milieu developed in the remnant kidney. It would be important to clarify 
the mechanisms underlying this hyporesponse to endogenous EPO, as it could give new 
insights into the mechanisms of development of resistance to rHuEPO therapy in CKD 
patients. Moreover, it would be also important to further clarify the impact of the 
treatment of anemia with high doses of rHuEPO that are usually used in non-responders 
patients.  
The aim of our study was to elucidate the mechanisms explaining the persistence 
of the anemia in the remnant kidney rat model of CKD induced by 5/6 nephrectomy, by 
treating the rats with rHuEPO and focusing our studies on iron metabolism, kidney 
hypoxia, inflammation and fibrosis.  
 
 
3. Material and methods 
3.1. Animals and experimental protocol 
Male Wistar rats (Charles River Lab., Inc., Barcelona, Spain) weighing ±300 g were 
maintained in an air conditioned room, subjected to 12 h dark/light cycles and given 
standard rat chow (IPM-R20, Letica, Barcelona, Spain) ad libitum and free access to tap 
water. Animal experiments were conducted according to the European Communities 
Council Directives on Animal Care and the National Authorities. 
The rats were divided into four groups (7 rats each): Sham group – submitted to 
surgical process but without kidney mass reduction and rHuEPO treatment; chronic 
renal failure (CRF) group - induced by a two-stage (5/6) nephrectomy (about 2/3 of the 
left kidney was removed by left flank incision and, one week later, the right kidney was 
removed through identical procedure); CRF+50IU rHuEPO  group - treated with rHuEPO 
(beta epoetin) - 50 IU/Kg/week s.c., Recormon (Roche Pharmaceuticals – Roche 
Farmacêutica Química, Lda., Amadora, Portugal) after the third week of surgery; and 
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CRF+200 IU rHuEPO group - treated with rHuEPO (beta epoetin) - 200 IU/Kg/week s.c, 
after the third week of surgery (Figure IV-1). All animals completed the 12 weeks of 
protocol. Body weight (BW) was monitored throughout the study and blood pressure 
(BP) and heart rate (HR) measures were obtained using a tail-cuff sphygmomanometer 
LE 5001 (Letica, Barcelona, Spain). 
 
 
Figure IV-1. Experimental protocol. 
 
 
3.2. Sample collection and preparation 
At the beginning of the experiments (T0) and at 3 (T1), 6 (T2), 9 (T3) and 12 (T4) 
weeks after the surgical (5/6) nephrectomy, the rats were subjected to intraperitoneal 
anesthesia with a 2 mg/kg BW of a 2:1 (v:v) 50 mg/mL ketamine (Ketalar, Parke-Davis, 
Lab. Pfeizer Lda, Seixal, Portugal) solution in 2.5% chlorpromazine (Largactil®, Rhône-
Poulenc Rorer, Lab. Vitória, Amadora, Portugal). Blood samples were collected by 
venipuncuture, from the jugular vein, into vacutainer tubes without anticoagulant (to 
obtain serum) or with K3EDTA for hematological and biochemical studies; only 3 mL of 
blood were collected at T0, T1, T2 and T3, to minimize interference with erythropoiesis 
mechanism and to monitor anemia and renal function; at the end of protocol (T4), 10 mL 
of blood were collected to perform all the biochemical and hematological assays.   
At the end of the protocol, after collection of blood, the rats were sacrificed by 
cervical dislocation and the kidneys, heart, liver and duodenum were removed, placed in 
ice-cold Krebs-Henseleit buffer. The body weight (BW) and the weight of kidney (KW) or 
of the 1/6 remnant kidney; the heart (HW) and the liver (LW) were measured to 
calculate the trophism indexes (KW/BW, HW/BW and LW/BW). 
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3.3. Biochemical and hematological assays 
The following serum markers were analyzed on a Hitachi 717 analyser (Roche 
Diagnostics Inc., Massachuasetts, USA) using standard methods: creatinine, blood urea 
nitrogen (BUN), as renal function markers; glycose, serum total cholesterol (Total-c), 
triglycerides (TGs), creatine kinase (CK), aspartate transaminase (AST), and alanine 
transaminase (ALT). Quantification of total bilirubin was performed by the colorimetric 
test of diazotized sulfanilic acid reaction (Roche Diagnostics Inc., Massachusetts, USA). 
Serum levels of interleukin-6 (IL-6), interferon- (IFN-), transforming growth factor beta 
1 (TGF-β1) and vascular endothelial growth factor (VEGF) were all measured by rat-
specific Quantikine ELISA kits from R&D Systems (Minneapolis, USA). High-sensitive C-
reactive protein (hsCRP) was determined by using a rat-specific Elisa kit from Alpha 
Diagonostic International (San Antonio, USA). Serum levels of erythropoietin (EPO) were 
evaluated by rat specific ELISA kit (MyBioSource, USA). All assays were performed 
according to the manufacturers’ recommendations. Red blood cell (RBC) count, 
hematocrit (Hct), hemoglobin concentration (Hb), mean corpuscular hemoglobin (MCH), 
mean cell hemoglobin concentration (MCHC), mean corpuscular volume (MCV), RBC 
distribution width (RDW), platelet distribution width (PDW), platelets (PLT) and white 
blood cell (WBC) count were assessed in whole blood K3EDTA (Coulter Counter®, 
Beckman Coulter, Inc., Fullerton, California, USA); reticulocyte (RET) count was 
performed by microscopic counting on blood smears after vital staining with New 
methylene blue (Reticulocyte stain, Sigma-Aldrich, St Louis, MO, USA). 
Serum iron concentration was determined using a colorimetric method (Iron, 
Randox Laboratories Ltd., North Ireland, UK), whereas serum ferritin and transferrin 
were measured by immunoturbidimetry (Laboratories Ltd., North Ireland, UK).  
 
 
3.4. Detection of anti-EPO antibodies  
To detect anti-EPO antibodies we used an ELISA technique,  according to Urra et 
al. (1997), using rHuEPO (Recormon, Roche Pharmaceuticals) as antigen and, as 
secondary antibody, goat anti-rat IgG conjugated with horseradish peroxidase (Sigma; 
100 ng/ml for 1h, at room temperature).35 The substrate tetramethylbenzidine (TMB) 
(Sigma) was added and the reaction was stopped by the addition of sulphuric acid 
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1.25mol/l. The optical density at 450 nm (OD450) was determined with an automatic 
plate reader. 
 
 
3.5. Gene expression analysis 
In order to isolate total RNA, 0.2 g samples of liver, duodenum and kidney, from 
each rat, were immersed in RNA laterTM (Ambion, Austin, USA) upon collection and 
stored at 4°C for 24h; afterwards, samples were frozen at -80ºC. Subsequently, tissue 
samples weighing 50±10 mg were homogenized in a total volume of 1 mL TRI Reagent 
(Sigma, Sintra, Portugal) using a homogenizer, and total RNA was isolated according to 
TRI Reagent Kit recomendations. To ensure inactivation of contaminating RNAses, all 
material used was cleaned and immersed in RNAse-free water (0.2% diethyl 
pyrocarbonate) for 2h and finally heated at 120ºC for 1h. RNA integrity (RIN, RNA 
Integrity Number) was analyzed using 6000 Nano ChipW kit, in Agilent 2100 bioanalyzer 
(Agilent Technologies, Walbronn, Germany) and 2100 expert software, following 
manufacturer instructions. The yield from isolation was from 0.5 to 1.5 μg; RIN values 
were 7.0–9.0 and purity (A260/A280) was 1.8–2.0. The concentration of the RNA 
preparations were confirmed with NanoDrop1000 (ThermoScientific,Wilmington, DE, 
USA). Possible contaminating remnants of genomic DNA were eliminated by treating 
these preparations with deoxyribonuclease I (amplification grade) prior to RT-qPCR 
amplification. Reverse transcription and relative quantification of gene expression were 
performed as previously described.36 Real-time qPCR reactions were performed using 
the following primer sequences for erythropoietin (EPO), erythropoietin receptor 
(EPOR), transferrin receptor 2 (TfR2), hepcidin (Hamp), ferroportin (SLC40A1), 
hemojuvelin (HJV), transferrin (TF), hemochromatosis (Hfe), divalent metal transporter 1 
(DMT1), transferrin receptor 1 (TfR1), matriptase-2 (TMPRSS6), Interleukin-6 (Il-6) and 
bone morphogenic protein 6 (BMP6), transforming growth factor beta 1 (TGF-1); 
vascular endothelial growth factor (VEGF), interleukin-1 beta (IL-1), nuclear 
transcription factor kappa B (NF-kB), connective tissue growth factor (CTGF), 
thrombospondin-1 (TSP-1), pro (III) collagen (Pro (III) collagen), cytocrome C (CytC), 
hypoxia inducible factor 2 alpha (HIF-2) and hypoxia inducible factor 2 beta (HIF-2β), 
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which were normalized in relation to the expression of beta-actin (Actb), and 18S 
ribosomal subunit (18S). Primer sequences are listed on Table IV-1.  
 
Table IV-1. List of primer sequences (F: forward; R: reverse). 
Gene Primer sequences 
EPO 
F: 5’-AGGGTCACGAAGCCATGAAG-3’ 
R: 5’-GAT TTC GGC TGT TGC CAG TG-3’ 
EPOR 
F: 5’-GCG ACT TGG ACC CTC TCA TC-3’ 
R: 5’-AGT TAC CCT TGT GGG TGG TG-3’ 
Hamp 
F: 5’-GAA GGC AAG ATG GCA CTA AGC-3’ 
R: 5’-CAG AGC CGT AGT CTG TCT CG-3’ 
TfR2 
F: 5’-CAA GCT TCG CCC AGA AGG TA-3’ 
R: 5’-CGT GTA AGG GTC CCC AGT TC-3’ 
SLC40A1 
F: 5’-CAG GCT TAG GGT CTA CTG CG-3’ 
R: 5’-CCG AAA GAC CCC AAA GGA CA-3’ 
HJV 
F: 5’-GCC TAC TTC CAA TCC TGC GT-3’ 
R: 5’-GGT CAA GAA GAC TCG GGC AT-3’ 
TF 
F: 5’-GGC ATC AGA CTC CAG CAT CA-3’ 
R: 5’-GCA GGC CCA TAG GGA TGT T-3’ 
Hfe 
F: 5’-CTG GAT CAG CCT CTC ACT GC-3’ 
R: 5’-GTC ACC CAT GGT TCC TCC TG-3’ 
DMT1 
F: 5’-CAA CTC TAC CCT GGC TGT GG-3’ 
R: 5’-GTC ATG GTG GAG CTC TGT CC-3’ 
TfR1 
F: 5’-GCT CGT GGA GAC TAC TTC CG-3’ 
R: 5’-GCC CCA GAA GAT GTG TCG G-3’ 
TMPRSS6 
F: 5’-CCG AAT ATG AGG TGG ACC CG-3’ 
R: 5’-GGT TCA CGT AGC TGT AGC GG-3’ 
BMP6 
F: 5’-GCT GCC AAC TAT TGT GAC GG-3’ 
R: 5’-GGT TTG GGG ACG TAC TCG G-3’ 
Il-6 
F: 5’- CGA GCC CAC CAG GAA CGA AAG TC-3’ 
R: 5’- CTG GCT GGA AGT CTC TTG CGG AG-3’ 
HIF-2 
F: TGA AAG AAG GAG AAG CCC AAT A-3’ 
R: CAT CAG AGT TAT GCC GAG ACA G-3’ 
18S 
F: 5’-CCA CTA AAG GGC ATC CTG GG-3’ 
R: 5’-CAT TGA GAG CAA TGC CAG CC-3’ 
Actb 
F: 5’-GAG ATT ACT GCC CTG GCT CC-3’ 
R: 5’-CGG ACT CAT CGT ACT CCT GC-3’ 
Il-1 
F: 5’-CTC TGT GAC TCG TGG GAT GAT G-3’ 
R: 5’-CAC TTG TTG GCT TAT GTT CTG TCC-3’ 
CTGF 
F: 5’-CGT AGA CGG TAA AGC AAT GG-3’ 
R: 5’-AGT CAA AGA AGC AGC AAA CAC-3’ 
NF-kB 
F: 5’-ACC TGA GTC TTC TGG ACC GCT G-3’ 
R: 5’-CCA GCC TTC TCC CAA GAG TCG T-3’ 
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Table IV-1 (Continuation). List of primer sequences (F: forward; R: reverse). 
Gene Primer sequences 
VEGF 
F: 5’ -GAA GTT CAT GGA CGT CTA CCA G -3’ 
R: 5’ -CAT CTG CTA TGC TGC AGG AAG CT -3’ 
Pro (III) Collagen 
F: 5’- CCA CCC TGA ACT CAA GAG TGG-3’ 
R: 5’ -CCA TCC AGA ACT GTG TAA GTG-3’ 
TSP-1 
F: 5’- CCG GTT TGA TCA GAG TGG T-3’ 
R: 5’ GGT TTC GGA AGG TGC AAT-3’ 
Cyt C 
F: 5’- CTT GTC ATA AAG TGG ATA TGA TC-3’ 
R: 5’ CAA TAG GTT TGA GGC GAC ACC CTC-3’ 
HIF-2 
F: 5’- TGA CTT CAC TCA TCC TTG CGA CCA-3’ 
R: 5’- ATT CAT AGG CAG AGC GGC CAA GTA-3’ 
 
Results were analyzed with SDS 2.1 software (Applied Biosystems, Foster City, 
CA, USA) and relative quantification calculated using the 2ΔΔCt method.37 In liver tissue 
we studied the EPO, EPOR, TfR1, TfR2, Hamp, Il-6, SLC40A1, HJV, TF, Hfe, BMP6 and 
TMPRSS6 gene expression; in duodenum tissue the gene expression of DMT1 and 
SLC40A1 were studied, and in the kidney we evaluated the expression of EPO, EPOR, IL-
1,  TSP-1, Pro (III) collagen, CytC, NF-kB, CTGF, VEGF , HIF-2 and  HIF-2 genes. 
 
 
3.6. Histopathological analysis 
Tissue samples were fixed in Bock’s fixative and embedded in paraffin wax; 4μm 
thick sections were stained for routine histopathological studies with hematoxylin and 
eosin (HE). Periodic acid of Shiff (PAS) was used to evaluate and confirm the levels of 
mesangial expansion, thickening of basement membranes and sclerotic parameters. For 
PAS staining, the samples were fixed in neutral formalin 10%, embedded in paraffin wax, 
and 4μm thick sections were immersed in water and subsequently treated with an 
aqueous solution of periodic acid (1%), then washed to remove any traces of the 
periodic acid, and finally treated with Schiff’s reagent. All samples were examined by 
light microscopy using a Microscope Zeiss Mod. Axioplan 2. The degree of injury visible 
by light microscopy was scored in a double-blinded fashion by two pathologists. Lesions 
were evaluated on the total tissue on the slide. Glomerular and tubulointerstitial kidney 
lesions were classified as mild and advanced. Mild glomerular damage was assessed by 
evaluating thickening of Bowman capsule, hyalinosis of the vascular pole, glomerular 
atrophy, hypercellularity and dilatation of Bowman´s space. Advanced glomerular 
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damage was assessed by grading sequentially four main lesions, from the less to the 
worse one: 1 – thickening of glomerular basement membrane (GBM), 2 – mesangial 
expansion, 3 – nodular sclerosis and 4 – global glomerulosclerosis. When advanced 
lesions were presented at a given glomeruli, the analysis of mild lesions become 
unavailable. Mild tubulointerstitial lesions included tubular hyaline droplets, tubular 
basement membrane (TBM) irregularity, tubular dilatation, interstitial inflammatory 
infiltration and vacuolar tubular degeneration. Advanced tubulointerstitial lesions were 
assessed by the presence of hyaline cylinders, tubular calcification, necrosis and the 
association of interstitial fibrosis and tubular atrophy (IFTA). The evaluation of vascular 
lesions was focused on arteriolar hyalinosis, arteriolosclerosis and arteriosclerosis. A 
semiquantitative rating for each slide, ranging from normal (or minimal) to severe 
(extensive damage), was assigned to each component. Severity of lesions was graded 
according to the extension occupied by the lesion (% area): 0 – absent/normal: 0 %; 1 – 
<25%; 2 – 25–50%; 3 – >50%. The final score of each sample was obtained by the 
average of scores observed in individual glomeruli in the observed microscopic fields. 
Tubulointerstitial damage was evaluated and graded by the same semiquantitative 
method. When using PAS, the rating was set for intensity and extension of staining, 
ranging from 0 (no staining) to 3 (intense and extensive staining), referring tissue 
specificity scoring when adequate. We performed Perl’s staining of kidney slides to 
search for iron accumulation within rat kidney tubules.  
 
 
3.7. Immunohistochemistry analysis 
Liver and renal cortex/medulla paraffin sections (4 µm) were dewaxed in xylene, 
rehydrated in a series of ethanol washes, and placed in distilled water before staining 
procedures. The samples were processed by indirect immune detection technique with 
mousse and rabbit specific horseradish peroxidase (HRP)/ diaminobenzidine (DAB) 
detection IHC kit (ab80436, Abcam Inc, Cambridge, UK), according to the manufactory’s 
protocol. Negative controls were included in each staining series, by omission of the 
primary antibodies. Antigen retrieval was performed for 20 minutes for paraffin-
embedded tissue in the preheated citrate buffer (10mM citric acid, pH 6.0) using a 
pressure cooker. Between incubations, specimens were washed two to four times in PBS 
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(pH 7.4). All incubations were performed in a humidified chamber.  In this study, we 
employed primary antibodies from Abcam Inc. (Cambridge, UK) for detection of hepcidin 
(dilution 1:150; ab81010) and CTGF (dilution 1:250, ab6992) and from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA) from detection of NF-κB p50 (dilution 1:500, sc-114), 
HIF-2 (dilution 1:250, sc-28706), and HIF-2 (dilution 1:100, sc-5581). For 
immunohistochemical quantification, five 400x microscopic views of liver and renal 
cortex and medulla per slide were selected randomly and photographed using a Leica 
DFC480 microscope (Leica Microsystems, Wetzlar, Germany). The area of positive 
staining was detected by brown staining in the liver and renal cortex, and measured. The 
mean average staining was defined as the percentage of positive area in the total area of 
livers and renal cortex and medulla. Then the percentage of weakly (1), moderately (2), 
and strongly (3) staining cells was determined. A staining score (Quick Score) was then 
calculated according to previously described,38 using the formula: Quick Score = intensity 
(1, 2 or 3) multiplied by area (percentage). The final score (out of maximum of 300) for 
each group was obtained averaging the individual scores of each animal. 
 
 
3.8. Data analysis 
For statistical analysis, we used the IBM SPSS Statistics 20 (2011). Significance 
level was accepted at p less than 0.05. Results are presented as means ± standard error 
of means (SEM). Comparisons between groups were performed using ANOVA and the 
Post hoc Tukey test.  
 
 
4. Results 
4.1. Body and tissue weights and blood pressure 
The CRF rats presented a reduced (p<0.05) BW when compared with the Sham 
group. In addition, significantly higher (p<0.01) values of KW/BW and HW/BW ratios 
were found versus those of the Sham animals, although, KW and HW were similar. 
Despite the lowest LW in the CRF group, LW/BW showed a trend to increased values 
when compared with the Sham group (Table IV-2). The CRF rats under 50IU rHuEPO 
treatment presented similar body and tissue weights when compared with the CRF rats 
without rHuEPO therapy, excepting for the significantly (p<0.05) increased KW. The CRF 
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rats treated with 200IU rHuEPO exhibited values similar to those found for CRF animals, 
excepting a significantly lower (p<0.05) KW/BW. 
 
 
Table IV-2. Effects of rHuEPO treatment on body and tissue weights and blood pressure at the 
end of protocol. 
Parameters/Groups 
Sham  
(n=7) 
CRF  
(n=7) 
CRF+50IU 
rHuEPO (n=7) 
CRF+200IU 
rHuEPO(n=7) 
Body and tissues weights  
BW (Kg) 0.45±0.02  0.36±0.01 a 0.37±0.01
aa
 0.39±0.01 
KW (g) 1.22±0.03 1.65±0.04  2.14±0.27 
aaa b
 1.69±0.08 
a
 
KW/BW (g/Kg) 2.72±0.05 4.61±0.22 aa 5.83±0.74 aaa 4.34±0.20 aa b 
HW (g) 1.16±0.03 1.24 ± 0.07 1.39±0.07 1.25±0.04 
HW/BW (g/Kg) 2.58±0.08 3.48±0.25 aa 3.73±0.19 aaa 3.21±0.14 a 
LW (g/Kg) 13.33±0.48 11.32±0.34  13.45±0.91 13.44±0.42 
LW/BW (g/Kg) 29.61±0.65 31.43±0.71  36.06±2.19a  34.41±1.14 a 
Blood pressures     
SBP (mmHg)  117.7  1.15 134.1  4.6aa 176.1±0.9aaa bbb 169.1±1.5aaa bbb 
DBP (mmHg)  110.1  0.59 113.2  2.08 124.,8±2.7 
a
  133.3±7.2
aaa bb
 
MBP (mmHg)  115.0  0.97 117.5  1.21 144.8±5.6
aaa bbb
 143.9±4.8
aaa bbb
 
HR (beats/min)  357.7 2.74 367.6  5.19 383.7±7.2 a 376.4±3.2 
Results are presented as mean ± SEM (7 rats per group): a- p < 0.05, aa- p < 0.01, and aaa- p < 
0.001 vs Sham; b- p < 0.05, bb- p < 0.01, and bbb- p < 0.001 vs CRF; c- p < 0.05, cc- p < 0.01, and 
ccc- p < 0.001 vs CRF+50IU rHuEPO group. BW, body weight; DBP, diastolic blood pressure; HR, 
heart rate; HW, heart weight; KW, kidney weight; LW, liver weight; MBP, mean blood pressure; 
SBP, systolic blood pressure. 
 
 
The CRF rats presented significantly increased (p<0.01) SBP, and similar DBP, 
MBP and HR, when compared with the normotensive animals of the Sham rats. The CRF 
rats treated with 50 IU rHuEPO showed a significant increase in SBP (p<0.001) and MBP 
(p<0.001) when compared with the CRF group. The CRF rats treated with 200 IU rHuEPO, 
presented significantly higher values of SBP (p<0.001), DBP (p<0.01) and MBP (p<0.001) 
when compared with CRF rats (Table IV-2). No significant changes were observed 
between CRF rats treated with 50 IU rHuEPO or with 200 IU rHuEPO.  
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4.2. Biochemical and hematological data 
The hematological and biochemical data for the different groups are presented in 
Figure IV-2 and Table IV-3. The Sham rats showed normal sustained hematologic values 
throughout the entire study (Figure IV-2A – IV-2D, respectively).  
 
Figure IV-2. Hematological and renal data throughout the follow-up period of 12 weeks. 
Hemoglobin concentration (A), red blood cell count (B), hematocrit (C), reticulocyte count (D), 
creatinine (E) and BUN concentrations (F). Results are presented as mean ± SEM (7 rats per 
group): a- p < 0.05, aa- p < 0.01, and aaa- p < 0.001 vs Sham; b- p < 0.05, bb- p < 0.01, and bbb- p 
< 0.001 vs CRF; c- p < 0.05, cc- p < 0.01, and ccc- p < 0.001 vs CRF+50IU rHuEPO group. BUN, 
blood urea nitrogen. 
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Three weeks after the 5/6 nephrectomy, the CRF rats developed anemia, as 
showed by the reduced Hb concentration, RBC count and HTC (p<0.001 for all), when 
compared to Sham group; RET count presented also a decrease (p<0.05). The anemia 
persisted until the end of the protocol. In the CRF rats were treated with 50 IU of 
rHuEPO, the anemic profile remained until the 9th week, after which there was a further 
reduction (p <0.05) of RBC count and HTC, as compared to CRF rats. In opposition, 3 
weeks after starting 200IU rHuEPO therapy in CRF rats (the 6th week of the protocol), the 
anemia was corrected and the rats presented significantly increased Hb concentration, 
HTC, RBC and RET counts, when compared to CRF rats. This erythropoietic response 
remained until the 9th week, after which the values returned to basal levels (Figure IV-2A 
– IV-2D).  
Concerning the other hematological measures, similar values (WBC, MCV, MCH, 
PLT and PDW) were found between CRF and Sham groups, excepting an increased 
(p<0.01) MCHC in the CRF rats. No significant differences were obtained between CRF 
rats and CRF rats under rHuEPO treatment, excepting for a reduced (p<0.05) RDW in the 
rats treated with the highest rHuEPO dose, when compared with the other groups (Table 
IV-3). In CRF rats, significantly (p<0.001) increased serum creatinine and BUN 
concentrations were found three weeks after 5/6 nephrectomy, as compared to Sham 
(Figures IV-2E and IV-2F, respectively). These values remained high until the 9th week, 
after which a further increment was observed at the final time (p<0.001 and p<0.05, 
respectively), when compared with the Sham group. Similar values of serum creatinine 
and BUN were observed between the CRF rats treated with rHuEPO (both doses) and 
those without treatment, throughout the entire protocol. Regarding the other 
biochemical data, the CRF rats presented increased (p<0.05) total-c, ALT and VEGF, 
when compared with Sham rats (Table IV-3). All the analysed parameters were similar 
between untreated and rHuEPO treated CRF rats, excepting for a reduced AST in the 
group under 200IU rHuEPO treatment. The 200IU rHuEPO group showed significantly 
higher levels of VEGF, as compared to Sham, and significantly lower levels of VEGF when 
compared with 200IU rHuEPO group.  
Serum samples from all animals were also analyzed for anti-rHuEPO antibodies. 
These antibodies were detected in 6 CRF rats under 50 IU rHuEPO treatment (85.7%), as 
well as in 7 CRF rats treated with 200 IU rHuEPO (100%). 
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Table IV-3. Effects of rHuEPO treatment on hematological and biochemical parameters at the 
end of protocol. 
Parameters/Groups 
Sham  
(n=7) 
CRF  
(n=7) 
CRF+50IU 
rHuEPO (n=7) 
CRF+200IU 
rHuEPO (n=7) 
Hematological data    
WBC (x 103/µL)  1.780.30 5.011.76 3.740.95 3.160.70 
MCV (fL)  52.520.53 51.930.69 52.360.67 52.830.81 
MCH(pg)  18.080.18 18.360.24 18.460.24 18.600.19 
MCHC (g/dL)  34.600.08 35.370.19 
aa
 35.300.07a 35.260.30 
RDW (%)  11.482.53 18.343.23 15.030.48 17.880.67
abc
 
PLT (x 103/µL)  713.7515.19 769.0073.17 914.7177.05 786.0050.83 
PDW (%)  16.340.18 16.440.20 16.000.11 16.440.24 
Biochemical parameters   
Glicose (mmol/L)  9.460.31 8.660.60 7.500.69 8.540.21 
TGs(mmol/L)  1.050.14 1.580.32 1.880.37 1.580.29 
Total-c (mmol/L) 1.250.06 2.440.54 
a
 2.980.47 2.74 0.25 
CK (U/L)  540.5758.94 473.0085.57 237.1474.26 
a
 294.8635.86
ab
 
ALT (U/L)  35.172.21 42.0018.53a 21.862.09 a 26.141.18 a 
AST (U/L)  80.577.84 139.4370.70 57.576.23 54.573.02ab 
Bilirubin (µmol/L)  8.04e-51.03e-5 1.03e-41.71e-5 8.55e-51.71e-5 1.20e-41.71e-5 
IL-6 (pg/mL)  132.294.28 138.334.22 130.162.20 138.731.70 
hsCRP (µg/mL)  262.2512.43 225.317.95 a 219.989.85 a 244.237.99 
INF- (pg/mL)  23.303.10 25.512.26 28.981.89 25.511.22 
TGF-β1 (ng/mL) 75.745.62 84.133.85 87.828.03 72.374.55 
VEGF (pg/mL)  4.230.94 14.162.24 a 19.081.95a 10.031.00ac 
Results are presented as mean ± SEM (7 rats per group): a- p < 0.05, aa- p < 0.01, and aaa- p < 0.001 
vs Sham; b- p < 0.05, bb- p < 0.01, and bbb- p < 0.001 vs CRF; c- p < 0.05, cc- p < 0.01, and ccc- p < 
0.001 vs CRF+50IU rHuEPO group. ALT, alanine transaminase, AST, aspartate transaminase; CK, 
creatine kinase; hsCRP - high-sensitive C reactive protein; MCH, mean corpuscular hemoglobin; 
MCHC, mean cell hemoglobin concentration; MCV, mean corpuscular volume; PDW, platelet 
distribution width ; PLT, platelets; RDW, RBC distribution width; Total-c, total cholesterol; TGs, 
triglycerides; WBC, white blood cells 
 
 
4.3. Serum EPO, liver and kidney EPO and EPOR mRNA expression 
The CRF rats and both groups of CRF rats treated with 50IU and 200IU rHuEPO 
showed  significantly higher (p<0.001) serum EPO concentrations, when compared with 
Sham group (Figure IV-3A). A trend towards increased serum EPO concentration was 
observed with increasing rHuEPO dose. There was a notable (p<0.05) overexpression of 
EPO and EPOR mRNA in the kidney tissue of CRF rats, when compared with Sham rats. 
The EPO and EPOR mRNA expressions in CRF rats treated with rHuEPO (both doses) 
(Figure IV-3B and IV-3D, respectively) was similar, and significantly lower than their 
expression in CRF rats.  In the liver tissue, a significant overexpression (p<0.001) of EPO 
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mRNA was found in CRF rats, when compared with Sham rats, which was not observed 
in rats under rHuEPO treatment (both doses) (Figure IV-3C). EPOR mRNA levels were 
similar for all groups, excepting for a significant (p<0.001) overexpression in CRF rats 
treated with 200IU rHuEPO (Figure IV-3E). 
 
 
Figure IV-3. Serum EPO (A), EPO mRNA levels/18S expression (% of Sham group) in kidney (B) 
and liver (C) tissues at the end of the study (12 weeks); and EPOR mRNA levels/18S expression 
(% of Sham group) in kidney (D) and liver (E) tissues. Results are presented as mean ± SEM (7 
rats per group): a- p < 0.05, aa- p < 0.01, and aaa- p < 0.001 vs Sham; b- p < 0.05, bb- p < 0.01, 
and bbb- p < 0.001 vs CRF; c- p < 0.05, cc- p < 0.01, and ccc- p < 0.001 vs CRF+50IU rHuEPO 
group. 
 
 
4.4. Iron metabolism  
At the end of the experimental protocol, there was a significant (p<0.001) 
decrease in serum iron and transferrin levels, and similar ferritin contents in CRF and in 
50IU rHuEPO treated CRF rats, when compared to those found in Sham animals (Figure 
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IV-4A). The 200IU rHuEPO CRF rats presented serum iron levels similar to those of the 
Sham rats; a trend towards a reduction in ferritin, versus CRF rats, was also found (Figure 
IV-4A). In the duodenum, no significant differences were observed for SLC40A1 and 
DMT1 mRNA expression in CRF rats and in the CRF+50IU rHuEPO group, when compared 
with Sham. However, in the CRF+200IU rHuEPO rats, there was a significant (p<0.001) 
overexpression of DMT1 and a trend to increased expression of SLC40A1, versus the CRF 
rats (Figure IV-4B). 
 
 
Figure IV-4. Mediators of iron metabolism in serum, liver and duodenum. Serum iron, ferritin 
and transferrin (A); relative gene expression mRNA levels /18S in the duodenum (B) and liver (C) at 
the end of protocol. Results are presented as mean ± SEM (7 rats per group): a- p < 0.05, aa- p < 0.01, 
and aaa- p < 0.001 vs Sham; b- p < 0.05, bb- p < 0.01, and bbb- p < 0.001 vs CRF; c- p < 0.05, cc- p < 
0.01, and ccc- p < 0.001 vs CRF+50IU rHuEPO group. BMP6, bone morphogenic protein 6; DMT1, 
divalent metal transporter 1; Hamp, hepcidin antimicrobial peptide; HFE, hemochromatosis; HJV, 
hemojuvelin; IL-6, interleukin-6; SLC40A1, ferroportin-1; sTfR2, soluble transferrin receptor 2; Tf, 
transferrin; TfR1, transferrin receptor 1 and TMRPSS6, matriptase-2. 
 
In the liver tissue, no significant changes were found for mRNA expression of 
several iron regulatory proteins (sTfR1, sTfR2, Hfe, HJV, BMP6, TMPRSS6, IL-6 and HIF-
2) in the CRF group versus the Sham (Figures IV-4C and IV-5B1), and the same occurred 
when comparing CRF rats with CRF+50 IU rHuEPO group. However, there was a 
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significantly reduced (p<0.05) expression of Hamp mRNA in CRF rats and in CRF+50 IU 
rHuEPO rats, when compared with Sham animals (Figure 3D1).The CRF rats under 200 IU 
rHuEPO, as compared to CRF, showed significant changes in the liver expression of most 
of those mediators of iron metabolism, namely, a significant (p<0.001) overexpression of 
sTfR1, sTfR2, Hfe, HJV, BMP6 and IL-6, and a significantly reduced expression of 
TMPRSS6; Hamp and HIF-2 presented similar values versus CRF rats (Figures IV-4B, IV-
5A1 and IV-5B1). In addition, no significant differences were observed between groups 
for hepcidin and HIF-2 protein immunostaining in liver tissue (Figures IV-5A2 – IV-5A6; 
IV-5B2 – IV-5B6). 
 
 
Figure IV-5. Liver protein expression (by immunohistochemistry) of hepcidin (A1-A6) and HIF-2 
(B1-B6). Results are presented as mean ± SEM (7 rats per group): a- p < 0.05, aa- p < 0.01, and aaa- p 
< 0.001 vs Sham; b- p < 0.05, bb- p < 0.01, and bbb- p < 0.001 vs CRF; c- p < 0.05, cc- p < 0.01, and ccc- 
p < 0.001 vs CRF+50IU rHuEPO group. HIF-2, hypoxia inducible factor 2 alpha. 
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4.5. Kidney lesions  
No significant changes were found in kidneys histomorphology of Sham rats after 
the experimental period (Tables IV-4, IV-5 and IV-6; Figures IV-6A1 and IV-6B1).  
 
 
Table IV-4. Scoring and distribution (%) of mild and advanced glomerular kidneys lesions of rat 
groups under study. 
Mild Lesions Rat Group 
Score (n, %) 
0  
Absent 
1  
<25% 
2 
25-50% 
3 
>50% 
Total Score 
Thickening of 
Bowman´s 
Capsule 
Sham  7 (100%) 0 0 0 0.000.00 
CRF  1 (14.3%) 3 (42.9 %) 1 (14.3%) 2 (28.6 %) 1.570.43
a
 
CRF+50IU rHuEPO 3 (42,9 %) 4 (57,1%) 0 0 2.140.40
aaa
 
CRF+200IU rHuEPO 3 (42,9 %) 3 (42,9 %) 1 (14,3%) 0 0.71 0.28 
Hyalinosis of 
the vascular 
pole 
Sham  7 (100%) 0 0 (0 %) 0 (0 %) 0.000.00 
CRF  1 (14.3%) 6 (85.7%) 0 0 0.860.14 
CRF+50IU rHuEPO 0 5 (71,4%) 0 2 (28,6%) 1.570.37
aa
 
CRF+200IU rHuEPO 5 (71,4%) 1 (14,3%) 0 1 (14,3%) 0.570.43 
Glomerular 
atrophy 
Sham  7 (100%) 0 0 0 0.000.00 
CRF  1 (14,3%) 6 (85.7%) 0 0 0.860.14
a
 
CRF+50IU rHuEPO 1 (14,3%) 4 (57,1%) 2(28,6%) 0 1.140.26
aaa
 
CRF+200IU rHuEPO 5 (71,4%) 2 (28,6%) 0 0 0.290.18 
Hypercellularity 
 
Sham  7 (100%) 0 0 0 0.000.00 
CRF  0 7 (100%) 0 0 1.000.00
aa
 
CRF+50IU rHuEPO 4 (57,1%) 1 (14,3%) 2 (28,6%) 0 0.71  0.36
a
 
CRF+200IU rHuEPO 7 (100%) 0 0 0 0.00 0.00
bb
 
Dilatation of the 
Bowman’s Space 
Sham  7 (100%) 0 0 0 0.000.00 
CRF  5 (71.4%) 2 (28.6%) 0 0 0.290.18 
CRF+50IU rHuEPO 6 (85,7%) 1(14,3%) 0 0 0.14  0.14 
CRF+200IU rHuEPO 5 (71,4%) 2 (28,6%) 0 0 0.28  0.18 
TOTAL GROUP 
SCORE 
Sham   0.000.00 
CRF   0.910.12
aaa
 
CRF+50IU rHuEPO  1.140.18
aaa
 
CRF+200IU rHuEPO  0.37 0.12
b
 
    
Rat Groups 
Advanced glomerular lesions (n, %) 
None of the 
previous 
lesions (0) 
Thickening 
of GBM 
(1) 
Mesangial 
expansion 
(2) 
Nodular 
sclerosis 
(3) 
Global 
Glomerulosclerosis 
(4) 
TOTAL 
GROUP 
SCORE 
Sham  7 (100%) 0 0 0 0 0.000.00 
CRF  0 1 (14.3%) 5 (71.4%)  1 (14.3%) 0 2.000.22
aaa
  
CRF+50IU rHuEPO       0 0 0 1 (14,3%)         6 (85,7%) 3.85 0.14
aaa bbb
 
CRF+200IU rHuEPO       0 0 2 (28,6%)  0        5 (71,4%) 3.43 0.37
aaa bbb
 
Results are presented as mean ± SEM (7 rats per group): a- p < 0.05, aa- p < 0.01, and aaa- p < 
0.001 vs Sham; b- p < 0.05, bb- p < 0.01, and bbb- p < 0.001 vs CRF; c- p < 0.05, cc- p < 0.01, and 
ccc- p < 0.001 vs CRF+ 50IU rHuEPO group. 
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However, CRF rats presented several glomerular (cortex) and tubulointerstitial 
(medulla) lesions. Concerning mild glomerular lesions, most of the CRF rats presented 
thickening of Bowman’s capsule, hyalinosis of vascular pole, glomerular atrophy and 
hypercellularity (Table IV-4; Figure IV-6). In addition, all CRF rats presented at least one 
of the advanced glomerular lesions, and mesangial expansion was present in 5 out of 7 
rats (Table IV-4; Figure IV-6A5).  
 
 
Table IV-5. Scoring and distribution (%) of mild tubulointerstitial kidney lesions of rat groups 
under study. 
Mild  
Lesions 
 
Score (n, %) 
0  
Absent 
1  
 <25% 
2 
25-50% 
3  
>50% 
Total 
Score 
Tubular 
Hyaline 
Droplets 
Sham  7 (100%) 0 0 0 0.000.00 
CRF  0 7 (100%) 0 0 1.000.00 
aaa
 
CRF+50IU rHuEPO 6 (85,4%) 1 (14,3%) 0 0 0.14  0.14 
CRF+200 IU rHuEPO 0 7 (100%) 0 0 1.00 0.00 
aaa
 
TBM 
Irregularity 
Sham  7 (100%) 0 0 0 0.000.00 
CRF  0 3 (42.9%) 2 (28.5%) 2 (28.5%) 1.860.34
aaa
 
CRF+50IU rHuEPO 0 3 (42,9%) 1 (14,3%) 3 (42,9%) 2.000.38 
aaa
 
CRF+200 IU rHuEPO 0 5 (71,4 %) 2 (28,5%) 0 1.29  0.18 
a
 
Tubular 
Dilatation 
Sham  7 (100%) 0 0 0 0.000.00 
CRF  2 (28.5%) 1 (14.3%) 2 (28.5%) 2 (28.5%) 1.570.48 
a
 
CRF+50IU rHuEPO 5 (71,4%) 1 (14,3%) 1 (14,3%) 0 0.43   0.30 
b
 
CRF+200 IU rHuEPO 7 (100%) 0 0 0 0.00  0.00 
bb
 
Interstitial 
Inflammatory 
Infiltrate 
Sham  4 (57.2 %) 3 (42.9%) 0 0 0.290.18 
CRF  0 0 7 (100%) 0 2.000.00 
aaa
 
CRF+50IU rHuEPO 0 0 7 (100%)  2.000.00 
aaa
 
CRF+200 IU rHuEPO 0 0 7 (100%)  2.000.00 
aaa
 
Vacuolar 
Tubular 
Degeneration 
Sham  0 7 (100%) 0 0 1.000.00 
CRF  3 (42.9%) 3 (42.9%) 1 (14.3%) 0 0.71  0.29 
aaa
 
CRF+50IU rHuEPO 3 (42,9%) 4 (57,1%) 0 0 0.57  0.20 
aa bb
 
CRF+200 IU rHuEPO 0 7 (100%) 0 0 1.00  0.00 
bb
 
TOTAL GROUP 
SCORE 
Sham   0.260.08 
CRF   1.430.15 
aaa
 
CRF+50IU rHuEPO  1.03  0.17 
aaa
 
CRF+200 IU rHuEPO  1.06  0.12 
aaa
 
Results are presented as mean ± SEM (7 rats per group): a- p < 0.05, aa- p < 0.01, and aaa- p < 
0.001 vs Sham; b- p < 0.05, bb- p < 0.01, and bbb- p < 0.001 vs CRF; c- p < 0.05, cc- p < 0.01, and 
ccc- p < 0.001 vs CRF+50IU rHuEPO group. TBM, tubular basement membrane. 
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The CRF animals treated with 50IU rHuEPO, when compared with the CRF rats, 
presented only a slight worsening (though without statistical significance) aggravation of 
mild glomerular lesions; however, a significant aggravation of advanced glomerular 
lesions was observed, due to an increase in global glomerulosclesosis that was present 
in 6 out of 7 rats (Table IV-4 and Figure IV-6A). The CRF+200IU rHuEPO rats, as compared 
to CRF ones, displayed an improvement in mild glomerular lesions; however, the 
advanced lesions were unchanged, with a predominance of global glomerulosclesosis (5 
out of 7 rats). The changes reported are viewed by the total scores of mild and advanced 
glomerular lesions (Table IV-4 and Figure IV-6A).  
 
Table IV-6. Scoring and distribution (%) of advanced tubulointerstitial kidney lesions of rat 
groups under study. 
Advanced 
Lesions 
 
Socre (n ,%) 
0 
Absent 
1 
 <25% 
2  
25-50% 
3 
>50% 
Total Score 
Hyaline 
cylinders 
Sham  6 (85.7%) 1 (14.3%) 0 0 0.140.14 
CRF  0 1 (14.3%) 6 (85.7%) 0 1.860.14
aa
 
CRF+50IU rHuEPO 0 0 2 (28,6%) 5 (71,4%) 2.71  0.18 
aaa bbb
 
CRF+200 IU rHuEPO 0 0 4 (57,1%) 3 (42,9%) 2.43 0.20
aaa
 
Tubular 
Calcification 
Sham  7 (100%) 0 0 0 0.000.00 
CRF  7 (100%) 0 0 0 0.000.00 
CRF+50IU rHuEPO 6 (85,7%) 1 (14,3%) 0 0 0.14  0.14 
CRF+200 IU rHuEPO 1 (14,3%) 6 (85,7%) 0 0 0.85  0.14
aaa bbb
 
Necrosis 
Sham 7 (100%) 0 0 0 0.000.00 
CRF 2 (28.6%) 5 (71.4%) 0 0 0.710.18 
CRF+50IU rHuEPO 3 (42,9%) 2 (28,5%) 2 (28,5%) 0 0.86  0.34 
a
 
CRF+200 IU rHuEPO 0 0 4 (57,1%) 3 (42,9%) 2.43 0.20
aaa bbb
 
IFTA 
Sham 7 (100%) 0 0 0 0.000.00 
CRF 0 3 (42.9%) 4 (57.1%) 0 1.570.20
aaa
 
CRF+50IU rHuEPO 0 0 2 (28,5%) 5 (71,4%) 2.71  0.18
aaa bbb
 
CRF+200 IU rHuEPO 0 0 0 7 (100%) 3.00  0.00
aaa bbb
 
TOTAL GROUP 
SCORE 
Sham   0.040.04 
CRF   1.040.16
aaa
 
CRF+50IU rHuEPO  1.61  0.24
aaa
 
CRF+200 IU rHuEPO  2.18  0.17
aaa bbb
 
Results are presented as mean ± SEM (7 rats per group): a- p < 0.05, aa- p < 0.01, and aaa- p < 
0.001 vs Sham; b- p < 0.05, bb- p < 0.01, and bbb- p < 0.001 vs CRF; c- p < 0.05, cc- p < 0.01, and 
ccc- p < 0.001 vs CRF+50IU rHuEPO group. IFTA, interstitial fibrosis and tubular atrophy. 
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Figure IV-6. Glomerular and tubulointerstitial lesions. Representative glomerular (cortex) and 
tubulointerstitial (medulla) lesions observed in kidneys of rat groups under study, at the final 
time (PAS staining): A1 – normal glomerulus histology in a Sham rat; A2 – glomerular 
hypercellularity; A3 - dilatation of the Bowman’s Space and glomerular atrophy; A4 – Total score 
of mild glomerular lesions for each rat group; A5 - mesangial expansion; A6-  nodular sclerosis; 
A7- global glomerulosclerosis; A8- total score of advanced glomerular lesions for each rat group; 
B1- normal tubulointerstitial histology in Sham group of rats; B2- interstitial inflammatory 
infiltration; B3 – tubular basements membrane irregularity; B4- total score of mild 
tubulointerstitial lesions in lesions for each rat group. B5-hyaline cylinders; B6- interstitial fibrosis 
and tubular atrophy (IFTA); B7- tubular calcification; B8- Total score of advanced tubulointerstitial 
lesions for each rat group. Results are presented as mean ± SEM (7 rats per group): a- p < 0.05, 
aa- p < 0.01, and aaa- p < 0.001 vs Sham; b- p < 0.05, bb- p < 0.01, and bbb- p < 0.001 vs CRF; c- p 
< 0.05, cc- p < 0.01, and ccc- p < 0.001 vs CRF+50IU rHuEPO group. 
 
 
Comparing CRF rHuEPO treated groups it seems there is a trend towards a 
protection of glomerular kidney tissue by increasing rHuEPO dose. Concerning the mild 
tubulointerstitial lesions, all animals of the CRF group presented tubular hyaline 
droplets, TBM irregularity, interstitial inflammatory infiltration, and most of them 
presented tubular dilatation, as compared to Sham rats (Table IV-5 and Figure IV-6B). 
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The two groups of CRF rats treated with rHuEPO, as compared to the CRF animals 
showed a trend towards a reduction in mild tubulointerstitial lesions; however, a trend 
to worsening of advanced lesions, namely the formation of hyaline cylinders and IFTA, 
was observed in CRF+50 IU rHuEPO rats. The CRF rats treated with 200rHuEPO 
presented a significant increase in advanced lesions, namely in hyaline cylinders, 
calcification, necrosis and IFTA (Table IV-6 and Figure IV-6B). 
As the changes in serum iron presented by CRF rats and CRF rats treated with 
rHuEPO could be due to iron leakage due to kidney lesions, we performed iron staining 
according to Perls method. We found that iron deposits were almost undetectable in 
Sham rats, increased in CRF+200 IU rHuEPO rats and were even more enhanced in CRF 
rats and in CRF+50 IU rHuEPO rats (Figure IV-7). 
 
 
Figure IV-7. Illustration of iron deposits (Perls staining) in kidney tubules of rats, at the final 
time. Sham group (A), CRF group (B), CRF+50 IU rHuEPO group (C), and CRF+200 IU rHuEPO 
group (D). 
 
 
4.6. Mediators of kidney lesions  
No significant changes were observed in kidney mRNA expression of IL-1, TSP-1, 
Pro(III) collagen and CTGF in CRF rats, when compared with Sham, however a down-
regulation (p<0.05 and p<0.01, respectively) of CytC and NF-kB expression was observed 
(Figure IV-8). 
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Figure IV-8. Mediators of kidney lesions. RHuEPO effects on relative gene expression mRNA 
levels/18S (% of Sham group) of some mediators of kidney lesions (A) and kidney protein expression 
(by immunohistochemistry) of NF-kB (B1-B6) and CTGF (C1-C6) in renal medulla. Results are presented 
as mean ± SEM (7 rats per group): a- p < 0.05, aa- p < 0.01, and aaa- p < 0.001 vs Sham; b- p < 0.05, 
bb- p < 0.01, and bbb- p < 0.001 vs CRF; c- p < 0.05, cc- p < 0.01, and ccc- p < 0.001 vs CRF+50IU 
rHuEPO group. CytC, cytocrome C; CTGF, connective tissue growth factor; IL-1β, interleukin-1 beta; 
IL-6, interleukin-6; NF-Kb, nuclear transcription factor kappa B; TNF-, tumor necrosis factor alpha; 
TSP-1, thrombospondin-1. 
 
In the CRF rats treated with 50IU of rHuEPO, revealed an overexpression of TSP-
1, NF-kB and CTGF was found, without significant changes in the expression of IL-1, 
Pro(III) collagen, and CytC, versus CRF rats. Major changes on kidney mRNA expression 
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were observed in the CRF+200 IU rHuEPO rats versus CRF animals; in fact, a significant 
overexpression of IL-1, TSP-1, CytC, NF-kB and CTGF were encountered; no significant 
changes were observed for the expression of Pro(III) collagen (Figure IV-8). Kidney 
immunostaining for NF-kB and CTGF showed increased protein expression in CRF rats 
when compared with Sham animals, as well as in CRF rats treated with rHuEPO (both 
doses). 
 
4.7. Kidney mRNA and protein expression of hypoxia inducible factors 
No significant changes were observed in kidney mRNA HIF-2 expression in the 
CRF rats, when compared to Sham animals, although a trend towards an increased 
protein expression (immunostaining) was found. 
 
Figure IV-9. RHuEPO effects on relative gene expression mRNA levels/18s (% of Sham group) 
and kidney protein expression (by immunohistochemistry) of HIF-2 (A) and HIF-2 (B). Results 
are presented as mean ± SEM (7 rats per group): a- p < 0.05, aa- p < 0.01, and aaa- p < 0.001 vs Sham; 
b- p < 0.05, bb- p < 0.01, and bbb- p < 0.001 vs CRF; c- p < 0.05, cc- p < 0.01, and ccc- p < 0.001 vs 
CRF+50IU rHuEPO group. HIF-2, hypoxia-inducible factor 2 alpha; HIF-2β, hypoxia-inducible factor 2 
beta. 
Chapter IV  | 
146  |Resistance to rHuEPO therapy - studies in experimental models of anemia and CKD 
The CRF+50IU rHuEPO rats showed a trend to increased HIF-2 mRNA expression 
and significant protein immunoreactivity, when compared with CRF rats. The same was 
observed for the CRF+200IU rHuEPO rats, presenting an overexpression of both mRNA 
and protein in the kidney tissue. In addition, increased mRNA and protein HIF-2β 
expression was found in CRF+200IU rHuEPO rats, when compared with CRF rats (Figure 
IV-9). 
 
 
5. Discussion 
Anemia is prevalent in patients with CKD and contributes to a lower quality of life 
and numerous adverse outcomes, including cardiovascular disease events. Inadequate 
production of erythropoietin is commonly thought to be the most important factor in 
the pathogenesis of anemia in these patients. RHuEPO is, therefore, usually used in the 
treatment of CKD anemia, however, some patients are poorly responsive to ESAs, 
requiring higher doses,39 being important to understand the impact of increased rHuEPO 
doses on key aspects of CKD associated-anemia, including erythropoiesis and iron 
metabolism, inflammation and kidney damage. Animal models have been important 
tools to study the cellular and molecular changes in CKD, and the remnant kidney model 
is one of the most used models.40-42 
By using the remnant kidney model (5/6 nephrectomy) in the present study, we 
found that the rats developed a sustained renal failure (Figure IV-2), as showed by the 
significantly increased values of creatinine and BUN from 3 to 9 weeks after the second 
nephrectomy, worsening afterwards. 
As referred, the anemia secondary to CKD development is one of the most severe 
complications of CKD patients.43 In accordance with previously described in Chapter III, 
the CRF rats developed anemia 3 weeks after nephrectomy, which persisted throughout 
the protocol (Figure IV-2); however, the CRF rats were still able to produce EPO, almost 
doubling serum EPO levels, and, in accordance, the kidney and liver showed an 
increased EPO gene expression (Figure IV-3). The persistence of the anemia was 
associated with low serum iron and transferrin levels, although iron storage was normal, 
as showed by ferritin levels (Figure IV-4). This kind of disturbance in iron metabolism is 
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common in inflammatory conditions, however, serum IL-6 and CRP levels showed the 
absence of systemic inflammation (Table IV-3). Actually, we observed a reduced 
expression of hepcidin that favours iron absorption, as suggested by the increased 
mRNA expression of duodenal ferroportin (Figure IV-4); however, serum iron was 
reduced. This reduced might be due to iron loss through damaged kidney glomerulus 
(Tables IV-4, IV-5 and IV-6). It was reported that in proteinuric conditions, due to 
glomerular leakage of transferrin, iron might be released from transferrin in the acid 
milieu of the tubular lumen,44 leading to iron accumulation in the proximal tubule 44-47 
and worsening of CKD. Actually, we found that iron deposits were almost undetectable 
in Sham rats, increased in CRF+200 IU rHuEPO rats and were even more increased in CRF 
rats and in 50 IU rHuEPO rats (Figure IV-7), suggesting that the leakage of iron through 
damaged glomerulus may explain the reduced serum iron and transferrin that we 
observed in CRF rats. Another hypothesis for the persistence of the anemia in CRF rats is 
that an altered activity/function of EPO has occurred, resulting from kidney cell damage. 
It was reported that in healthy individuals erythropoietin may present up to four 
residues on each N-linked carbohydrate chain, or up to two residues on the O-linked 
chain. A variability in sialic acid composition may,48 therefore, affect the circulating half-
life of erythropoietin and the interactions with its receptor; in general, increasing sialic 
acid correlates with longer and greater potency of EPO.49 Thus, the persistence of the 
anemia, in spite of the serum EPO levels, may be explained by iron disturbances and/or 
by a reduced (altered) EPO activity, and both changes may result from the glomerular 
kidney lesions and from the developed local inflammatory milieu, as showed by the 
increased gene expression of different protein mediators of inflammation and fibrosis in 
the remnant kidney (Figure IV-8). Extra-renal EPO production has been also described in 
the liver, although its contribution to the circulating EPO concentration in adults is highly 
debatable, even in kidney disease states.50 
We treated CRF rats with two therapeutic doses of rHuEPO - 50 and 200 IU - to 
clarify the mechanisms explaining the persistence of anemia, in spite of the normal EPO 
bood levels. 
The CRF rats treated with the lowest dose of rHuEPO (50 IU) presented anemia, 
though a slight rise in Hb and in reticulocyte count was observed, until the ninth week; 
afterwards Hb, HTC and RBC count showed a decrease. In opposition, the anemia of CRF 
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rats under treatment with the highest rHuEPO dose (200IU) was rapidly corrected and 
the Hb concentration reached values significantly higher, as compared to Sham and CRF 
rats, until the ninth week, after which the hematological values declined to values 
similar to those of the Sham group. This decrease, observed in both CRF groups treated 
with rHuEPO was due to the formation of EPO-neutralizing antibodies (Abs). This 
condition, although rare, has been also reported in humans,51,52 and, more recently, has 
increased due to the introduction of EPO biosimilars to treat the anemia, in some 
countries.29,30 At the final time, the anemia presented by both CRF treated groups was 
more severe in CRF rats treated with the lowest rHuEPO dose (50IU) (Figure IV-2); both 
groups (50 and 200 IU) presented similar levels of serum EPO, although slightly higher in 
the CRF+200 IU rHuEPO group (Figure IV-3). This slight increase in EPO serum levels 
might be explained by a compensatory production of EPO by the liver, given the 
significant overexpression of EPOR mRNA in liver tissue, and considering that EPO mRNA 
expression was similar for the remnant kidney of both CRF treated rats. While the liver 
has a role in EPO production in the fetal age, in the adulthood the main producer of EPO 
is the kidney.53-55 However, in renal disease conditions the extra-renal tissues, such as 
the liver, might assume a higher part on the compensatory synthesis of EPO. In spite of 
the anemia, both CRF treated groups presented a similar down-regulation of kidney and 
liver EPO gene expression, suggesting a deregulation of the kidney hypoxia sensing 
mechanisms. 
We must remind that the anemia developed in CRF rats was not due to deficient 
EPO production, but, instead, it seems to result from a reduced (altered) erythropoietic 
activity of endogenous EPO, once the treatment of CRF rats with rHuEPO was able to 
improve the anemia until the ninth week. 
Renal insufficiency was accompanied by a compensatory renal hypertrophy and 
angiogenesis, as revealed by the increase in KW/BW and serum VEGF levels in CRF rats; 
a high HW/BW ratio was also found in CRF group, which might be caused by the 
supplementary effort of the left ventricle muscle to pump blood in this condition of 
anemia secondary to renal failure development, was also found in CRF group (Table IV-
2). CKD patients, usually present a concomitant rise in systolic blood pressure,56-61 which 
was also observed in CRF rats. The correction of anemia along 6 weeks in CRF treated 
with 200IU rHuEPO seems to explain, the improvement in KW/BW, serum VEGF levels, 
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HW/BW and in hypertension, as compared to CRF rats and CRF+50IU rHuEPO treated 
rats (Table IV-2). In fact, while the lowest dose (50 IU) was unable to correct the anemia 
(only a slight improvement) leading to kidney hypertrophy and angiogenesis, as 
compared to CRF rats, while the highest (200 IU) reduced kidney hypertrophy and 
angiogenesis, as it was able to correct anemia until the 9th week. 
Worsening of hypertension associated to rHuEPO therapy have been assigned to 
several possible mechanisms, apart from the rHuEPO - hyperviscosity due to increasing 
RBC concentration, such as, several vascular mechanisms, including changes in the 
production or sensitivity to endogenous vasopressors, alterations in vascular smooth-
muscle ionic milieu, deregulation of production or response to endogenous vasoactive 
factors, a direct vasopressor action of EPO, and, finally, arterial remodeling through 
stimulation of vascular cell growth.60,62,63 Blood hyperviscosity and hypertension among 
other  cardiovascular risk factors may contribute to the high morbidity and mortality in 
CKD patients.31 In the present study, we found that the highest rHuEPO dose attenuated 
the rHuEPO associated increase in SBP, MBP and HR, when compared to the lowest 
rHuEPO dose, as occurred with KW/BW and HW/BW.  
By evaluating the changes/damages occurring in the remnant kidney we found 
that the treatment with rHuEPO was associated with increased glomerular and 
tubulointerstitial lesions (Tables IV-4, IV-5 and IV-6, Figure IV-6), as compared to CRF 
rats; however, the glomerular lesions were significantly higher in CRF+50IU rHuEPO rats, 
as compared to CRF+200IU rHuEPO rats, while the tubulointerstitial lesions were 
significantly higher in the latter group. Moreover, CRF rats treated with 200IU rHuEPO 
also presented significantly higher values in protein and/or gene expression of several 
mediators/markers of kidney inflammation and fibrosis, namely, Cyt C, IL-1, NF-kB and 
CTGF (Figure IV-8). 
Under hypoxic conditions HIFs promote the transcription of regenerative factors, 
such as EPO, GLUT receptor, VEGF and CTGF, among others.64-66 However, some of them 
(namely, VEGF and CTGF) might contribute to worsening of kidney disease by promoting 
inflammation and fibrosis.66,67 It is becoming widely accepted that, regardless of the 
initial cause of renal failure, tubulointerstitial fibrosis is the major cause of disease 
progression,68,69 although glomerulosclerosis is one of the major signs of ESRD. 
Tubulointerstitial damage is typically associated with accumulation of extracellular 
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matrix (ECM), infiltration of inflammatory cells, increased number of interstitial 
fibroblasts, tubular atrophy and finally loss of peritubular capillaries.70 Given the close 
association between hypoxia, EPO, fibrosis and inflammation, it is of major importance 
to elucidate how rHuEPO therapy affects the evolution of kidney lesions. In fact, EPO 
interaction with its receptor leads to activation of several important pathways related 
with proliferation, angiogenesis, inflammation and oxidative stress, which might deeply 
affect influence the renal tissue.71-73 
Lower impact of the treatment with the highest rHuEPO dose (200IU) on the 
glomerulus, as compared to the lowest dose, may explain the improvement in iron 
metabolism, with an increase in serum iron and transferrin and a slight decrease in 
ferritin levels, as well as an increase in duodenal ferroportin and DMT1 mRNA 
expression suggesting that mild glomerular lesions were able to reduce the loss of iron 
and transferrin levels. 
Hepcidin has been described as a major regulator of body iron homeostasis, 
acting directly on a number of cell types, including iron recycling macrophages, intestinal 
epithelial cells and hepatocytes. Hepcidin, synthesized by the liver, acts by inhibiting 
cellular iron efflux in hepatocytes, enterocytes and macrophages, through binding to 
ferroportin, inducing its degradation.74 Hepatic Hamp expression is regulated by several 
proteins, namely, Hfe, TfR1, TfR2, HJV, BMP6, matriptase-2 and transferrin.75-77 In the 
liver, diferric transferrin competes with TfR1 for binding to Hfe, and, when iron is 
increased, more Hfe is available to bind to TfR2; this complex, TfR2-Hfe, promotes HJV 
binding to BMP6, increasing hepcidin synthesis.78,79 Moreover, hypoxia and EPO, as well 
as twisted gastrulation protein 1 (TWSG1) and growth differentiation factor 15 
(GDF15),80 both produced by erythroblasts, are also important modulators of hepcidin 
synthesis, by inducing a downregulation of hepcidin synthesis.80  
We found that increased serum iron in the CRF+200 IU rHuEPO group, as 
compared to CRF+50IU rHuEPO group, was associated with an overexpression of Tf, 
TfR2, BMP6, Hfe and HJV in the liver, and, in accordance, with an overexpression of 
Hamp in the CRF+50IU rHuEPO group; moreover, a downregulation in matriptase-2 
mRNA expression was observed in the liver that might further contribute to the 
overexpression of hepcidin (Figure IV-5). However, this hepcidin overexpression in 
CRF+200IU rHuEPO group was not traduced in a higher protein expression, as showed by 
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the immunochemical studies. The same was observed for HIF-2, which presented a 
slightly increased overexpression that was associated with a slight decrease in the 
protein expression. Thus, it seems that the less severe anemia/hypoxia, as well as the 
reduced glomerular kidney lesions, at the final time, in the CRF+200IU rHuEPO rats, as 
compared to CRF+50IU rHuEPO rats, might explain the decrease in hepcidin and HIF-2 
protein expression; however, we must notice that the decrease in Hb concentration, 
almost thrice in the CRF+200IU rHuEPO group, as compared to CRF+50IU rHuEPO group, 
might result, apart from the action of the anti-rHuEPO antibodies, from the synthesis of 
EPO with a reduced (altered) erythropoietic activity, due to the high enhancement in the 
inflammatory and fibrotic kidney milieu, as shown by the increased gene and/or protein 
expression of Cyt C, IL-1, NF-kB and CTGF. Actually, the kidney tubules, where EPO is 
synthesized, of the CRF+200IU rHuEPO rats presented significantly higher advanced 
kidney lesions, as compared with rats treated with the lowest dose of rHuEPO, showing 
a more unfavorable environment for a normal EPO synthesis. 
In summary, our data suggest that the anemia developed in rats with long term 
of CRF is due to a reduced (altered) erythropoietic activity, as the CRF rats were able to 
overcome the anemia when treated with rHuEPO; the local kidney inflammation and the 
type of kidney lesions seem to be crucial for the outcome of the anemia. A long-term 
treatment of CRF rats with rHuEPO leads to the development of rHuEPO antibodies and, 
therefore, to anemia, after about 6 weeks of treatment; the impact of rHuEPO 
treatment depends on the rHuEPO dose, which should be enough to correct anemia, 
preventing kidney and heart hypertrophy, but not too high as it will lead to worsening of 
advanced glomerular and tubulointerstitial kidney lesions. Further studies are needed to 
understand how hypoxia and/or kidney lesions induce a reduced (altered) EPO activity 
and how kidney glomerular lesions/iron leakage may contribute to the functional iron 
deficient anemia, usually observed in hemodialysis CKD patients and enhanced in case 
they develop resistance to rHuEPO treatment.  
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1. Abstract 
Erythroid hypoplasia (EH) is a rare complication associated with recombinant 
human erythropoietin (rHuEPO) therapies, due to development of anti-rHuEPO 
antibodies. The use of EPO biosimilars has increased the number of cases; however, the 
underlying mechanism and its treatment remain poorly clarified. Our aim was to manage 
a rat model of antibody-mediated EH induced by rHuEPO, and study the impact on iron 
metabolism and erythropoiesis at blood and molecular levels, by evaluating the 
expression of mRNA-encoding erythropoiesis and iron metabolism regulatory proteins, 
on duodenum, liver and kidney tissues.  
The model was developed by long-term treatment of Wistar male rats with a high 
rHuEPO dose (200IU epoietin beta/Kg bw/week during 9 weeks), as showed by the 
presence of anemia, reduced erythroblasts, reticulocytopenia and the formation of 
plasmatic anti-rHuEPO antibodies. Serum iron was increased and associated with 
significant overexpression of hepatic hepcidin, hemochromatosis protein, hemojuvelin, 
transferrin receptor 2 and bone morphogenic protein 6 mRNAs, and up-regulation of 
matriptase-2; overexpression of divalent metal transporter 1 and ferroportin was 
observed in duodenum and liver. Decreased EPO expression was observed in kidney and 
liver, while EPO receptor was overexpressed in liver. Endogenous EPO levels were 
normal, suggesting that anti-rHuEPO antibodies blunted EPO function.  
In our model, anti-rHuEPO antibodies inhibited both rHuEPO and endogenous 
EPO leading to anemia, iron was increased, triggering hepatic hepcidin expression, 
despite no evidence of inflammation, and it is the key modulator of hepcidin synthesis. 
These findings might contribute to improve new therapeutic strategies against rHuEPO 
resistance and/or development of antibody-mediated EH in patients under rHuEPO 
therapy.  
 
 
 
Key words: Erythroid hypoplasia; Recombinant human erythropoietin; Hepcidin; Anti-
EPO antibodies; Iron 
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2. Introduction 
Erythropoietin (EPO), a 30.4 kDa glycoprotein, is a key hormone in the regulation 
of erythropoiesis, supporting proliferation, survival and terminal differentiation of 
erythroid progenitor cells in the bone marrow.1,2 These effects are mediated through the 
interaction of EPO with its specific transmembrane receptor – erythropoietin receptor 
(EPOR).3 Acquired EPO deficiency has been associated with chronic kidney disease (CKD) 
and with chronic inflammatory diseases. Treatment with recombinant human 
erythropoietin (rHuEPO) achieves correction of these types of anemia; however, 5-10% 
of CKD patients develop resistance to the erythropoietic stimuli of rHuEPO. Several 
factors have been proposed to play a role in the development of this resistance, but the 
etiology of the impaired erythropoiesis, leading to worsening of anemia or even to pure 
red cell aplasia (PRCA) is still unknown.4 Casadevall et al. (1996) 5 reported the presence 
of anti-EPO antibodies in a patient with transient PRCA, which functionally blocked the 
interaction between EPO and EPOR, thus resulting in impaired erythropoiesis.5 Hara et 
al. (2008)6 also reported that serum from a patient with PRCA inhibited EPO-dependent 
cell proliferation, suggesting that the anemia was mediated by anti-EPO antibodies.6 In 
several other cases, antibodies have been described in PRCA patients' sera that were 
selectively cytotoxic for marrow erythroid cells or were directed against EPO.7-9 
The current therapeutic use of rHuEPO to correct anemia in CKD patients has 
been associated to some cases of PRCA, due to the development of cross-reactive anti-
EPO antibodies.10,11 Although this complication is very rare, the mechanisms underlying 
the break in immune tolerance to rHuEPO remain poorly clarified. The development of 
PRCA should be suspected in patients who have been under rHuEPO therapy for more 
than 3 months and develop a sudden severe unexplained fall in hemoglobin levels, 
reticulocytopenia and a marked decrease in bone marrow erythroblasts, despite 
continuing with rHuEPO treatment.12 The diagnosis is confirmed by low serum EPO 
levels and detection of anti-EPO antibodies.13 The production of anti-EPO antibodies and 
the inhibition of EPO-dependent erythroid cells are important mechanisms that might 
lead to erythroid hypoplasia (EH)/PRCA. The reduction in functional EPO affects the 
proliferative state of bone marrow erythroid cells, which will trigger several changes in 
iron metabolism, including in serum iron, transferrin and ferritin levels, among others.14-
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16 Considering the scarce data in literature about how, facing a PRCA condition mediated 
by anti-EPO antibodies, the depression of marrow erythroid activity affects iron 
metabolism, our goal was to assess in male Wistar rats, the effects of this condition 
upon iron metabolism (iron absorption, iron traffic and storage), as well as upon 
erythropoiesis. For that purpose, we performed hematological and biochemical studies 
to evaluate the erythropoietic and iron status, and measured the expression of several 
mRNA-encoding erythropoiesis and iron metabolism regulating proteins, on duodenum, 
liver and kidney tissues.  
 
 
3. Material and methods 
3.1. Animals and experimental protocol 
Male Wistar rats (Charles River Lab. Inc., Barcelona, Spain), weighing 200-250g, 
were maintained in an air conditioned room, subjected to 12h dark/light cycles and 
given standard laboratory rat diet (IPM-R20, Letica, Barcelona, Spain) and free access to 
tap water. Animal experiments were conducted according to the European Communities 
Council Directives on Animal Care and the National Authorities. 
 
 
 
 
Figure V-1. Experimental protocol. 
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The rats were divided into 3 groups (8 rats each): control - treated with saline 
solution; 50IU rHuEPO - a therapeutic dose of 50 IU/Kg body weight (bw)/week of 
epoietin beta (Recormon - Roche Pharmaceuticals); 200 IU rHuEPO – treated with 200 
IU/Kg bw/week of rHuEPO, a high dose, usually used on rHuEPO resistant patients. All 
the animals have completed the 9-week protocol (Figure V-1).  
 
 
3.2. Sample collection and preparation 
At the beginning of the experiments (T0) and at 3 (T1), 6 (T2) and 9 (T3) weeks 
after the first rHuEpo dose, the rats were subjected to intraperitoneal anesthesia with a 
2 mg/kg bw of a 2:1 (v:v) 50 mg/mL ketamine (Ketalar, Parke-Davis, Lab. Pfeizer Lda, 
Seixal, Portugal) solution in 2.5% chlorpromazine (Largactil, Rhône-Poulenc Rorer, Lab. 
Vitória, Amadora, Portugal). Blood samples were immediately collected by venipuncture, 
from the jugular vein, into vacutainer tubes without anticoagulant (to obtain serum) and 
with EDTA (to obtain whole blood and plasma) for hematological and biochemical 
studies; 3 mL blood samples were collected at T0, T1, T2, to minimize interference with 
erythropoiesis mechanism; at the end of protocol (T3) a 10 mL sample was collected in 
order to perform all the biochemical and hematological assays. 
At the end of the protocol, blood was collected and, afterwards, the rats were 
sacrificed by cervical dislocation; duodenum, liver and kidneys were immediately 
removed, placed in ice-cold Krebs-Henseleit buffer and carefully cleaned. A bone 
marrow aspirate from the femur was also performed. 
 
 
3.3. Biochemical and hematological assays 
Serum creatinine and urea concentrations were used as renal function indexes 
through automatic validated methods and equipments (Hitachi 717 analyser, Roche 
Diagnostics Inc., Massachusetts, USA). Red blood cell (RBC), hematocrit and hemoglobin 
(Hb) concentration were assessed in whole blood EDTA by using an automatic Coulter 
Counter (Beckman Coulter Inc., USA, CA). Serum levels of erythropoietin were 
evaluated by rat specific ELISA kit (MyBioSource, USA). Serum iron concentration was 
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determined using a colorimetric method (Iron, Randox Laboratories Ltd., North Ireland, 
UK), whereas serum ferritin and transferrin were measured by immunoturbidimetry 
(Laboratories Ltd., North Ireland, UK). Quantification of total bilirubin was performed by 
a colorimetric test (diazotized sulfanilic acid reaction, Roche Diagnostics). Circulating 
levels of glucose and uric acid were determined by routine automated technology (ABX 
Diagnostics). Serum levels of interleukin-6 (IL-6), interferon- (IFN-), transforming 
growth factor beta 1 (TGF-β1) and vascular endothelial growth factor (VEGF) were 
measured by rat-specific Quantikine ELISA kits from R&D Systems (Minneapolis, USA). 
High-sensitive C-reactive protein (hsCRP) was determined by using a rat-specific Elisa kit 
from Alpha Diagnostics International (San Antonio, USA). 
 
 
3.4. Detection of anti-EPO antibodies  
The detection of anti-EPO antibodies was carried out by ELISA,  according to Urra 
et al. (1997) using rHuEPO (Recormon, Roche Pharmaceuticals) as antigen and, as 
secondary antibody, goat anti-rat IgG conjugated with horseradish peroxidase (Sigma; 
100 ng/mL for 1h, at room temperature).17 The substrate tetramethylbenzidine (TMB) 
(Sigma) was added and the reaction was stopped by the addition of sulphuric acid 1.25 
mol/L. The optical density at 450 nm (OD450) was determined with an automatic plate 
reader. 
 
 
3.5. Gene expression analysis 
In order to isolate total RNA, 0.2 g of liver, duodenum and kidney samples, from 
each rat, were immersed in RNA laterTM (Ambion, Austin, USA) upon collection and 
stored at 4°C, for 24h; afterwards, samples were frozen at -80ºC. Subsequently, tissue 
samples weighing 50±10 mg were homogenized in a total volume of 1 mL TRI Reagent 
using a homogenizer, and total RNA was isolated according to manufacturer instructions 
(Sigma, Sintra, Portugal). To ensure inactivation of contaminating RNAses, all material 
used was cleaned and immersed in RNAse-free water (0.2% diethyl pyrocarbonate) for 
2h and finally heated at 120ºC for 1h. RNA integrity (RIN, RNA Integrity Number) was 
analyzed using 6000 Nano ChipW kit, in Agilent 2100 bioanalyzer (Agilent Technologies, 
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Walbronn, Germany) and 2100 expert software, following manufacturer instructions. 
The yield from isolation was from 0.5 to 1.5 μg; RIN values were 7.8–9.0 and purity 
(A260/A280) was 1.8–2.0.  
 
Table V-1. List of primer sequences (F: forward; R: reverse). 
Gene Primer sequences 
EPO 
F: 5’-AGGGTCACGAAGCCATGAAG-3’ 
R: 5’-GAT TTC GGC TGT TGC CAG TG-3’ 
EPOR 
F: 5’-GCG ACT TGG ACC CTC TCA TC-3’ 
R: 5’-AGT TAC CCT TGT GGG TGG TG-3’ 
Hamp 
F: 5’-GAA GGC AAG ATG GCA CTA AGC-3’ 
R: 5’-CAG AGC CGT AGT CTG TCT CG-3’ 
TfR2 
F: 5’-CAA GCT TCG CCC AGA AGG TA-3’ 
R: 5’-CGT GTA AGG GTC CCC AGT TC-3’ 
SLC40A1 
F: 5’-CAG GCT TAG GGT CTA CTG CG-3’ 
R: 5’-CCG AAA GAC CCC AAA GGA CA-3’ 
HJV 
F: 5’-GCC TAC TTC CAA TCC TGC GT-3’ 
R: 5’-GGT CAA GAA GAC TCG GGC AT-3’ 
TF 
F: 5’-GGC ATC AGA CTC CAG CAT CA-3’ 
R: 5’-GCA GGC CCA TAG GGA TGT T-3’ 
Hfe 
F: 5’-CTG GAT CAG CCT CTC ACT GC-3’ 
R: 5’-GTC ACC CAT GGT TCC TCC TG-3’ 
DMT1 
F: 5’-CAA CTC TAC CCT GGC TGT GG-3’ 
R: 5’-GTC ATG GTG GAG CTC TGT CC-3’ 
TfR1 
F: 5’-GCT CGT GGA GAC TAC TTC CG-3’ 
R: 5’-GCC CCA GAA GAT GTG TCG G-3’ 
TMPRSS6 
F: 5’-CCG AAT ATG AGG TGG ACC CG-3’ 
R: 5’-GGT TCA CGT AGC TGT AGC GG-3’ 
BMP6 
F: 5’-GCT GCC AAC TAT TGT GAC GG-3’ 
R: 5’-GGT TTG GGG ACG TAC TCG G-3’ 
18S 
F: 5’-CCA CTA AAG GGC ATC CTG GG-3’ 
R: 5’-CAT TGA GAG CAA TGC CAG CC-3’ 
Actb 
F: 5’-GAG ATT ACT GCC CTG GCT CC-3’ 
R: 5’-CGG ACT CAT CGT ACT CCT GC-3’ 
 
The concentration of the RNA preparations were confirmed with NanoDrop1000 
(ThermoScientific, Wilmington, DE, USA). Possible contaminating remnants of genomic 
DNA were eliminated by treating these preparations with deoxyribonuclease I 
(amplification grade) prior to RT-qPCR amplification. Reverse transcription and relative 
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quantification of gene expression were performed as previously described.18 Real-time 
qPCR reactions were performed for erythropoietin (EPO), erythropoietin receptor 
(EPOR), transferrin receptor 2 (TfR2), hepcidin (Hamp), ferroportin (SLC40A1), 
hemojuvelin (HJV), transferrin (TF), hemochromatosis (Hfe), divalent metal transporter 1 
(DMT1), transferrin receptor 1 (TfR1), matriptase-2 (TMPRSS6), and bone morphogenic 
protein 6 (BMP6), which were normalized in relation to the expression of beta-actin 
(Actb), and 18S ribosomal subunit (18S). Primer sequences are listed on Table II-1. 
Results were analyzed with SDS 2.1 software (Applied Biosystems, Foster City, CA, USA) 
and relative quantification calculated using the 2-ΔΔCt method.19 In liver tissue we studied 
the EPO, EPOR, TfR2, Hamp, SLC40A1, HJV, TF, Hfe, BMP6 and TMPRSS6 gene 
expression; in duodenum tissue the gene expression of DMT1 and SLC40A1 were 
studied, and in the kidney we evaluated the expression of EPO gene. 
 
 
3.6. Data analysis 
For statistical analysis, we used the Statistical Package for Social Sciences (SPSS), 
version 22.0. Results are presented as mean ± standard error of means (SEM). Multiple 
comparisons between groups were performed by one-way ANOVA supplemented with 
Turkey’s HSD post-hoc test. For single comparisons, we used the Mann–Whitney U-test. 
Significance was accepted for a p minor than 0.05. 
 
 
4. Results 
4.1. Biochemical and hematological data 
The changes in RBC count, Hb concentration, hematocrit and in the number of 
reticulocytes for the three groups are presented in Figure V-2. During the 9 week 
experimental protocol, the 50 IU rHuEPO group, when compared to the control group, 
showed similar values for RBC count, Hb concentration, hematocrit and reticulocytes, 
though a significant increase in reticulocyte count was observed at T2 and T3. 
Concerning the rats treated with 200 IU rHuEPO, in the first 3 weeks, we found a 
significant increase (> 30% the basal value) in hemoglobin levels, RBC count, hematocrit 
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and reticulocyte count, as compared to control and 50 IU rHuEPO groups; after this 
period, the hemoglobin concentration, hematocrit and RBC count, as well as the number 
of reticulocytes decreased, reaching significantly lower values at T2, as compared to T1; 
this trend towards decreasing values was maintained till the end of the experiment (9 
weeks). 
 
 
Figure V-2. Evolution of RBC count (A), hematocrit (B) hemoglobin (C) and reticulocyte count 
(D) during the follow-up period of 9 weeks under rHuEPO treatment. Results are expressed as 
mean ± SEM. ap <0.05 vs control; bp <0.05 vs 50 IU rHuEPO; cp <0.001 vs control; dp <0.001 vs 50 
IU rHuEPO; δp < 0.005 T0 vs T1; *p < 0.05 T1 vs T2; §p < 0.05 T2 vs T3. 
 
At the end of the protocol, serum erythropoietin levels were similar for the three 
groups (Table II-2). No changes were observed in glucose, creatinine, urea, uric acid and 
bilirubin levels for both rHuEPO groups, when compared to the control. The 
inflammatory marker, IL-6, presented a significant decrease in the 200 IU rHuEPO group 
when compared with the control and 50 IU rHuEPO groups; hsCRP, IFN-, TGF-1 and 
VEGF showed no significant differences between the three studied groups (Table II-2). 
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Table V-2. Hematological and biochemical data at the end of protocol (12 weeks). 
Results are expressed as mean ± SEM. ap < 0.05 vs control; bp < 0.05 vs 50 IU rHuEPO. WBC, 
white blood cells; PLT, platelets; IL-6, interleukin-6; hsCRP, high-sensitive C-reactive protein; IFN-
, interferon-; TGF-β1, transforming growth factor beta 1; VEGF, vascular endothelial growth 
factor. 
 
 
4.2. Anti-rHuEPO antibodies  
Serum samples from all animals were also analyzed for anti-rHuEPO antibodies. 
These antibodies were detected in 5 rats under 50 IU rHuEPO treatment, as well as in 5 
rats treated with 200 IU rHuEPO (62.5% for both groups); the antibody titer was fourfold 
higher in the group under 200 IU rHuEPO; the later presented a titer of 1:16,  and the 
group under the lower rHuEPO dose presented a titer of 1:4. Within each rHuEPO group, 
no other significant differences were found between the rats with or without anti-
rHuEPO antibodies. 
Bone marrow examination of rats treated with 200 IU rHuEPO showed a 
proportion of red-cell precursors significantly lower than those without rHuEPO 
treatment. The myeloid:erythroid ratio was 2.1:1 for the control group, while for the 200 
IU rHuEPO group the ratio was 6.8:1.; the 50 IU rHuEPO group presented a 
myeloid:erythroid ratio similar to that found for the control (2.5:1). 
 
 
Parameters 
Groups 
Control 50 IU rHuEPO  200 IU rHuEPO  
EPO (mIU/ml) 1.870.11 1.650.09 1.800.11 
WBC (x 109/L) 1.490.04 2.700.46a 1.470.18b 
PLT (x 109/L) 767.8819.68 803.2535.72 751.6738.70 
Glucose (mg/dL)  160.8810.27 174.627.14 187.7114.15 
Creatinine (mg/dL) 0.400.02 0.370.01 0.350.02 
Urea (mg/dL) 45.101.16 45.051.26 42.741.92 
Uric Acid (mg/dL)  0.940.46 0.700.13 1.030.52 
Bilirubin (ng/mL)  0.0430.006 0.0540.005 0.0640.0005 
IL-6 (pg/mL)  138.101.89 139.982.16 130.161.91a,b 
hsCRP (µg/mL)  229.318.68 237.4910.23 249.4612.66 
IFN- (pg/mL)  24.448.72 21.452.40 20.823.83 
TGF-β1 (ng/mL) 80.211.77 80.036.09 78.102.10 
VEGF (pg/mL)  5.361.74 5.841.46 6.041.33 
Chapter V  | 
170  |Resistance to rHuEPO therapy - studies in experimental models of anemia and CKD 
4.3. Iron metabolism 
Concerning iron metabolism, we found that serum iron was significantly higher 
for the 200 IU rHuEPO group, when compared with the control and 50 IU rHuEPO 
groups; no significant differences were found in ferritin and transferrin serum levels 
between the three studied groups (Figure V-3). 
 
 
 
Figure V-3. Serum iron, ferritin and transferrin at final the time. Results are expressed as mean 
± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 vs control group; #p < 0.05, ##p < 0.01, and ###p < 
0.001 vs 50 IU rHuEPO. 
 
Major changes were observed in the gene expression of iron and erythropoietic 
regulatory proteins in liver tissue (Figure V-4), particularly in the 200 IU rHuEPO group. 
Indeed, the 50 IU rHuEPO group showed significant overexpression of HJV and SLC40A1 
genes, as compared to control, while the 200 IU rHuEPO group presented significant 
overexpression of Hamp, Hfe, HJV, EPOR, SLC40A1, Tf , TfR2, and BMP6 genes, as 
compared to control and 50 IU rHuEPO groups. EPO gene was significantly down-
regulated in both groups, and TMPRSS6 gene expression was significantly down-
regulated only in the 200 IU rHuEPO group, as compared to the control and 50 IU 
rHuEPO groups. 
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Figure V-4. Relative mRNA expression of erythropoietin and iron regulatory proteins in the 
liver, at the end of the protocol (9 weeks). 18S rRNA was used as reference gene. Results are 
expressed as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 vs control group; #p < 0.05, ##p 
< 0.01, and ###p < 0.001 vs 50 IU rHuEPO. BMP6, Bone morphogenic protein 6; EPO, 
erythropoietin; EPOR, erythropoietin receptor; Hamp, hepcidin; HFE, Hemochromatosis; HJV, 
Hemojuvelin; SLC40A1, ferroportin; TMPRSS6, matriptase-2; sTfR2, soluble transferrin receptor 
2; Tf, transferrin.  
 
The evaluation of the expression of DMT1 and SLC40A1 genes in duodenum 
showed that only the 200 IU rHuEPO group presented a significantly up-regulation for 
both genes (Figure V-5), as compared to the control. Furthermore, as observed in liver, 
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the expression of EPO in kidney tissue presented a trend towards down-regulation in 
both rHuEPO groups, when compared to the control (Figure V-6). 
 
 
Figure V-5. Relative mRNA expression of DMT1 and SLC40A1 in the duodenum, at the end of 
the protocol (9 weeks). 18S rRNA was used as reference gene. Results are expressed as mean ± 
SEM. ***p < 0.001 vs control group; ##p < 0.01, and ###p < 0.001 vs 50 IU rHuEPO. DMT1, divalent 
metal transporter 1; SLC40A1, ferroportin. 
 
 
 
Figure V-6. Relative mRNA expression of erythropoietin in the kidney, at the end of the 
protocol (9 weeks). 18S rRNA was used as reference gene. Results are expressed as mean ± 
SEM. EPO, erythropoietin. 
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5. Discussion 
Antibody-mediated EH/PRCA is a rare pathological complication associated with 
the use of recombinant human erythropoietins and development of anti-EPO antibodies. 
However, the use of EPO biosimilars has increased the number of cases in the last 
years.11,20,21 Clinically, that condition not only abrogates the effect of the rHuEPO, but 
may also neutralize endogenous EPO, leading to severe EH and transfusion-dependent 
anemia. 
In this work we developed an animal model of antibody-mediated EH, by long-
term treatment with a high dose of rHuEPO (200 IU/Kg bw/week during 9 weeks) in 
Wistar rats. In order to confirm that we were in fact in the presence of an animal model 
of this hematological disorder, we assessed the parameters typically used as diagnostic 
criteria for EH/PRCA, which include normocytic anemia with sudden onset, 
normocellular bone marrow with a selective reduction in red blood cell precursors 
beyond proerythroblasts, reticulocytopenia, normal or slightly decreased leucocyte 
counts and increased serum iron.22 We found that the group treated with 200 IU/Kg 
bw/week of rHuEPO along 9 weeks fits all these criteria and the majority (65%) of the 
rats presented detectable anti-rHuEPO antibodies, suggesting that we achieved an 
antibody-mediated EH. The group under 50 IU/Kg bw/week rHuEPO treatment 
presented only slight changes, as compared to control; however, most of the rats (65%) 
presented anti-rHuEPO antibodies at a lower title (four times less), suggesting that a 
longer experimental protocol could also lead to the changes associated with EH. Indeed, 
Casadevall et al. (2005) reported that the detection of anti-erythropoietin antibodies in 
circulation is not immediately associated with PRCA.23 Moreover, no significant changes 
were observed in hsCRP, IL-6 and IFN-, for both rHuEPO treated groups, showing that 
no inflammatory changes could interfere with erythropoiesis and iron metabolism. 
Our data showed that the development of EH was due to the antibodies directed 
to rHuEPO that inhibited the erythropoietic stimuli of both rHuEPO and endogenous 
EPO. Indeed, in spite of the normal endogenous EPO levels that were similar to those of 
the control group, the 200 IU rHuEPO group developed anemia, suggesting that the anti-
rHuEPO antibodies also neutralized the action of endogenous EPO. It has been described 
that the presence of rHuEPO in circulation may increase several fold the expression of 
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EPOR.4 Indeed, we found an overexpression of EPOR in the liver of the 200 IU rHuEPO 
group. The decreased EPO expression observed in kidney and liver tissues, for both 
rHuEPO groups, seems to be in accordance with a physiological response to the 
increased circulating levels of rHuEPO, used in the treatment. 
Anemia, usually, triggers erythropoiesis by increasing EPO production through 
the HIF pathway, by mobilizing iron from the iron storage pool and by increasing iron 
absorption, in order to face the increased iron needs for erythropoiesis. Considering that 
in antibody-mediated EH, the erythropoietic stimuli fails, due to the inhibition of rHuEPO 
by anti-rHuEPO antibodies, the serum iron should increase, as its absorption and 
mobilization would be triggered by the anemic condition, and hepcidin should be 
repressed to favour iron absorption and mobilization. Actually, we found a significant 
increase in serum iron in the 200 IU rHuEPO group. It is known that increasing serum 
iron induces hepcidin synthesis by a complex pathway. Indeed, hepcidin, encoded by the 
Hamp gene, is believed to play a key regulatory role in iron absorption. It controls 
plasma iron concentration and tissue distribution of iron by inhibiting intestinal iron 
absorption, iron recycling by macrophages, and iron mobilization from stores.24 Hepcidin 
acts by inhibiting cellular iron efflux in hepatocytes, enterocytes and macrophages, 
through binding to ferroportin, inducing its degradation.25 Hepatic Hamp expression is 
regulated by a cohort of proteins, including Hfe, TfR2, HJV, BMP6, matriptase-2 and 
transferrin.26-28 Studies in both human and animal models indicate that Hfe and TfR2 are 
mild inducers of hepcidin expression,26 as compared to HJV and Tmprss6, which are 
robust modifiers of hepcidin expression.29-31 TfR2 has been hypothesized to act as a 
sensor for iron levels in the body because of its largely hepatocyte-specific expression 
and its ability to mediate cellular iron transport.32 Although TfR2 is a minor contributor 
to the uptake of transferrin-bound iron by the liver, experiments with mice have shown 
that its major role is to modulate the signalling pathway that controls Hamp induction.32 
Hfe has also been implicated in the iron signalling complex that modulates hepcidin 
transcription by sensing changes in iron levels.33 Increasing expression of HJV enhances 
Hamp expression by interacting with BMPs34 possibly as a co-receptor. Matriptase-2 has 
been shown to negatively regulate Hamp gene and, therefore, to decrease hepcidin 
expression and promote iron uptake.35 It is highly expressed in the liver and participates 
in a transmembrane signaling pathway triggered by iron deficiency and suppresses 
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hepcidin expression by cleaving membrane-bound hemojuvelin (mHJV) to increase iron 
absorption.36  
In the liver, diferric transferrin competes with TfR for binding to Hfe, and, when 
iron is increased, more Hfe is available to bind to TfR2; this complex, TfR2-Hfe, promotes 
HJV binding to BMP6, increasing hepcidin synthesis.32,34 Indeed, we found that increased 
serum iron in the 200 IU rHuEPO group was associated with an overexpression of Tf, 
TfR2, BMP6, Hfe, HJV in the liver, and, in accordance, with an overexpression of Hamp. 
Moreover, a downregulation in matriptase mRNA was observed in the liver that might 
further contribute to the overexpression of hepcidin. In accordance with the 
overexpression of hepcidin, a reduction in serum iron would be expected, due to the 
degradation of ferroportin by hecpcidin, instead of the increase that we found.  It is 
known that regulation of iron absorption is mediated by signals reflecting oxygen 
tension in enterocytes, intracellular iron levels and systemic iron needs. Enterocyte 
oxygen tension regulates iron absorption through its effects on the transcription of HIFs 
and subsequent changes in transcription of DMT1.37 Iron exits the enterocyte through 
the efflux transporter ferroportin 1 (FPN), the only member of the SLC40 family of 
transporters and the first reported protein that mediates the exit of iron from cells.38 
Actually, we found an overexpression of DMT1 and ferroportin in the duodenum and 
liver from the 200 IU rHuEPO group, in response to the anemic state. However, as the 
overexpression of hepcidin compromises iron absorption and mobilization, the observed 
increase in serum iron might result mainly from the decreased use of iron for the 
inhibited erythropoiesis. 
Hypoxia, EPO, as well as twisted gastrulation protein 1 (TWSG1) and growth 
differentiation factor 15 (GDF15),39 both produced by ertyhroblasts, are known to 
downregulate hepcidin synthesis. Considering the inhibition of erythropoiesis through 
the anti-rHuEPO antibodies, the production of TWSG1 and GDF15, might be reduced 
and, therefore, unable to downregulate hepcidin synthesis. We also found that rHuEPO 
treatment did not alter renal function, glucose levels and was not associated with an 
inflammatory process, when compared to the control.   
Considering the four functionally hepcidin regulatory pathways described,40-43 
erythropoiesis, iron status, oxygen tension, and inflammation, we found that in our 
model, erythropoiesis was blunted leading to anemia, iron was increased and there was 
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no inflammation. It seems, therefore, that the increased iron concentration is the key 
modulator of hepcidin synthesis in this type of erythroid hypoplasia. In fact, it has been 
recently reported that the reduction of serum iron by iron chelation therapy promoted 
an improvement in erythropoiesis in PRCA, though the mechanism whereby this is 
achieved is still unclear.44  
In conclusion, our data suggest that in the case of erythroid antibody-mediated 
hypoplasia/PRCA induced by a high rHuEPO dose (200 IU), as erythropoiesis is blunted 
through anti-rHuEPO antibodies, iron concentration becomes the key modulator for 
hepcidin synthesis, which will, probably, contribute to further aggravate the anemia. 
These findings might be important to improve new therapeutic strategies against 
rHuEPO resistance and/or development of antibody-mediated EH/PRCA in patients 
under rHuEPO therapy.  
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1. Final remarks 
CKD is a pathological condition that results from a gradual and permanent loss of 
kidney function over time, usually, months to years. CKD can result from primary 
diseases of the kidneys, however, diabetic nephropathy and hypertension are the main 
causes of CKD.1 Anemia is a common complication of CKD that develops early in the 
course of the disease, increasing its frequency and severity with the decline of renal 
function. Anemia has been associated to a reduced production of erythropoietin by 
failing kidneys, to disturbances in iron metabolism and to the undelying inflammatory 
process.  
Since the introduction of rHuEPO, the treatment of anemia with ESAs reduced 
the requirements for transfusion, improved the quality of life of the patients and 
reduced some associated complications of anemia.2-4 However, the management of the 
anemia is still under debate, as a worrying percentage of patients develop hypo 
responsiveness to rHuEPO therapy, worsening their prognosis. Actually, the mechanisms 
underlying the development of resistance to rHuEPO therapy remain unsolved, although 
several hypotheses have been raised and investigated during the last years. Until the 
precise cellular and molecular mechanism explaining the development of anemia in CKD 
patients remain to be clarified, the clinical/therapeutic managing of this serious 
condition will remain difficult and unsatisfactory, and the mortality rate will remain too 
high, when compared with the normal population. Studies on animal models, taking 
advantage of the availability of tissues and the ability to modulate experimental 
conditions, are crucial to elucidate the cellular and molecular mechanisms responsible 
for these pathological circumstances. Indeed, although an animal model can never be a 
perfect match for human diseases, adequate animal models have been used, providing 
valuable insights into the mechanisms of anemia/CKD. Molecular studies, supported by 
proper animal models, might improve the knowledge about some areas that remain to 
be elucidated, concerning the use of rHuEPO in kidney disease/anemia, including the 
mechanisms behind resistance to therapy and the impact of high doses.  
Uremic rat models have been characterized and used for long time by our group 
as well as by other authors as tools to study the pathophysiological events underlying 
kidney disease and the associated anemia, including those with renal failure induced by 
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nephrectomy and infarction.5-7 However, the information is still scarce concerning the 
disturbances in iron metabolism associated with the hypoxic anemia of chronic kidney 
disease, namely in the 5/6 nephrectomized rat, which is one of the most used rat model 
of CKD.7-9 
In this study, we opted to use the remnant kidney rat model of CKD induced by 5/6 
nephrectomy, in order to, firstly, elucidate the mechanisms underlying the development 
of anemia and the evolution of renal damage, focusing on the quantification of 
endogenous EPO levels and kidney and liver EPO and EPOR mRNA expression, on iron 
metabolism, as well as, on kidney lesion, namely hypoxia, inflammation and fibrosis; and, 
secondly, to analyse the impact of rHuEPO therapy, by focusing on the same analytical 
studies.  
Our CKD animal model produced a sustained degree of renal dysfunction, as 
shown by the significantly increased BUN and creatinine concentrations, together with 
presence of structural lesions, namely mild and advanced glomerular and 
tubulointerstitial lesions. In addition, we found a significant kidney hypertrophy 
(increased KW/BW index) showing a compensatory renal proliferation/hypertrophy of the 
remnant kidney, as previously described for this model.10 A significant increase of HW/BW 
ratio was also found, suggesting the development of left ventricule hypertrophy, 
accompanied with hypertension, which is a cardiac complication found in CKD patients 
(Figure VI-1).  
The progression of kidney disease and its associated cardiac/cardiovascular 
complications are the major causes of morbidity and mortality in these patients. One of 
the most prevalent co-morbidities is hypertension, which is present at all stages of 
CKD.36 The results confirmed the development of systolic hypertension, which is a 
typical feature in the CKD rat model. Usually, hypertension is inversely proportional to 
the residual functional renal mass, as occurs in human pathology.37,38 
In addition, and as expected, our CKD model developed anemia early after 
nephrectomy, which persisted throughout the study. The persistent anemia present in 
CRF rats was not due to EPO deficiency because the remnant kidney of CRF was still able 
to produce EPO (increased serum EPO levels), and the liver seems to increase EPO gene 
expression, suggesting that the remnant kidney or even extra-renal tissues were able to 
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compensate EPO production. Moreover, the reticulocyte count showed a trend towards 
reduced values, suggesting a reduced erythropoietic response to overcome the anemia. 
Iron is essential for the production of mature red blood cells and a normal iron 
metabolism is crucial to maintain body iron levels.10,48,49 Disturbances in iron 
homeostasis is a hallmark of the anemia of CKD, which, usually, presents as a functional 
iron deficient anemia, with low serum iron and transferrin alongside with normal or 
even high ferritin.50 In spite of the increased EPO blood levels, anemia persisted and was 
associated to low serum iron and transferrin levels. However, the reduced iron content 
cannot be due to deficiency in iron stores or absorption because normal serum ferritin 
levels were found in CRF animals, together with reduced liver Hamp mRNA expression, 
and overexpression of duodenal ferroportin mRNA, that altogether would contribute to 
iron availability. In addition, the absence of systemic inflammation (normal serum IL-6 
and hsCRP levels), could also not explain the presence of persistent anemia (Figure VI-1). 
 
 
 
Figure VI-1. Schematic diagram representing a putative mechanistic model of the relationship 
between CKD, anemia, EPO production, iron/hepcidin metabolism, inflammation, hypoxia and 
renal damage/fibrosis in the remnant kidney rat model. 
 
 
Regardless of the underlying molecular mechanism of reduction of Hamp 
expression during hypoxia, a decrease in hepcidin leads to an increased iron uptake and 
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absorption at the duodenum, as well as to an increased iron release from the 
macrophages, favoring Hb synthesis and erythropoiesis.14 Actually, we found a 
significant downregulation in liver mRNA expression of Hamp, sTfR1, TF, Hfe, HJV and 
BMP6 in CRF rats, together with a significant duodenal overexpression of SLC40A1 gene 
in CRF rats and similar values for the expression of DMT1 gene, suggesting that iron 
absorption in the enterocytes was normal or even enhanced, as the increase in duodenal 
ferroportin expression may occur to counteract the low iron levels observed in CRF rats; 
in addition, hypoxia might contribute to the significantly decreased liver Hamp mRNA 
expression in CRF rats (Figure VI-1). 
These results suggest that the reduction of Hb levels in CRF rats, by leading to a 
reduced oxygen kidney perfusion, induced renal EPO production in response to low 
oxygen tension. Under hypoxic conditions in renal injury, the HIF system is activated, 
even before any histological evidence of tubulointerstitial damage,68,69 and the degree of 
HIF expression seems to correlate with the extent of tubular injury. This persistent 
anemia in CRF rats, by leading to kidney hypoxia, activates the oxygen sensing pathway, 
increasing kidney protein expression of HIF-2 and HIF-2 and EPO. Some controversies 
exists about the role of HIF; some authors reported that HIF has a renoprotective 
role,11,12 while others proposed that HIF contributes to interstitial fibrosis and/or tubular 
atrophy.13,14 This duality of effects has also been described for vascular endothelial 
growth factor (VEGF), another target gene of HIFs.15 We found significantly high serum 
VEGF levels, probably explaining the repression in VEGF gene expression in the remnant 
kidney of CRF. 
All these conditions promoted the aggravation of renal damage, with mild and 
advanced glomerular and tubulointerstitial lesions, as well as the development of a local 
inflammatory milieu, as suggested by the increased expression of IL-6, IL-1 and TNF- 
mRNA in the kidney tissue. The damages and the inflammatory milieu in the remnant 
kidney may cause iron leakage, explaining the reduced iron availability and, eventually, 
an altered structure/configuration of EPO that compromise its activity/function. The 
persistence of anemia may result from the disturbance in iron metabolism and, 
eventually, by an altered activity/function of EPO that might result from hypoxic kidney 
cell damage and from the developed local inflammatory milieu (Figure VI-1). 
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As already referred, there is a large variability in the erythropoietic response to 
ESA treatment, with up to 10-fold variability in dose requirements to achieve correction 
of the anemia. Hyporesponsiveness to ESA has been associated with higher morbidity 
and mortality in end-stage renal disease (ESRD) patients;16,17 however, the target 
hemoglobin values are also crucial for the outcome of CKD patients; in fact, randomized 
studies and meta-analyses have demonstrated that correction of anemia for hemoglobin 
values higher than 12 g/dL is not associated with a better survival or a significant 
improvement in quality of life; instead, it has been associated with a potential increase 
in adverse cardiovascular effects, such as increased risk of stroke, venous 
thromboembolism and possibly death.18-20  
Therefore, we figured as important to study the impact of increasing rHuEPO 
doses on CKD associated-anemia, using the same animal model and focusing again on 
erythropoiesis, iron metabolism, inflammation and kidney damage. Moreover, this study 
could provide some insights for the persistence of anemia observed in the CRF rats and 
to the mechanisms of development of resistance to rHuEPO therapy in CKD patients.  
As previously commented, during the last few years the mechanisms underlying 
hepcidin and iron regulation have been largely studied. In addition, the impact of renal 
hypoxia, through hypoxia-inducible factors, on iron metabolism, on kidney lesion or 
regeneration, as well as on hepcidin expression has been increasingly debated.21-23 
Recent evidences suggest that CKD anemia might be due to defective hypoxic signaling 
rather than an inability of the EPO-producing cells to synthesize EPO. The long-term 
safety of therapeutic activation of the HIF system requires further study because of the 
broad biological potential of HIF in mediating hypoxia responses.24 Meanwhile, it is of 
great clinical important to understand the impact of rHuEPO, namely at high doses, on 
some key aspects of CKD anemia, including on iron metabolism and the pre-existing 
kidney damage.  
We used the animal model of CKD induced by 5/6 nephrectomy to evaluate the 
impact of two doses of rHuEPO - 50 and 200 IU - on the same analytical studies. The 
lower dose is used in responsive CKD patients, while the higher dose is used in patients 
presenting a poor response to rHuEPO therapy.  
The CRF rats treated with the lowest dose of rHuEPO (50 IU) presented anemia, 
though a slight rise in Hb and in reticulocyte count was observed, until the ninth week; 
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afterwards Hb, HTC and RBC count showed a decrease. In opposition, the anemia of CRF 
rats under treatment with the highest rHuEPO dose (200 IU) was rapidly corrected and 
the Hb concentration reached values significantly higher, as compared to Sham and CRF 
rats, until the ninth week, after which the hematological values declined to values 
similar to those of the Sham group. In fact, while the lowest dose (50 IU) was unable to 
correct the anemia (only a slight improvement) leading to kidney hypertrophy and 
angiogenesis, as compared to CRF rats, the highest dose (200 IU) reduced kidney 
hypertrophy and angiogenesis, as it was able to correct anemia until the 9th week.  
The decrease in hemoglobin, observed in both CRF groups treated with rHuEPO 
was due to the formation of EPO-neutralizing antibodies (Abs). This condition has been 
also reported in humans,25,26 and, more recently, has increased due to the introduction 
of EPO biosimilars to treat the anemia, in some countries.27,28 Although this complication 
is very rare, the mechanisms underlying the break in immune tolerance to rHuEPO 
remain poorly clarified.  
Actually, when studying the effect of rHuEPO treatment, per se, in Wistar rats, 
we managed to develop a rat model of antibody-mediated EH, by long-term treatment 
with a high dose of rHuEPO (200 IU/Kg bw/week during 9 weeks). To confirm that we 
were, in fact, in the presence of an animal model of this hematological disorder, we 
assessed the parameters typically used as diagnostic criteria for EH/PRCA.  
In this model, anti-rHuEPO antibodies inhibited both rHuEPO and endogenous 
EPO leading to anemia, iron was increased, triggering hepatic hepcidin expression, 
despite no evidence of inflammation. These results suggest that in erythroid antibody-
mediated hypoplasia/PRCA induced by a high rHuEPO dose (200 IU), as erythropoiesis is 
blunted through anti-rHuEPO antibodies, the increased iron concentration becomes the 
major key modulator of hepcidin synthesis, increasing its expression, which will, 
probably, contribute to further aggravate the anemia.  
The persistence of the anemia developed in the CRF model is not due to deficient 
EPO production, as viewed by unchanged serum EPO levels, normalization of kidney EPO 
and EPOR mRNA expression and an overexpression of liver EPOR mRNA, which might be 
explained by a compensatory production of EPO by the remnant kidney, as well as, most 
probably, by the liver tissue (Figure VI-2).  
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While the liver has a role in EPO production in the fetal age, in the adulthood the 
main producer of EPO is the kidney.29-31 However, in renal disease conditions the extra-
renal tissues, such as the liver, might assume a higher part on the compensatory 
synthesis of EPO.  
 
 
 
Figure VI-2. General synthesis of impact of rHuEPO therapy on key aspects of CKD associated-
anemia. 
 
 
In spite of the anemia, both CRF treated groups presented a similar down-
regulation of kidney and liver EPO gene expression, suggesting a deregulation of the 
kidney hypoxia sensing mechanisms. As just referred, the anemia developed in CRF rats 
was not due to deficient EPO production, but, instead, it seems to result from a reduced 
(altered) erythropoietic activity of endogenous EPO, once the treatment of CRF rats with 
rHuEPO was able to improve the anemia until the ninth week. 
A lower impact of the treatment with the highest rHuEPO dose (200IU) on the 
glomerulus, as compared to the lowest dose, may explain the improvement observed in 
iron metabolism, with an increase in serum iron and transferrin and a slight decrease in 
ferritin levels, as well as an increase in duodenal ferroportin and DMT1 mRNA 
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expression, suggesting that less damaged glomerulus were able to reduce the loss of 
iron and transferrin levels. This was strengthened by the observation of increased iron 
deposits on the tubular structures of CRF rats and of CRF animals treated with 50 IU 
rHuEPO, as compared to CRF rats under 200IU rHuEPO therapy, in whom iron deposits 
were almost absent. Furthermore, the improvement in iron metabolism achieved with 
the highest dose (200 IU), promoted also a profound impact on liver and duodenal gene 
expression profile of iron-hepcidin mediators: increased mRNA expression of sTfR1, 
sTfR2, Hfe, HJV, BMP-6 and IL-6 and reduced of TMRPSS6 (matriptase-2) in the liver and, 
as expected, an overexpression of hepcidin gene (Hamp), that was not traduced in a 
higher protein expression, as showed by the immunochemical studies in the liver. The 
same was observed for HIF-2, which presented a slightly increased overexpression that 
was associated with a slight decrease in the protein expression. An increased mRNA 
expression of DMT1 and SLC40A1 was also observed in the duodenum. Thus, it seems 
that for the highest rHuEPO dose, the less severe anemia/hypoxia is, probably, due to 
reduced glomerular kidney lesions associated to the improvement in iron metabolism, 
and might explain the decrease in hepcidin and HIF-2 protein expression. No changes 
were observed in systemic inflammation with the highest dose of rHuEPO (Figure VI-2).  
Both rHuEPO doses were unable to prevent kidney damage. The highest dose, 
indeed, aggravated tubulointerstitial lesions. The deleterious effect of the highest 
rHuEPO dose on the kidney tissue might be explained by the increase in mediators of 
kidney hypoxia, fibrosis, angiogenesis and local inflammation, as this dose promoted an 
overexpression of HIF-2 ( and ), IL-6, IL-1, NF-kB and CTGF, accompanied by 
increased kidney protein expression (immunorreactivity) of NF-kB and CTGF, showing 
the development of a fibrotic and inflammatory milieu. However, we must notice that 
the decrease in Hb concentration, in the last three weeks, almost thrice in the 
CRF+200IU rHuEPO group, as compared to CRF+50IU rHuEPO group, might result, 
besides the action of anti-rHuEPO antibodies, from the synthesis of EPO with a reduced 
(altered) erythropoietic activity, due to the high enhancement in the inflammatory and 
fibrotic kidney milieu. 
In summary, our data suggest that the anemia developed in rats with long term 
CRF is not due to reduced EPO synthesis, but to reduced (altered) erythropoietic activity, 
as the CRF rats were able to overcome the anemia when treated with rHuEPO; the local 
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kidney inflammation and the type of kidney lesions seems to be crucial for the outcome 
of the anemia. A long term treatment of CRF rats with rHuEPO leads to the development 
of rHuEPO antibodies and, therefore, to anemia, after about 6 weeks of treatment; the 
impact of rHuEPO treatment depends on the rHuEPO dose, which should be enough to 
correct anemia, preventing kidney and heart hypertrophy, but not too high as it will lead 
to worsening of glomerular and tubulointerstitial kidney lesions. Further studies are 
needed to understand how hypoxia and/or kidney lesions induce a reduced (altered) 
EPO activity and how kidney glomerular lesions/iron leakage may contribute to the 
functional iron deficient anemia, usually observed in hemodialysis CKD patients and 
enhanced in case they develop resistance to rHuEPO treatment. 
 
 
2. Conclusions 
The main goal of this thesis was to contribute to elucidate the cellular/molecular 
mechanisms underlying the development of resistance to endogenous EPO and to 
rHuEPO therapy, using experimental animal models of anemia and CKD. The main 
conclusions obtained were: 
 
I) The model of CKD induced by 5/6 nephrectomy presented a sustained degree 
of renal dysfunction with mild and advanced glomerular and tubulointerstitial lesions. 
This model developed anemia early after nephrectomy and persisted throughout the 
study, in spite of augmented EPO levels. 
 
II) The development of glomerular and tubular kidney damage in CKD model may 
underlie iron leakage, explaining the reduced iron availability. Actually, the reduced 
expression of hepcidin, probably induced by hypoxia, should favour iron absorption; 
indeed, iron absorption seems to be increased, as suggested by the increased expression 
of duodenal ferroportin. 
 
III) The persistence of anemia may result from the disturbance in iron 
metabolism and, eventually, by an altered activity/function of EPO that might result 
from hypoxic kidney cell damage and from the developed local inflammatory milieu. 
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IV) The anemia developed in rats with long term CRF is not due to reduced EPO 
synthesis, but probably to a limited EPO functionality (erythropoietic activity), as the CRF 
rats were able to overcome the anemia when treated with rHuEPO. 
 
V) Anemia correction by the high rHuEPO dose seems to result from an improved 
iron availability, which might result from an improved renal function given the 
amelioration of mild glomerular lesions. 
 
VI) However, despite correcting anemia, a long-term treatment of CRF rats with 
rHuEPO might cause formation of rHuEPO antibodies, becoming resistant to exogenous 
EPO (rHuEPO) therapy. 
 
VII) The impact of the treatment CRF of rats with rHuEPO depends on the dose, 
which should be enough to correct anemia, preventing kidney and heart hypertrophy, 
but not too high, as it will lead to worsening of glomerular and tubulointerstitial kidney 
lesions. 
 
VIII) The development of EH was due to antibodies directed to rHuEPO that 
inhibited the erythropoietic activity of both rHuEPO and endogenous EPO. 
 
IX) In erythroid antibody-mediated hypoplasia/PRCA model induced by a high 
rHuEPO dose, as erythropoiesis is blunted through anti-rHuEPO antibodies, iron 
concentration becomes the key modulator for hepcidin synthesis, which will contribute 
to further aggravate the anemia. 
 
In conclusion, the findings of this thesis give further insights into the mechanisms 
behind the different response to rHuEPO treatment observed in chronic kidney disease 
patients, as well as to the development of resistance to rHuEPO; moreover, it might 
open new windows to identify putative therapeutic targets for this condition, as well as 
for rHuEPO resistance, which occurs in about 10 % of CKD patients. We managed also to 
develop two experimental models, of CKD and of PRCA, which are useful tools for 
further studies, namely pharmacological, in this research area.   
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